## Patent Reference

- Title: Kits and methods of using kits
- URL: https://patents.google.com/patent/CN114730610A/en

### Abstract

Abstract Translated from Chinese 一种用于在设备中使用的用于遗传筛查的试剂盒，其中所述试剂盒在操作时执行湿实验室测定。所述测定包含处理来源于一个或多个细胞外显子组的遗传物质以及检测来自遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)。所述试剂盒可作为处理所述遗传物质的单一测定来执行。所述试剂盒包含软件产品，所述软件产品可在计算硬件上执行以使所述计算硬件调用算法以通过将所述遗传DNA读数的部分与DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定所述DNA读数数据中所述DNA序列转录物出现的概率。所述算法用于同时检测来自所述遗传物质的所述遗传DNA读数中的SNV和CNV两者，并且对临床相关的CNV进行注释。 A kit for genetic screening for use in a device, wherein the kit performs a wet lab assay when in operation. The assay comprises processing genetic material derived from one or more cellular exomes and detecting single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from the genetic material. The kit can be performed as a single assay for processing the genetic material. The kit includes a software product executable on computing hardware to cause the computing hardware to invoke an algorithm to process the genetic DNA reads by comparing portions of the genetic DNA reads to DNA sequence transcripts , in order to determine the probability of occurrence of the DNA sequence transcript in the DNA read data. The algorithm is used to simultaneously detect both SNVs and CNVs in the genetic DNA reads from the genetic material, and annotate clinically relevant CNVs.

### Description

Description Translated from Chinese 试剂盒和使用试剂盒的方法Kits and methods of using kits 技术领域technical field 本公开总体上涉及基因组学或用于临床基因组学的系统、设备和过程；更具体地，本公开涉及试剂盒或用于使用所述试剂盒执行用于对遗传物质进行处理的湿实验室测定以便在准确性和效率显著提高的单一测定中准确且成本有效地鉴定多种变体类型的试剂盒或方法。本公开进一步涉及有效获取和准确处理基因组序列数据集并且解决偏差的影响以准确检测给定基因组序列数据集中的拷贝数变体的系统和方法。The present disclosure generally relates to genomics or systems, devices and processes for clinical genomics; more particularly, the present disclosure relates to kits or for using the kits to perform wet laboratory assays for processing genetic material Kits or methods for accurate and cost-effective identification of multiple variant types in a single assay with significantly improved accuracy and efficiency. The present disclosure further relates to systems and methods for efficiently acquiring and accurately processing genomic sequence data sets and addressing the effects of bias to accurately detect copy number variants in a given genomic sequence data set. 背景技术Background technique 随着医学和计算技术的最新进展，在基因组测序和对应测序数据的分析方面取得了快速进展。测序数据通常以短读段序列生成，例如，在50个与300个脱氧核糖核酸(DNA)碱基之间，其中这些读段序列跨个体的基因组随机分布。遗传分析涉及许多复杂的湿实验室和计算机模拟过程的组合，其中所述过程从获取给定个体的生物样品以得到用于进行进一步分析的遗传物质开始。当代测序技术，例如下一代测序(NGS)，能够通过将长DNA分子转化为更小的片段分子，以扩增形式对所述片段分子进行测序以生成对应的片段序列，并且然后将所述片段序列拼接在一起以生成长DNA分子的DNA读段来对长DNA分子进行测序。在某些情景中，使用基因组技术对基因组中基因的蛋白质编码区(被称为外显子组)进行测序。可替代地，可以使用全基因组测序方法替代外显子组测序，但与外显子组测序方法相比实施起来成本高。全基因组测序与外显子组测序之间引入的偏差和数据错误存在很大差异，并且目前可用的外显子组测序测定中的每一种之间存在进一步差异，这使得鉴定不同突变类型更加困难。With recent advances in medical and computational technologies, rapid progress has been made in genome sequencing and the analysis of corresponding sequencing data. Sequencing data is typically generated in short read sequences, eg, between 50 and 300 deoxyribonucleic acid (DNA) bases, where these read sequences are randomly distributed across an individual's genome. Genetic analysis involves a combination of many complex wet laboratory and computer simulation processes that begin with obtaining a biological sample of a given individual to obtain genetic material for further analysis. Contemporary sequencing technologies, such as next-generation sequencing (NGS), enable sequencing of the fragment molecules in amplified form by converting long DNA molecules into smaller fragment molecules to generate corresponding fragment sequences, and then quantifying the fragments. The sequences are spliced together to generate DNA reads of the long DNA molecule for sequencing the long DNA molecule. In some scenarios, genomic technologies are used to sequence the protein-coding regions of genes in the genome, known as the exome. Alternatively, whole-genome sequencing methods can be used instead of exome sequencing, but are expensive to implement compared to exome sequencing methods. The biases and data errors introduced between whole-genome sequencing and exome sequencing vary widely, and there are further differences between each of the currently available exome sequencing assays, making the identification of different mutation types even more difficulty. 此外，此类测序技术，例如，NGS提供了输入数据(例如，外显子组序列数据)，这些输入数据形成了鉴定基因组中不同突变类型(即不同类型的变体)的基础，这些突变类型可能是或可能不是给定个体中表现为一种或多种表型的疾病或异常的出现的原因。存在于基因组中的此类不同突变类型或变体的实例包含但不限于单核苷酸变体(SNV)、拷贝数变异(CNV)和插入缺失。当基因组中的单一DNA碱基被不同的DNA碱基取代时，基因组中就会发生SNV。由于仅需要鉴定一个缺席者碱基对，因此可以容易地执行此类SNV的检测，并且因此在本领域中是众所周知的并且经过研究。另一方面，当DNA碱基对的序列在基因组中复制或缺失时，基因组中就会发生CNV。通常，CNV的大小可能从基因组的十多个碱基到几兆碱基不等。因此，与SNV相比，检测此类CNV是复杂的任务。Furthermore, such sequencing technologies, e.g., NGS, provide input data (e.g., exome sequence data) that form the basis for identifying different types of mutations (ie, different types of variants) in the genome that A disease or abnormality that may or may not be manifested by one or more phenotypes in a given individual may or may not be the cause. Examples of such different mutation types or variants present in the genome include, but are not limited to, single nucleotide variants (SNVs), copy number variations (CNVs), and indels. SNVs occur in the genome when a single DNA base in the genome is replaced by a different DNA base. Detection of such SNVs can be easily performed since only one absenter base pair needs to be identified, and is therefore well known and studied in the art. On the other hand, CNVs occur in the genome when the sequence of DNA base pairs is duplicated or deleted in the genome. Typically, CNVs may vary in size from more than a dozen bases of the genome to several megabases. Therefore, detecting such CNVs is a complex task compared to SNVs. 目前，在对遗传物质进行处理以鉴定不同的变体类型时遇到了许多技术问题。使用单独的测试、工具和平台对不同变体类型(SNV、CNV等)进行检测、可视化和分析的不连贯方法，执行多个测试以鉴定不同突变类型所涉及的高成本，以及进行单独测试时遗漏某些变体的风险是在处理遗传物质以鉴定不同突变类型时遇到的一些技术问题。通常，染色体微阵列已成为用于检测较大变体类型(如CNV)的细胞遗传学应用的已建立标准，而NGS通常被保留用于较小突变类型，如SNV或由少量碱基变异引起的突变。随着NGS测定成本的降低，正在开发许多系统和方法来从测序数据中获取CNV，因为据估计CNV占罕见疾病致病性的约10％-15％。目前，需要单独执行不同的测试来检测不同的突变类型，即SNV、CNV等。在最近的研究中，据估计，微阵列分析仅检测到患有遗传病症的患者中约12％的致病事件。然后将那些没有致病发现的患者送交到在大多数情况下为DNA测序的第二测试。因此，执行两项测试会导致更高的成本以及更长的时间来评估疾病是否存在。此外，据估计，约5％的样品具有多种致病变体，约12％的样品具有双重变体，即包含CNV和SNV的组合。如果在给定时间点单独进行外显子组测序或CNV分析，则会错过此类情况。Currently, many technical problems are encountered in the processing of genetic material to identify different variant types. Disjoint approaches to detection, visualization, and analysis of different variant types (SNVs, CNVs, etc.) using separate tests, tools, and platforms, the high cost involved in performing multiple tests to identify different mutation types, and the The risk of missing some variants is some of the technical problems encountered when processing genetic material to identify different mutation types. In general, chromosomal microarrays have become the established standard for cytogenetic applications for the detection of larger variant types such as CNVs, whereas NGS is usually reserved for smaller mutation types such as SNVs or caused by a small number of base variations mutation. As the cost of NGS assays decreases, many systems and methods are being developed to derive CNVs from sequencing data, as CNVs are estimated to account for ~10%-15% of rare disease pathogenicity. Currently, different tests need to be performed individually to detect different mutation types, i.e. SNV, CNV, etc. In recent studies, it was estimated that microarray analysis detected only about 12% of causative events in patients with genetic disorders. Those patients with no pathogenic findings are then sent to a second test, which in most cases sequences DNA. Therefore, performing two tests results in higher costs and a longer time to assess the presence or absence of disease. Furthermore, it is estimated that about 5% of the samples have multiple pathogenic variants, and about 12% of the samples have double variants, ie, comprising a combination of CNVs and SNVs. Such cases would be missed if exome sequencing or CNV analysis were performed alone at a given time point. 此外，如今，成本的降低使得执行NGS测序变得更加实惠，并且从NGS数据中得到CNV的需求一直在上升。有若干种工具可用于CNV检测，但此类工具对用户不友好，并且需要用户专业知识(即生物信息学专业知识)。例如，大多数现有的工具和系统仅可使用命令行(即文本界面，其中程序的命令以连续文本行的形式与计算机交互)进行操作，这并不易于使用。此外，每种工具仅擅长一个领域。例如，一些工具和系统擅长用于体细胞样品或原发性样品，而一些工具和系统则擅长分析来自全基因组测序(WGS)的数据，但同样不适合于外显子组测序数据。此外，一些工具和系统擅长使用来自靶向基因组的数据进行遗传分析，以检测具有临床可接受的敏感性和特异性的某些突变类型(即变体)。此外，大量致病性基因组改变落在从NGS和微阵列检测此类突变类型的空位之间。在临床上，对此类突变类型(变体)的另外的测试依赖于多重连接依赖性探针扩增(通常被称为MLPA)，这种方法执行起来价格昂贵并且每个基因需要一个试剂盒。另外，这可能会增加测试时间。此外，常规测定不允许数据分析、可视化和变体解释的综合方法，导致误解或遗漏变体(即由于低序列覆盖率)。因此，这是一个技术问题，因为常规的解决方案需要执行不同的测试，难以在临床实验室中实施，并且作为单独和不连贯的解决方案工作，即单独确定不同的突变类型，其中结果彼此不连贯，这导致下游处理效率低下，进一步导致相对地低覆盖(即仅适用于特定结构域区域)，并且提供较差的结果可视化。In addition, lower costs have now made it more affordable to perform NGS sequencing, and the need to derive CNVs from NGS data has been on the rise. Several tools are available for CNV detection, but such tools are not user friendly and require user expertise (ie, bioinformatics expertise). For example, most existing tools and systems can only be operated using a command line (ie, a text interface, where a program's commands interact with the computer in continuous lines of text), which is not easy to use. Furthermore, each tool only excels in one area. For example, some tools and systems are good at somatic samples or primary samples, while some are good at analyzing data from whole genome sequencing (WGS), but are equally unsuitable for exome sequencing data. In addition, some tools and systems excel at genetic analysis using data from targeted genomes to detect certain mutation types (ie, variants) with clinically acceptable sensitivity and specificity. Furthermore, a large number of pathogenic genomic alterations fall between the gaps in detecting such mutation types from NGS and microarrays. In the clinic, additional testing for such mutation types (variants) relies on multiplex ligation-dependent probe amplification (often referred to as MLPA), which is expensive to perform and requires one kit per gene . Also, this may increase testing time. Furthermore, conventional assays do not allow for an integrated approach to data analysis, visualization and variant interpretation, leading to misinterpretation or omission of variants (ie, due to low sequence coverage). Therefore, this is a technical problem, as the conventional solution requires performing different tests, is difficult to implement in clinical laboratories, and works as a separate and incoherent solution, i.e. identifying different mutation types individually, where the results are inconsistent with each other Coherence, which leads to inefficiencies in downstream processing, further results in relatively low coverage (ie only applies to specific domain regions), and provides poor visualization of results. 遇到的另一个挑战是样品跟踪。维持样品完整性对于变体的解释至关重要。例如，样品经历了从给定样品中提取DNA到生成测序数据的许多物理步骤，这使其成为导致样品混淆的易受攻击的过程。另外，样品混淆可能会带来临床风险，延迟提供结果，并且进一步地可能导致时间和试剂的浪费，从而产生不利的财务影响。Another challenge encountered was sample tracking. Maintaining sample integrity is critical for variant interpretation. For example, a sample goes through many physical steps from extracting DNA from a given sample to generating sequencing data, making it a vulnerable process that leads to sample confusion. In addition, sample mix-up may present clinical risks, delays in delivering results, and further may result in wasted time and reagents with adverse financial implications. 另外，药物基因组学是对个体的基因构成如何影响个体对药物的反应的研究，这可以为尝试个体化药物选择和药物给药以避免药物不良反应、副作用和最大化药物疗效提供重要信息。例如，食品和药物管理局(FDA)现在在几乎每个医学学科使用的超过100种药物的标签上都包含了药物基因组学信息，强调了药物基因组学信息的广泛覆盖和实施的潜在影响。个体中的这种基因变异可以影响给定药物从人体中激活或清除的速度以及引发期望的靶反应可能需要的给定药物的量。据估计，仅有30％-70％的患者对药物产生积极反应，并且患者甚至可能面临发生药物不良反应(ADR)的潜在风险。目前，药物基因组标志物的广泛采用在很大程度上仅限于预先设计的靶向测定，这意味着任何进行外显子组测序的人都需要运行单独的测定，这需要更多的样品并且产生另外的测试途径和成本。此外，许多标准NGS流水线通常不称为纯合野生型(由于另外的存储和计算要求，并且这些变体中的许多在人群中很常见，并且因此被标准过滤方法过滤掉)，这是不期望的。此外，在某些场景中，许多致病突变位于由一些现有的现成外显子组测定捕获的编码区之外。这可能会导致医生采取预防措施的决策支持不正确，或者由于在现成的基于外显子组测定的试剂盒中未捕获致病突变和对致病突变进行测序而导致错过对疾病的评估而导致治疗不正确。Additionally, pharmacogenomics is the study of how an individual's genetic makeup affects an individual's response to a drug, which can provide important information for attempts to personalize drug selection and drug administration to avoid adverse drug reactions, side effects, and maximize drug efficacy. For example, the Food and Drug Administration (FDA) now includes pharmacogenomics information on the labels of more than 100 drugs used in nearly every medical discipline, underscoring the potential impact of broad coverage and implementation of pharmacogenomics information. This genetic variation in an individual can affect how quickly a given drug is activated or cleared from the body and the amount of a given drug that may be required to elicit a desired target response. It is estimated that only 30%-70% of patients respond positively to the drug, and patients may even be at potential risk of developing adverse drug reactions (ADRs). Currently, widespread adoption of pharmacogenomic markers is largely limited to predesigned targeted assays, meaning anyone doing exome sequencing needs to run a separate assay, which requires more samples and generates Additional testing routes and costs. In addition, many standard NGS pipelines are often not called homozygous wild-type (due to additional storage and computational requirements, and many of these variants are common in the population and are therefore filtered out by standard filtering methods), which is not expected of. Furthermore, in some scenarios, many disease-causing mutations are located outside coding regions captured by some existing off-the-shelf exome assays. This can lead to incorrect decision support for physicians to take preventive actions, or to missed assessment of disease due to non-capturing and sequencing of disease-causing mutations in off-the-shelf exome assay-based kits Incorrect treatment. 因此，鉴于上述讨论，需要克服与用于处理遗传物质、分析基因组序列数据和鉴定多种突变类型的常规试剂盒、系统和方法相关联的上述缺陷。Accordingly, in view of the above discussion, there is a need to overcome the above-mentioned deficiencies associated with conventional kits, systems and methods for processing genetic material, analyzing genomic sequence data, and identifying multiple mutation types. 随着医学和计算技术的最新进展、基因组测序方面的快速进步、对应的测序数据的分析，如此通常在例如在50个与300个脱氧核糖核酸(DNA)碱基之间的短读段序列中生成的测序数据随机分布在患者的基因组中。此类短读段测序数据是使用许多不同的实验室技术产生的，所有这些技术都将其自己的数据错误或偏差引入到了生成的数据中，这是不期望的。With recent advances in medical and computational technology, rapid advances in genome sequencing, and analysis of the corresponding sequencing data, so often in short-read sequences, for example, between 50 and 300 deoxyribonucleic acid (DNA) bases The resulting sequencing data is randomly distributed across the patient's genome. Such short-read sequencing data are generated using many different laboratory techniques, all of which introduce their own data errors or biases into the generated data, which are undesirable. 在某些场景中，为了降低成本，经测序的基因组区域通常局限于在被称为“临床外显子组测序”的过程中的已知涉及发病机制的基因小组。所述基因小组被定义为基因组内的靶区列表，并且通常在其中含有一组选定的基因或基因区域，这些基因或基因区域与所研究的疾病或表型具有已知或疑似关联。有许多捕获测定试剂盒可供使用，所述试剂盒通常针对略有不同的基因小组进行定制，并且使用替代性设计和过程来捕获所关注序列。可替代地，可以使用全基因组测序方法替代外显子组测序，但与外显子组测序方法相比实施起来成本高。全基因组测序与外显子组测序之间引入的偏差和数据错误存在很大差异，并且目前可用的外显子组测序测定中的每一种之间存在进一步差异。In some scenarios, to reduce costs, the sequenced genomic regions are often limited to the panel of genes known to be involved in pathogenesis in a process known as 'clinical exome sequencing.' The genomic panel is defined as a list of target regions within the genome and typically contains within it a selected set of genes or gene regions that have known or suspected associations with the disease or phenotype under study. A number of capture assay kits are available, which are often customized for slightly different panels of genes and use alternative designs and procedures to capture sequences of interest. Alternatively, whole-genome sequencing methods can be used instead of exome sequencing, but are expensive to implement compared to exome sequencing methods. The biases and data errors introduced between whole-genome sequencing and exome sequencing vary widely, and further differences exist between each of the currently available exome sequencing assays. 进一步地，此类测序技术提供输入数据，所述输入数据形成了鉴定基因组中若干种遗传变体或突变的基础，所述遗传变体或突变可能是或可能不是给定个体中表现为表型的疾病或异常的出现的原因。存在于基因组中的此类遗传变体或突变的实例包含但不限于单核苷酸变体(SNV)、拷贝数变体(CNV)和结构变体(SV)。人类DNA通常包括被称为核苷酸的DNA碱基，即成对的腺嘌呤(A)、鸟嘌呤(G)、胞嘧啶(C)和胸腺嘧啶(T)，使得“A”与“T”配对(A-T)并且“C”与“G”配对(C-G)。当基因组中的单一DNA碱基被不同的DNA碱基取代时，基因组中就会发生SNV。例如，如果用“G”替换“A”，则原来的碱基对A-T被替换为碱基对G-T。在此类情况下，由于有缺陷的碱基对G-T，个体的基因组中会出现异常。然而，由于仅需要鉴定一个缺席者碱基对，因此可以容易地执行此类SNV的检测，并且因此在本领域中是众所周知的并且经过研究。另一方面，当DNA碱基对的序列在基因组中复制或缺失时，基因组中就会发生CNV。通常，CNV的大小可能从基因组的十多个碱基到几兆碱基不等。因此，检测此类CNV是复杂的任务，并且没有很多现有系统和方法能够有效鉴定基因组中的CNV，并且即使鉴定出一些CNV，也存在许多假阳性，并且某些其它CNV被遗漏。此外，在生成的短读段测序数据中引入的偏差(或数据错误)、在全基因组测序与外显子组测序之间引入的偏差以及当前可用的外显子组测序测定中的每个测定之间的进一步差异，使得CNV识别(即检测)过程更成问题。此外，存在一些已知的应用程序用于检测拷贝数变体。然而，由于上述偏差(或数据错误)问题以及由于使用多种不同的测序测定类型，此类应用程序的性能各不相同，并且因此不可靠且不准确。Further, such sequencing technologies provide input data that forms the basis for identifying several genetic variants or mutations in the genome that may or may not be phenotypes in a given individual the cause of the disease or abnormality. Examples of such genetic variants or mutations present in the genome include, but are not limited to, single nucleotide variants (SNVs), copy number variants (CNVs), and structural variants (SVs). Human DNA generally includes DNA bases called nucleotides, namely pairs of adenine (A), guanine (G), cytosine (C), and thymine (T), making 'A' and 'T' ' is paired (A-T) and 'C' is paired with 'G' (C-G). SNVs occur in the genome when a single DNA base in the genome is replaced by a different DNA base. For example, if you replace 'A' with 'G', the original base pair A-T is replaced with the base pair G-T. In such cases, abnormalities occur in the individual's genome due to the defective base pair G-T. However, since only one absentee base pair needs to be identified, detection of such SNVs can be easily performed and is therefore well known and studied in the art. On the other hand, CNVs occur in the genome when the sequence of DNA base pairs is duplicated or deleted in the genome. Typically, CNVs may vary in size from more than a dozen bases of the genome to several megabases. Therefore, detecting such CNVs is a complex task, and there are not many existing systems and methods that can effectively identify CNVs in the genome, and even if some CNVs are identified, there are many false positives, and some other CNVs are missed. In addition, the biases (or data errors) introduced in the generated short-read sequencing data, the biases introduced between whole-genome sequencing and exome sequencing, and each of the currently available exome sequencing assays Further discrepancies between CNVs make the process of CNV identification (ie, detection) more problematic. Furthermore, there are some known applications for the detection of copy number variants. However, due to the bias (or data errors) issues described above and due to the use of many different sequencing assay types, the performance of such applications varies and is therefore unreliable and inaccurate. 因此，鉴于上述讨论，需要克服与用于处理和分析基因组序列数据的常规系统和方法相关联的上述缺陷。Accordingly, in view of the above discussion, there is a need to overcome the above-mentioned deficiencies associated with conventional systems and methods for processing and analyzing genomic sequence data. 发明内容SUMMARY OF THE INVENTION 本公开寻求提供一种用于设备中的改进的试剂盒，其中所述试剂盒用于遗传筛查以及执行湿实验室测定，所述湿实验室测定包含处理来源于一个或多个细胞外显子组的遗传物质，以及检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)。本公开还寻求提供一种用于使用试剂盒的方法，所述试剂盒执行湿实验室测定，所述湿实验室测定包含处理来源于一个或多个细胞外显子组的遗传物质，以及检测来自所述遗传物质的遗传DNA读数中的SNV、插入缺失和CNV。本公开寻求提供一种针对现有的低覆盖率问题的解决方案，所述低覆盖率表示来自一个或多个细胞外显子组的基因组测序读数数据中对变体的误解或遗漏变体。本公开进一步寻求提供一种针对使用单独的测试、工具和平台进行检测、可视化和/或进一步分析不同变体类型(SNV、CNV和插入缺失)的不连贯方法以及为鉴定不同变体类型而执行多个测试所涉及的高成本的现有问题的解决方案。The present disclosure seeks to provide an improved kit for use in a device, wherein the kit is used for genetic screening and for performing wet lab assays comprising treatment derived from one or more cellular exosomes Subgroups of genetic material, and detection of single nucleotide variants (SNVs), indels, and copy number variations (CNVs) in genetic DNA reads from the genetic material. The present disclosure also seeks to provide a method for using a kit for performing a wet lab assay comprising processing genetic material derived from one or more cellular exomes, and detecting SNVs, indels and CNVs in genetic DNA reads from the genetic material. The present disclosure seeks to provide a solution to the existing problem of low coverage, which represents misinterpreted or missed variants in genome sequencing read data from one or more cellular exomes. The present disclosure further seeks to provide an incoherent method for detection, visualization and/or further analysis of different variant types (SNVs, CNVs and indels) using separate tests, tools and platforms and to perform for the identification of different variant types Solutions to high-cost existing problems involved in multiple tests. 本公开的目的是提供至少部分地克服现有技术中遇到的问题的解决方案，以及提供改进的试剂盒和提供集成解决方案的方法，所述集成解决方案是用户友好的、具有成本效益的并且能够以相对较高的覆盖率从单一测定中同时检测不同的变体类型(SNV、CNV和插入缺失)，从而导致遗漏变体的概率显著降低，并且进一步允许以连接的和集成的方法对检测到的不同变体类型进行可视化和进一步分析。It is an object of the present disclosure to provide solutions that at least partially overcome the problems encountered in the prior art, as well as to provide improved kits and methods of providing integrated solutions that are user-friendly and cost-effective and enables simultaneous detection of different variant types (SNVs, CNVs, and indels) from a single assay with relatively high coverage, resulting in significantly reduced probability of missing variants and further allowing for concatenated and integrated approaches to The different variant types detected are visualized and further analyzed. 一方面，本公开提供了一种用于在设备中示意并且用于遗传筛查的试剂盒，其中所述试剂盒在操作时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，In one aspect, the present disclosure provides a kit for representation in a device and for genetic screening, wherein the kit, when in operation, performs a wet laboratory assay, wherein the assay comprises treatment derived from one or more genetic material of an exome of a single cell, wherein the assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from the genetic material, 所述试剂盒的特征在于，The kit is characterized in that, 所述试剂盒可作为处理所述遗传物质的单一测定来执行；并且The kit can be performed as a single assay for processing the genetic material; and 所述试剂盒包含软件产品，所述软件产品可在计算硬件上执行以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，The kit includes a software product executable on computing hardware to cause the computing hardware to invoke one or more algorithms to transcribe portions of the genetic DNA reads with one or more DNA sequences processing said genetic DNA reads in order to determine the occurrence of variants corresponding to said one or more DNA sequence transcripts in said DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (i)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(i) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (ii)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(ii) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (iii)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；(iii) an algorithm for prioritizing said one or more portions of said genetic DNA reads from said genetic material according to a phenotype associated with said one or more portions; (iv)检测药物基因组学(PGx)标志物的变体识别的算法；以及(iv) algorithms to detect variant recognition of pharmacogenomics (PGx) markers; and (V)被配置成在所述单一测定中样品跟踪SNP的算法。(V) An algorithm configured to sample track SNPs in the single assay. 另一方面，本公开提供了一种用于使用试剂盒的方法，其中所述试剂盒在使用时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，所述方法的特征在于所述方法包含：In another aspect, the present disclosure provides a method for using a kit, wherein the kit, in use, performs a wet lab assay, wherein the assay comprises processing exomes derived from one or more cells Genetic material, wherein said assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from said genetic material, said method characterized in that said method comprises: (i)将所述试剂盒作为处理所述遗传物质的单一测定应用；以及(i) applying the kit as a single assay for processing the genetic material; and (ii)在计算硬件上执行所述试剂盒的软件产品，以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，(ii) executing the software product of the kit on computing hardware such that the computing hardware invokes one or more algorithms to perform analysis by comparing portions of the genetic DNA reads with one or more DNA sequence transcripts comparing said genetic DNA reads to determine the occurrence of variants corresponding to said one or more DNA sequence transcripts in said DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (a)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(a) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (b)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(b) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (c)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；以及(c) an algorithm that prioritizes the one or more portions of the genetic DNA reads from the genetic material according to the phenotype associated with the one or more portions; and (d)检测药物基因组学(PGx)标志物的变体识别的算法；以及(d) algorithms to detect variant recognition of pharmacogenomics (PGx) markers; and (e)被配置成在所述单一测定中样品跟踪SNP的算法。(e) An algorithm configured to sample track SNPs in the single assay. 本公开的实施例基本上消除或至少部分地解决了现有技术中的上述问题，并且使所述试剂盒能够作为对遗传物质进行处理的单一测定来执行，使得从单一测定中经济有效地确定不同的变体类型(SNV、CNV、插入缺失和PGx标志物)，并且同时具有高覆盖率，从而导致遗漏变体的概率显著降低。本公开还通过提供一种集成解决方案来解决不连贯方法的问题，所述集成解决方案不仅使得能够以连接的、用户友好的和集成的方法对不同变体类型进行检测，而且还使得能够同时可视化和进一步分析，这降低了误解遗传变体的风险。Embodiments of the present disclosure substantially obviate or at least partially address the above-mentioned problems of the prior art and enable the kit to be performed as a single assay for processing genetic material, allowing cost-effective determination from a single assay Different variant types (SNVs, CNVs, indels and PGx markers) and at the same time have high coverage, resulting in a significantly lower probability of missing variants. The present disclosure also addresses the problem of incoherent approaches by providing an integrated solution that not only enables detection of different variant types in a connected, user-friendly and integrated approach, but also enables simultaneous Visualization and further analysis, which reduces the risk of misinterpreting genetic variants. 本公开还寻求提供一种改进的系统，所述系统获取和处理基因组序列数据集以检测拷贝数变体。本公开还寻求提供一种用于获取和处理基因组序列数据集以检测拷贝数变体的改进的方法。本公开寻求提供对由于给定基因组序列数据集中的偏差而对给定基因组序列数据集中的拷贝数变体的低效和不可靠检测的现有问题的解决方案。此外，本公开进一步寻求解决现有问题，即如何从多个不同应程序中鉴定用于特定基因组序列数据集的有效且最佳的应用程序，这有助于准确且可靠地检测可能存在偏差(或数据错误)的特定基因组序列数据集中的拷贝数变体。The present disclosure also seeks to provide an improved system for acquiring and processing genomic sequence data sets to detect copy number variants. The present disclosure also seeks to provide an improved method for acquiring and processing genomic sequence data sets to detect copy number variants. The present disclosure seeks to provide a solution to the existing problem of inefficient and unreliable detection of copy number variants in a given genome sequence dataset due to bias in the given genome sequence dataset. Furthermore, the present disclosure further seeks to address the existing problem of how to identify an efficient and optimal application for a particular genome sequence dataset from a number of different applications, which facilitates accurate and reliable detection of possible biases ( or data errors) copy number variants in specific genome sequence datasets. 本公开的目的是提供一种解决方案，所述解决方案至少部分地克服了现有技术中遇到的问题并且提供了改进的系统和方法，所述系统和方法通过鉴定对给定基因组序列数据集可靠且有效的最佳应用程序，解决了偏差对有效且准确检测给定基因组序列数据集中的拷贝数变体的影响。It is an object of the present disclosure to provide a solution that at least partially overcomes the problems encountered in the prior art and provides an improved system and method by identifying Set reliable and efficient best-of-breed applications that address the impact of bias on efficient and accurate detection of copy number variants in a given genome sequence dataset. 一方面，本公开提供了一种获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的系统，所述系统包括：In one aspect, the present disclosure provides a system for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, the system comprising: -被配置成处理受试者的基因组的至少一部分以生成原始基因组序列数据集的设备；以及- a device configured to process at least a portion of a subject's genome to generate a raw genome sequence data set; and -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -从所述设备中获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining the raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in the data storage device from the device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 另一方面，本公开的实施例提供了一种处理原始基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的系统，所述系统包括：In another aspect, embodiments of the present disclosure provide a system for processing a raw genome sequence data set to detect one or more copy number variants (CNVs) therein, the system comprising: -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said data storage device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 又另一方面，本公开的实施例提供了一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括设备和计算布置的系统来实施，其中所述方法包括：In yet another aspect, embodiments of the present disclosure provide a method for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method uses equipment and computing A system of arrangements is implemented, wherein the method comprises: -通过使用所述设备处理受试者的基因组的至少一部分以生成原始基因组序列数据集；- by processing at least a portion of the subject's genome using the device to generate a raw genome sequence data set; -通过使用所述计算布置的控制电路系统，从所述设备中获取所述原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining from said apparatus said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said computationally arranged data memory means by using said computationally arranged control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating an artificial set of CNVs in at least one target region of said original genome sequence dataset by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 又另一方面，本公开的实施例提供了一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括计算布置的系统来实施，其中所述方法包括：In yet another aspect, embodiments of the present disclosure provide a method for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method uses a The system is implemented, wherein the method includes: -通过使用所述计算布置的控制电路系统，获取原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining a raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in a data memory device of the computing arrangement by using the control circuitry of the computing arrangement; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating an artificial set of CNVs in at least one target region of said original genome sequence dataset by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 又另一方面，本公开的实施例提供了一种计算机程序产品，其包括其上存储有计算机可读指令的非暂时性计算机可读存储介质，所述计算机可读指令可由包括处理硬件的计算机化装置执行以上述方法。In yet another aspect, embodiments of the present disclosure provide a computer program product including a non-transitory computer-readable storage medium having computer-readable instructions stored thereon, the computer-readable instructions being executable by a computer including processing hardware The chemical device performs the method described above. 又另一方面，本公开的实施例提供了一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括计算布置的系统来实施，其中所述方法包括：In yet another aspect, embodiments of the present disclosure provide a method for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method uses a The system is implemented, wherein the method includes: -通过使用所述计算布置的控制电路系统，获取原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining a raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in a data memory device of the computing arrangement by using the control circuitry of the computing arrangement; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence data set by simulating an artificial CNV set in at least one target region of said original genome sequence data set by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 本公开的实施例基本上消除或至少部分地解决了现有技术中的上述问题，并且使得能够选择用于检测基因组序列数据集中的拷贝数变体的最佳应用程序。针对特定基因组序列数据集的所选最佳应用程序有助于准确且可靠地检测此基因组序列数据集中的拷贝数变体。Embodiments of the present disclosure substantially eliminate or at least partially address the above-mentioned problems of the prior art, and enable selection of optimal applications for detecting copy number variants in genomic sequence data sets. The selected best application for a specific genome sequence dataset facilitates accurate and reliable detection of copy number variants in this genome sequence dataset. 本公开的另外的方面、优点、特征和目的将从附图和结合下面所附权利要求解释的说明性实施例的详细描述中变得显而易见。Additional aspects, advantages, features and objects of the present disclosure will become apparent from the accompanying drawings and the detailed description of illustrative embodiments, which are explained in conjunction with the appended claims below. 应当理解，本公开的特征易于以各种组合进行结合，而不背离由所附权利要求限定的本公开的范围。It should be understood that the features of the present disclosure may be easily combined in various combinations without departing from the scope of the disclosure, which is defined by the appended claims. 附图说明Description of drawings 当结合附图阅读时，将更好理解以上发明内容以及以下说明性实施例的具体描述。出于说明本公开的目的，在附图中示出了本公开的示例性构造。然而，本公开不限于本文所公开的具体方法和工具。此外，本领域的技术人员将理解附图并不是按比例绘制的。在可能的情况下，相似的元件已用相同的数字指示。The foregoing summary, as well as the following detailed description of illustrative embodiments, will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the disclosure, there are shown in the drawings exemplary constructions of the disclosure. However, the present disclosure is not limited to the specific methods and instrumentalities disclosed herein. Furthermore, those skilled in the art will appreciate that the drawings are not to scale. Where possible, similar elements have been designated by the same numerals. 现在将通过举例并且参考以下图来描述本公开的实施例，其中：Embodiments of the present disclosure will now be described by way of example and with reference to the following figures, in which: 图1A是根据本公开的实施例的在设备中使用的试剂盒的框图；1A is a block diagram of a kit for use in a device according to an embodiment of the present disclosure; 图1B是根据本公开的另一个实施例的在设备中使用的试剂盒的框图；Figure IB is a block diagram of a kit for use in a device according to another embodiment of the present disclosure; 图2是根据本公开的实施例的用于实施用于执行定制的湿实验室外显子组测定的试剂盒的示例性场景的图解；2 is an illustration of an exemplary scenario for implementing a kit for performing customized wet lab exome assays in accordance with an embodiment of the present disclosure; 图3是描绘根据本公开的实施例的使用执行湿实验室测定的试剂盒的方法的步骤的流程图；并且3 is a flowchart depicting the steps of a method of using a kit for performing a wet lab assay according to an embodiment of the present disclosure; and 图4是描绘根据本公开的另一个实施例的使用执行湿实验室测定的试剂盒的方法的步骤的流程图。4 is a flowchart depicting the steps of a method of using a kit for performing a wet lab assay according to another embodiment of the present disclosure. 图5A是根据本公开的实施例的获取和处理基因组序列数据集以检测拷贝数变体(CNV)的系统的框图；5A is a block diagram of a system for acquiring and processing genomic sequence data sets to detect copy number variants (CNVs) according to an embodiment of the present disclosure; 图5B是根据本公开的另一个实施例的获取和处理基因组序列数据集以检测拷贝数变体(CNV)的系统的网络环境的图解；并且5B is an illustration of a network environment of a system for acquiring and processing genomic sequence data sets to detect copy number variants (CNVs) according to another embodiment of the present disclosure; and 图6A和6B是描绘根据本公开的实施例的用于获取和处理基因组序列数据集以检测拷贝数变体(CNV)的方法的步骤的流程图。6A and 6B are flowcharts depicting the steps of a method for obtaining and processing a genomic sequence data set to detect copy number variants (CNVs), according to embodiments of the present disclosure. 在附图中，带下划线的数字用来表示带下划线的数字所定位的项或与所述带下划线的数字相邻的项。未加下划线的数字涉及通过线所标识的项，所述线将未加下划线的数字与项连接。当数字未加下划线并带有相关联的箭头时，未加下划线的数字将用于标识箭头所指向的常规项。In the drawings, an underlined number is used to indicate the item to which the underlined number locates or an item adjacent to the underlined number. An ununderlined number refers to an item identified by a line connecting the ununderlined number with the item. When a number is ununderlined and has an associated arrow, the ununderlined number will be used to identify the regular item to which the arrow points. 具体实施方式Detailed ways 以下详细描述说明了本公开的实施例以及可以实施所述实施例的方式。尽管已经公开了执行本公开的一些模式，但是本领域技术人员将认识到用于执行或实践本公开的其它实施例也是可能的。The following detailed description illustrates embodiments of the present disclosure and the manner in which they may be practiced. Although some modes of carrying out the disclosure have been disclosed, those skilled in the art will recognize that other embodiments for carrying out or practicing the disclosure are possible. 一方面，本公开提供了一种用于在设备中使用的用于遗传筛查的试剂盒，其中所述试剂盒在操作时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，In one aspect, the present disclosure provides a kit for genetic screening for use in a device, wherein the kit, when in operation, performs a wet laboratory assay, wherein the assay comprises treatment derived from one or more genetic material of an exome of a single cell, wherein the assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from the genetic material, 所述试剂盒的特征在于，The kit is characterized in that, 所述试剂盒可作为处理所述遗传物质的单一测定来执行；并且The kit can be performed as a single assay for processing the genetic material; and 所述试剂盒包含软件产品，所述软件产品可在计算硬件上执行以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，The kit includes a software product executable on computing hardware to cause the computing hardware to invoke one or more algorithms to transcribe portions of the genetic DNA reads with one or more DNA sequences processing the genetic DNA reads in order to determine the occurrence of variants corresponding to the one or more DNA sequence transcripts in the DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (i)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(i) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (ii)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(ii) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (iii)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；(iii) an algorithm for prioritizing said one or more portions of said genetic DNA reads from said genetic material according to a phenotype associated with said one or more portions; (iv)检测药物基因组学(PGx)标志物的变体识别并且在所述单一测定中单独检测样品跟踪SNP的算法。(iv) Algorithms to detect variant recognition of pharmacogenomic (PGx) markers and to detect sample tracking SNPs individually in the single assay. 另一方面，本公开的实施例提供了一种用于使用试剂盒的方法，其中所述试剂盒在使用时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，所述方法的特征在于所述方法包含：In another aspect, embodiments of the present disclosure provide a method for using a kit, wherein the kit, in use, performs a wet lab assay, wherein the assay comprises treatment derived from one or more cells ex vivo A subset of genetic material, wherein said assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from said genetic material, said method characterized by said method Methods include: (i)将所述试剂盒作为处理所述遗传物质的单一测定应用；以及(i) applying the kit as a single assay for processing the genetic material; and (ii)在计算硬件上执行所述试剂盒的软件产品，以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，(ii) executing the software product of the kit on computing hardware such that the computing hardware invokes one or more algorithms to perform analysis by comparing portions of the genetic DNA reads with one or more DNA sequence transcripts comparing said genetic DNA reads to determine the occurrence of variants corresponding to said one or more DNA sequence transcripts in said DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (a)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(a) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (b)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(b) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (c)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；以及(c) an algorithm that prioritizes the one or more portions of the genetic DNA reads from the genetic material according to the phenotype associated with the one or more portions; and (d)检测药物基因组学(PGx)标志物的变体识别并且在单一测定中单独检测样品跟踪SNP的算法。(d) Algorithms to detect variant recognition of pharmacogenomics (PGx) markers and individually detect sample-tracking SNPs in a single assay. 本公开提供了一种集成解决方案，所述集成解决方案用于从使用上述试剂盒和方法执行的单一测定中同时检测、可视化和进一步分析不同的变体类型(即SNV、CNV和插入缺失的组合)。所公开的试剂盒可作为对遗传物质(如外显子组或靶向基因(即外显子组)小组小组)进行处理的单一测定来执行，以从遗传物质中获得遗传DNA读数。试剂盒用于遗传筛查。遗传筛查的实例包含但不限于孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用。以连接和集成的方式在单一测定中一起检测不同的变体类型(即SNV、CNV、插入缺失和PGx标志物)，这显著增加了遗传变体检测的覆盖率并且减少了对变体的误解并且避免在来源于细胞外显子组的遗传DNA读数中意外遗漏潜在变体(即临床相关的不同变体类型)。试剂盒利用软件产品和具有DNA序列转录物的广泛数据集来确定与DNA读数数据中的一个或多个DNA序列转录物相对应的变体的出现，这有效地处理和减少了偏差(如果外显子组测序中有的话)的影响，并且为试剂盒提供了直接从提取的样品中检测多种(即双重、三重等)致病变体(即CNV和SNV、或CNV、SNV和PGx标志物的组合)的能力。试剂盒允许以连接和集成的方式对检测到的不同变体类型进行可视化和进一步分析。The present disclosure provides an integrated solution for the simultaneous detection, visualization and further analysis of different variant types (i.e. SNVs, CNVs and indels) from a single assay performed using the kits and methods described above combination). The disclosed kits can be performed as a single assay that processes genetic material, such as the exome or targeted gene (ie, exome) panels, to obtain genetic DNA reads from the genetic material. Kits are used for genetic screening. Examples of genetic screening include, but are not limited to, preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology. Detect different variant types (i.e. SNVs, CNVs, indels, and PGx markers) together in a single assay in a linked and integrated manner, which significantly increases the coverage of genetic variant detection and reduces variant misinterpretation And avoid accidental omission of potential variants (ie, clinically relevant distinct variant types) in genetic DNA reads derived from the cellular exome. The kit utilizes software products and extensive datasets with DNA sequence transcripts to determine the occurrence of variants corresponding to one or more DNA sequence transcripts in the DNA read data, which efficiently handles and reduces bias (if extraneous). effects of exome sequencing, if any), and provides the kit to detect multiple (i.e. double, triple, etc.) pathogenic variants (i.e. CNV and SNV, or CNV, SNV and PGx directly from extracted samples) combination of markers). The kit allows visualization and further analysis of the different variant types detected in a linked and integrated manner. 贯穿本申请，变体或遗传变异是指任何物种、群组或群体或可以在任何物种、群组或群体中的个体的背景下看到，并且可在基因和等位基因中观察到。导致遗传变异的事实可能包含但不限于基因突变、交叉、重组、遗传漂变、基因流动和环境因素或加剧自然选择过程。变体可能会带来进化上的变化。Throughout this application, a variant or genetic variation refers to any species, group or population or may be seen in the context of individuals in any species, group or population, and may be observed in genes and alleles. Facts that lead to genetic variation may include, but are not limited to, genetic mutation, crossover, recombination, genetic drift, gene flow, and environmental factors or exacerbate natural selection processes. Variants may bring about evolutionary changes. 进一步地，术语单核苷酸变体(SNV)和单核苷酸多态性(SNP)在本文中等同地使用。Further, the terms single nucleotide variant (SNV) and single nucleotide polymorphism (SNP) are used equivalently herein. 上述试剂盒不需要进行多次测定和测试，并且因此是高度成本有效的。此外，试剂盒防止样品混淆，由此提高临床安全，防止浪费时间和试剂，并且因此提供时间和成本方面的节省。在设备中使用的试剂盒可以使用易于使用的图形用户界面进行操作，并且整个试剂盒和方法易于在临床实验室中实施。试剂盒在计算硬件上执行软件产品，使计算硬件系统地调用一种或多种算法来处理遗传DNA读数，从而确保对不同变体类型的连贯分析；计算硬件可以是当代膝上型计算机、计算工作站或类似物(例如，当代四核处理器计算机，其处理器在大约3GHz下运行)。试剂盒还使得能够通过底层算法来识别纯合野生型，以鉴定其中变体的存在，而无需过滤掉此类变体，从而进一步减少遗漏任何临床使用变体的机会。试剂盒可以容易地被设计为专门用于实体的定制临床外显子组测定，以便根据所述实体的应用领域而更有效。例如，在由试剂盒执行的定制临床外显子组测定中有效地捕获了表现为表型(例如疾病)的致病变体。可替代地阐述的，试剂盒使得能够检测、可视化和分析导致个体(目前由于处理来源于一个或多个细胞外显子组的遗传物质的不连贯方法而被忽视)的罕见疾病的多种变体类型，并且分析从此类经处理的遗传物质中获得的遗传DNA读数。The above-described kits do not require multiple assays and tests, and are therefore highly cost-effective. In addition, the kits prevent sample mix-ups, thereby increasing clinical safety, preventing wasting of time and reagents, and thus providing savings in time and cost. The kit used in the device can be operated using an easy-to-use graphical user interface, and the entire kit and method are easy to implement in a clinical laboratory. The kit executes a software product on computing hardware that causes the computing hardware to systematically invoke one or more algorithms to process genetic DNA reads, thereby ensuring coherent analysis of different variant types; the computing hardware may be contemporary laptop computers, computing Workstation or similar (eg, contemporary quad-core processor computers with processors running at about 3GHz). The kit also enables homozygous wild-type to be identified by an underlying algorithm to identify the presence of variants therein without the need to filter out such variants, further reducing the chance of missing any clinically used variants. Kits can easily be designed specifically for an entity's custom clinical exome assay to be more effective depending on the entity's field of application. For example, pathogenic variants manifesting as phenotypes (eg, disease) are efficiently captured in custom clinical exome assays performed by the kit. Alternatively stated, the kit enables the detection, visualization and analysis of multiple variants that cause rare diseases in individuals (currently overlooked due to incoherent methods of processing genetic material derived from one or more cell exomes) body type, and analyze genetic DNA reads obtained from such processed genetic material. 本公开提供了一种用于设备中的试剂盒。所述试剂盒在操作时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，并且其中所述测定检测来自所述遗传物质的遗传脱氧核糖核酸(DNA)读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)。本文中“试剂盒”是指外显子组捕获试剂盒。具体地，所述试剂盒是用于检测多种变体类型的单一测定外显子组捕获试剂盒。所述试剂盒包含使得能够处理来自于至少一个外显子组的遗传物质的组件，以及软件产品，所述组件被配置成在所述软件产品上操作；例如，所述组件任选地包含，例如，预先制备的板阵列。术语“设备”是指试剂盒是其一部分或试剂盒在其中与设备相关联地操作的机器或系统。在一个实例中，所述设备可以是脱氧核糖核酸(DNA)读数设备，如测序平台。测序平台可以是大型测序仪或紧凑型台式测序仪。试剂盒当在设备中使用时被配置成执行湿实验室测定以获得遗传DNA读数。术语“细胞外显子组”是指受试者的基因组中蛋白质编码基因中的一个或多个外显子的完整序列。根据一个实施例，细胞外显子组是外显子组加(exome+)。外显子组加是指蛋白质编码外显子以及对发病机制有已知贡献的非编码区(例如，已知的剪接修饰位点和/或转录因子结合位点)。基因中的一个或多个外显子的序列被转录，使得外显子保留在mRNA内，而内含子(基因的非编码区)通过mRNA剪接去除并且有助于由此基因编码的最终蛋白质产物。与设备一起使用的试剂盒被配置成处理靶区，如细胞外显子组，以得到遗传物质。对受试者细胞外显子组中的变体(如SNV、插入缺失和CNV)的鉴定可以提供关于受试者可能患有的遗传病症和遗传疾病的信息。The present disclosure provides a kit for use in a device. The kit is operative to perform a wet lab assay, wherein the assay comprises processing genetic material derived from one or more cellular exomes, and wherein the assay detects genetic deoxyribonucleic acid from the genetic material Single nucleotide variants (SNVs), indels and copy number variations (CNVs) in (DNA) reads. 'Kit' herein refers to an exome capture kit. Specifically, the kit is a single assay exome capture kit for detection of multiple variant types. The kit comprises components enabling processing of genetic material from at least one exome, and a software product, the components being configured to operate on the software product; for example, the components optionally comprising, For example, pre-prepared plate arrays. The term 'device' refers to a machine or system of which a kit is a part or in which the kit operates in association with the device. In one example, the device may be a deoxyribonucleic acid (DNA) reading device, such as a sequencing platform. The sequencing platform can be a large sequencer or a compact benchtop sequencer. The kit, when used in the device, is configured to perform wet lab assays to obtain genetic DNA reads. The term 'cellular exome' refers to the complete sequence of one or more exons of a protein-coding gene in a subject's genome. According to one embodiment, the cellular exome is exome plus (exome+). Exome plus refers to protein-coding exons as well as noncoding regions with known contributions to pathogenesis (eg, known splicing modification sites and/or transcription factor binding sites). The sequence of one or more exons in a gene is transcribed such that the exons remain within the mRNA, while the introns (noncoding regions of the gene) are removed by mRNA splicing and contribute to the final protein encoded by this gene product. The kit used with the device is configured to process a target region, such as the exome of a cell, to obtain genetic material. Identification of variants (eg, SNVs, indels, and CNVs) in the exome of a subject's cells can provide information about genetic disorders and diseases that the subject may have. 根据一个实施例，套件在多个阶段中操作。具体地，多个阶段是指四个连续的阶段，如第一选择阶段、第二湿实验室阶段、第三数据处理阶段和第四可视化阶段，所述四个连续的阶段以连接和集成的方式相互同步地工作。第一选择阶段是指使用试剂盒的实体能够根据定制要求从多个特征中选择所关注特征集的选择阶段(即，试剂盒作为可根据特定供应商、实体或最终用户的要求进行配置的定制临床外显子组测定来操作)。第二湿实验室阶段是指遗传物质处理阶段，使用试剂盒根据第一选择阶段中所选的所关注特征集从遗传物质中获得遗传DNA读数。第三数据处理阶段是指数据处理流水线阶段，其中根据在第一选择阶段中所选的所关注特征集处理来自第二数据处理阶段的输出(即遗传DNA读数数据)。第四可视化阶段是指渲染图形用户界面以用于可视化和进一步分析在第三数据处理阶段处理的数据的可视化阶段。According to one embodiment, the kit operates in multiple stages. Specifically, multiple stages refer to four consecutive stages, such as the first selection stage, the second wet lab stage, the third data processing stage, and the fourth visualization stage, which are connected and integrated in a The modes work in sync with each other. The first selection stage refers to the selection stage in which the entity using the kit is able to select the set of features of interest from a number of features according to the customization requirements (i.e. the kit is a customization that can be configured according to the requirements of a specific supplier, entity or end user). clinical exome assay). The second wet lab stage refers to the genetic material processing stage, where the kits are used to obtain genetic DNA reads from the genetic material based on the set of features of interest selected in the first selection stage. The third data processing stage refers to the data processing pipeline stage in which the output from the second data processing stage (ie the genetic DNA read data) is processed according to the set of features of interest selected in the first selection stage. The fourth visualization stage refers to the visualization stage in which the graphical user interface is rendered for visualization and further analysis of the data processed in the third data processing stage. 在第一选择阶段中，向(购买中或任选地购买试剂盒后的)用户提供根据要求选择特征的选项。试剂盒允许数据处理、变体过滤、变体优先级排序和经处理数据(例如报告)的可视化。数据处理特征和可视化特征是可配置的，并且可根据需要提供给试剂盒的所有者。在一个实施方案中，令牌提供对某些所选特征的访问(或激活某些所选特征)。试剂盒允许根据选择来选择的多个特征的实例包含但不限于外显子组测序偏好和多个定制变体鉴定模块。使用试剂盒可配置此类多个特征。在一个实例中，允许用户使用试剂盒来选择全外显子组测序(WES)、浅全基因组测序(sWGS)或其组合(即，WES±sWGS或sWGS±WES)，以及外显子组加分析特征。WES和sWGS使用下一代测序(NGS)来鉴定基因编码区(外显子)中的遗传变体，涵盖致病变体。术语“外显子组加”是指蛋白质编码外显子以及对发病机制有已知贡献的非编码区(例如，已知的剪接修饰位点和/或转录因子结合位点)。因此，外显子组加是用于鉴定具有临床和药物基因组学用途的不同类型的变体(例如，蛋白质截短变体)的更强大工具。In a first selection stage, the user (either during purchase or optionally after purchase of the kit) is presented with the option to select features as required. The kit allows for data processing, variant filtering, variant prioritization, and visualization of processed data (eg, reports). Data processing features and visualization features are configurable and provided to the kit owner as needed. In one embodiment, the token provides access to (or activates) certain selected features. Examples of multiple features that the kit allows for selection upon selection include, but are not limited to, exome sequencing preferences and multiple custom variant identification modules. Such multiple features can be configured using a kit. In one example, the user is allowed to use the kit to select whole exome sequencing (WES), shallow whole genome sequencing (sWGS), or a combination thereof (ie, WES±sWGS or sWGS±WES), and exome plus Analyze features. WES and sWGS use next-generation sequencing (NGS) to identify genetic variants in the coding regions (exons) of genes, including pathogenic variants. The term 'exome plus' refers to protein-coding exons as well as noncoding regions known to contribute to pathogenesis (eg, known splicing modification sites and/or transcription factor binding sites). Therefore, Exome Plus is a more powerful tool for identifying different types of variants (eg, protein truncating variants) with clinical and pharmacogenomics applications. 除了外显子组测序偏好外，还可根据选择来选择(即，可以选择加入或选择退出)以下特征：i)产前模块；ii)早期婴儿型癫痫性脑病(EIEE)神经医学模块；和携带者筛查面板模块。产前模块包含用于鉴定产前测试中的变体的处理的和已知的DNA序列转录物数据集的组合。例如，产前模块包含至少2598种胎儿异常基因转录物。EIEE神经医学模块包含用于鉴定与EIEE相关的变体的处理的和已知的DNA序列转录物数据集的组合。例如，EIEE神经医学模块包含至少5019种癫痫基因哈瓦那转录物特征。EIEE是以癫痫为特征的罕见神经病症。EIEE是严重的进行性综合征，发病较早(例如，通常在一岁之前)，并且一些患有EIEE的儿童在以后的生活中可能继续发展为其它癫痫病症。观察到，在相当大比例的儿童中，癫痫被错误地鉴定为胃肠道病症并且作为胃肠道病症来治疗。已知存在300多种导致EIEE的基因，并且因此神经医学模块提供了对需要覆盖此类基因的相对更广泛和全面的覆盖率(例如，与仅包含这些基因的子集的常规面板相比)。携带者筛查面板模块尝试鉴定生下患上一种或预先选择的一组孟德尔病状(Mendelian condition)的孩子的风险较高的受试者(或夫妇)，由此使得能够考虑替代性的生产选择和早期干预策略。任选地，使用扩展的携带者筛查(ECS)面板模块，其鉴定多种(例如，超过10种)疾病的生殖风险。In addition to exome sequencing preferences, the following features may be selected (i.e., can be opted in or out) by choice: i) prenatal module; ii) early infantile epileptic encephalopathy (EIEE) neuromedical module; and Carrier Screening Panel Module. The prenatal module contains a combination of processed and known DNA sequence transcript datasets for identifying variants in prenatal testing. For example, the prenatal module contains at least 2598 fetal abnormal gene transcripts. The EIEE Neuromedicine Module contains a combination of processed and known DNA sequence transcript datasets for the identification of EIEE-related variants. For example, the EIEE Neuromedicine Module contains at least 5019 epilepsy gene Havana transcript signatures. EIEE is a rare neurological disorder characterized by epilepsy. EIEE is a severe, progressive syndrome with early onset (eg, usually before the age of one year), and some children with EIEE may go on to develop other epileptic disorders later in life. It has been observed that, in a significant proportion of children, epilepsy is incorrectly identified and treated as a gastrointestinal disorder. More than 300 genes that cause EIEE are known to exist, and thus the neuromedical module provides a relatively broader and comprehensive coverage of the genes that need to be covered (e.g., compared to conventional panels that include only a subset of these genes) . The Carrier Screening Panel module attempts to identify subjects (or couples) at higher risk of having children with one or a pre-selected group of Mendelian conditions, thereby enabling consideration of alternative Production options and early intervention strategies. Optionally, an Extended Carrier Screening (ECS) panel module is used that identifies reproductive risk for multiple (eg, more than 10) diseases. 在第二湿实验室阶段，试剂盒允许出于测序的目的在本地提取DNA样品。使用已知的DNA/RNA分离方法从生物受试者中提取DNA样品。从任何生物样品类型中提取DNA的任何方法都应满足的基本标准包含：高效提取、为下游过程(如下一代测序(NGS))提取足够量的DNA/RNA、去除污染物和DNA的质量和纯度。在一个实例中，紫外线吸光度通常用于评估所提取的DNA的纯度。对于纯DNA样品，260nm处的吸光度与280nm处的吸光度的比率为约1.8。受试者的生物样品是指通过在受控环境下采样而优选地非侵入性地采集的实验室样本，即，医学受试者的组织、液体或来源于受试者的其它材料的收集物质。生物样品的实例包含但不限于血液、咽拭子、痰、手术引流液、组织活检、羊水或胎儿样品。In the second wet lab stage, the kit allows for the local extraction of DNA samples for sequencing purposes. DNA samples are extracted from biological subjects using known DNA/RNA isolation methods. The basic criteria that any method of DNA extraction from any biological sample type should meet include: efficient extraction, extraction of sufficient amounts of DNA/RNA for downstream processes such as next-generation sequencing (NGS), removal of contaminants and DNA quality and purity. In one example, UV absorbance is commonly used to assess the purity of extracted DNA. For pure DNA samples, the ratio of absorbance at 260 nm to absorbance at 280 nm is about 1.8. A biological sample of a subject refers to a laboratory sample, preferably non-invasively collected by sampling in a controlled environment, i.e. a collection of tissue, fluid or other material derived from a subject from a medical subject . Examples of biological samples include, but are not limited to, blood, throat swabs, sputum, surgical drainage, tissue biopsies, amniotic fluid, or fetal samples. 根据一个实施例，DNA样品被剪切。剪切是酶剪切(例如，使用限制酶)或声剪切。本领域普通技术人员应当理解，可以使用任何其它DNA片段化方法(如雾化或长DNA分子可能被化学片段化或使用转座元件)，而不限制本公开的范围。剪切后的片段化DNA样品用于制备sWGS(浅-低水平)文库，在序列偏好中选择了sWGS特征的情况下，所述文库并入唯一分子标识符(UMI)和对应样品的索引(即，样品索引)。此外，剪切后的片段化DNA样品也用于WES文库制备，所述文库还包含UMI和样品索引，以防在第一选择阶段中在序列偏好中选择了WES特征。在WES中，通过基因组片段与互补寡核苷酸或“诱饵”的特异性杂交来靶向和富集基因组的蛋白质编码区。然后使用高通量下一代测序(NGS)技术对这些靶向区域进行测序。此后，合并sWGS和WES文库(即，将sWGS与WES文库结合)进行高覆盖率的双末端外显子组测序(这使得能够进行全外显子组加下游分析)。对此类所选文库执行测序。在一个实例中，使用限定数量的碱基对(bp)配对末端读段(短读段)进行测序(例如，使用NGS测序)。在另一个实例中，用长读段测序(即，具有对单一读段中平均超过10kb进行测序的能力)执行测序。According to one embodiment, the DNA sample is sheared. The cleavage is enzymatic cleavage (eg, using restriction enzymes) or sonic cleavage. One of ordinary skill in the art will appreciate that any other DNA fragmentation method (such as nebulization or the possible chemical fragmentation of long DNA molecules or the use of transposable elements) may be used without limiting the scope of the present disclosure. Sheared fragmented DNA samples were used to prepare sWGS (shallow-low level) libraries that incorporated a Unique Molecular Identifier (UMI) and an index of the corresponding sample ( i.e., sample index). In addition, sheared fragmented DNA samples were also used for WES library preparation, which also contained UMI and sample index in case WES features were selected in sequence preference in the first selection stage. In WES, the protein-coding regions of the genome are targeted and enriched by specific hybridization of genomic fragments to complementary oligonucleotides or 'bait'. These targeted regions are then sequenced using high-throughput next-generation sequencing (NGS) technology. Thereafter, the sWGS and WES libraries were combined (ie, the sWGS and WES libraries were combined) for high coverage paired-end exome sequencing (which enabled whole-exome plus downstream analysis). Sequencing is performed on such selected libraries. In one example, sequencing (eg, using NGS sequencing) is performed using a defined number of base pairs (bp) paired-end reads (short reads). In another example, sequencing is performed with long-read sequencing (ie, with the ability to sequence more than 10 kb on average in a single read). 在一个实例中，在NGS中，在DNA区段长度相对较长，例如，超过250个碱基对的一些情况下，片段与通用衔接子(即位于读段末端的小片段已知DNA)连接并且使用衔接子粘接到载玻片(例如，在基于Illumina的测序中)。在一些情况下，例如在外显子组测序中分离出对应于功能性基因的编码区的mRNA转录物。使此类mRNA转录物经受逆转录以获得cDNA片段。根据一个实施例，与设备一起使用的试剂盒被进一步配置成在下一代测序(NGS)过程中同时执行对多个互补脱氧核糖核酸(cDNA)片段分子的测序以产生遗传物质以获得遗传DNA读数。值得注意的是，测序(例如，DNA测序)是确定给定DNA区段中核苷酸序列的过程。在NSG中，测序是使用边合成边测序的并行方式完成的，以产生由数百万个短测序读段构成的并发数据的集合。然后采用计算装置检测每个图像中每个读段位置位点的碱基，然后将所述碱基用于构建序列。由设备获得的序列读数对应于遗传DNA读数数据(即测序数据)。In one example, in NGS, in some cases where DNA segments are relatively long in length, eg, in excess of 250 base pairs, the fragments are ligated with universal adaptors (ie, small fragments of known DNA at the ends of the reads) And attach to slides using adapters (eg, in Illumina-based sequencing). In some cases, mRNA transcripts corresponding to coding regions of functional genes are isolated, eg, in exome sequencing. Such mRNA transcripts are subjected to reverse transcription to obtain cDNA fragments. According to one embodiment, the kit for use with the device is further configured to simultaneously perform sequencing of multiple complementary deoxyribonucleic acid (cDNA) fragment molecules in a next-generation sequencing (NGS) process to generate genetic material to obtain genetic DNA reads . Notably, sequencing (eg, DNA sequencing) is the process of determining the sequence of nucleotides in a given segment of DNA. In NSG, sequencing is done using a parallel sequencing-by-synthesis approach to generate a collection of concurrent data consisting of millions of short sequencing reads. Computing means are then used to detect the bases at each read position site in each image, which are then used to construct the sequence. The sequence reads obtained by the device correspond to genetic DNA read data (ie, sequencing data). 根据一个实施例，试剂盒不需要设置数千个PCR反应。试剂盒允许在单一测定(例如，单一溶液试管)中富集外显子组加区。靶向外显子组加测序允许在一个简单的步骤中并行富集靶区，以评估潜在的疾病相关区和候选基因。将从测序中获得的测序数据上传到基于云的序列分析和可视化平台。在一个实例中，测序数据(即遗传DNA读数数据)以二进制碱基识别(BCL)、FASTQ、二进制比对映射(BAM)、变体识别格式(VCF)或浏览器可扩展数据(BED)格式的形式上传。试剂盒通信地耦接到基于云的序列分析和可视化平台。According to one embodiment, the kit does not require setting up thousands of PCR reactions. The kit allows enrichment of exome plus regions in a single assay (eg, a single solution tube). Targeted exome plus sequencing allows parallel enrichment of target regions in one simple step to assess potential disease-relevant regions and candidate genes. Upload sequencing data obtained from sequencing to a cloud-based sequence analysis and visualization platform. In one example, sequencing data (ie, genetic DNA read data) is in Binary Base Calling (BCL), FASTQ, Binary Alignment Map (BAM), Variant Calling Format (VCF) or Browser Extensible Data (BED) format upload in the form. The kit is communicatively coupled to a cloud-based sequence analysis and visualization platform. 在一个实例中，原始基因组测序读数是指二进制碱基识别(BCL)数据，即直接来自测序仪的原始测序读数。FASTQ格式是基于文本的格式，用于存储碱基识别和对应的质量信息。BAM格式是序列比对格式(SAM)文件的压缩二进制版本，用于表示经比对的序列。VCF格式是文本文件，用于存储基因序列变异(基因的变异)。BED格式提供了灵活的方式来定义在注释跟踪中显示的数据线。使用在第一选择阶段提供对所选模块(即，特征)的访问的所选令牌来上传测序数据。任选地，所选样品跟踪测定(即，根据在第一选择阶段中执行的选择)也在本地运行。在此类情况下，先前执行的样品跟踪测定的输出也会上传到基于云的序列分析和可视化平台中。在一个实例中，样品跟踪测定的输出包含用作标志物以避免样品混淆的SNP数据。In one example, raw genome sequencing reads refer to binary base calling (BCL) data, ie, raw sequencing reads directly from the sequencer. The FASTQ format is a text-based format for storing base calls and corresponding quality information. The BAM format is a compressed binary version of the Sequence Alignment Format (SAM) file used to represent aligned sequences. The VCF format is a text file used to store genetic sequence variants (variations in genes). The BED format provides a flexible way to define the data lines displayed in the annotation trace. Sequencing data is uploaded using the selected token that provides access to the selected modules (ie, features) in the first selection stage. Optionally, the selected sample tracking assay (ie, according to the selection performed in the first selection phase) is also run locally. In such cases, the output of previously performed sample tracking assays is also uploaded into the cloud-based sequence analysis and visualization platform. In one example, the output of the sample tracking assay includes SNP data used as markers to avoid sample confounding. 根据一个实施例，第三数据处理阶段，即，数据处理流水线阶段开始于遗传DNA读数数据(即，测序数据)的上传。在第一选择阶段根据所选特征(例如，模块令牌)触发特定处理流水线。在一个实例中，测序数据的初始比对与参考基因组数据集一起执行。测序数据与例如GRCh38/hg38人类基因组构建组装比对。在一个实例中，检查所有读段在每个位置处都具有高于阈值(例如，大于10)的质量评分。这减少了容易出错的读段的数量，由此改进了比对结果。通过使用比对数据或原始测序数据，生成有质量控制的样品跟踪SNP。SNP和在一些情况下短串联重复序列标志物可能用于遗传样品跟踪以避免样品混淆。进一步地，UMI去重易受在测序数据(即上传的原始测序数据或比对数据)上执行的影响。长DNA分子的DNA片段在其扩增之前包含标识符，被称为唯一分子标识符(UMI)。值得注意的是，UMI是长度在8个到16个碱基对范围内的随机核苷酸序列。在扩增期间，对应于给定片段分子的给定UMI连接到从给定片段分子产生的重复分子中的每个重复分子上。在测序期间，UMI作为单独的一条读段数据被读取。对测序数据(即，上传的原始测序数据或从与参考基因组数据集一起执行的测序数据的初始比对中获得的比对数据)执行UMI去重。作为解复用的结果，UMI序列(或其它条形码，如果有的话)与每个DNA片段分子的实际测序数据(即，正向读段组和反向读段组)分离。According to one embodiment, the third data processing stage, ie, the data processing pipeline stage, begins with the upload of genetic DNA read data (ie, sequencing data). A specific processing pipeline is triggered in the first selection stage according to the selected characteristic (eg, module token). In one example, an initial alignment of sequencing data is performed with a reference genome dataset. Sequencing data is aligned with, eg, the GRCh38/hg38 human genome construct assembly. In one example, all reads are checked to have a quality score above a threshold (eg, greater than 10) at each position. This reduces the number of error-prone reads, thereby improving alignment results. Generate quality-controlled samples to track SNPs by using alignment data or raw sequencing data. SNPs and in some cases short tandem repeat markers may be used for genetic sample tracking to avoid sample confusion. Further, UMI deduplication is susceptible to being performed on sequencing data (ie, uploaded raw sequencing data or alignment data). DNA fragments of long DNA molecules contain an identifier before their amplification, known as a Unique Molecular Identifier (UMI). Notably, UMIs are random nucleotide sequences ranging from 8 to 16 base pairs in length. During amplification, a given UMI corresponding to a given fragment molecule is ligated to each of the repeat molecules generated from the given fragment molecule. During sequencing, UMIs are read as a single piece of read data. UMI deduplication is performed on sequencing data (ie, uploaded raw sequencing data or alignment data obtained from an initial alignment of sequencing data performed with a reference genome dataset). As a result of demultiplexing, the UMI sequences (or other barcodes, if any) are separated from the actual sequencing data (ie, sets of forward and reverse reads) for each DNA fragment molecule. 此外，所述试剂盒可作为处理所述遗传物质的单一测定来执行。试剂盒通常执行单一湿实验室测定来对遗传物质进行处理，以获得遗传DNA读数，所述遗传物质进而用于检测遗传DNA读数中的SNV、插入缺失和CNV。单一测定本身能够检测来自遗传物质的遗传DNA读数中的SNV、插入缺失和CNV。应当理解，当细胞外显子组内的单一DNA碱基被不同的DNA碱基取代时，细胞外显子组中就会发生SNV。例如，如果用“G”替换“A”，则原来的碱基对“A-T”被替换为碱基对“G-T”。在此类情况下，由于有缺陷的碱基对“G-T”，受试者的外显子组中会出现异常。SNV可能导致若干种类型的遗传病症或疾病，如镰状细胞性贫血、β-地中海贫血、囊性纤维化等。值得注意的是，受试者疾病的严重程度和受试者对治疗的反应方式也是遗传变异(如SNV)的表现。例如，载脂蛋白E(APOE)基因中的单碱基变体与较低的阿尔茨海默氏病(Alzheimer′s disease)风险有关；应当理解，UMI去重是指在处理遗传读数数据时去除非生物重复的过程。此外，“插入缺失”是指与受试者的基因组中的碱基(如A、T、C或G)的插入或缺失相关联的小的遗传变异或变体。在一个实例中，插入缺失的长度可以从1个碱基对到10,000个碱基对变化，包含可能相隔多年的插入和删除事件，并且可能以任何方式彼此不相关。值得注意的是，插入缺失可以进一步包含微插入缺失，使得微插入缺失对应于导致长度改变1个到50个碱基对的插入缺失。插入缺失也可能导致若干种类型的遗传病症或疾病，如布卢姆综合征(Bloom syndrome)，这是罕见的常染色体隐性遗传病症，其特征在于受试者身材矮小、易患癌症和基因组不稳定。值得注意的是，布卢姆综合征主要在犹太人口和日本人口中观察到。因此，为了处理犹太人受试者或日本人受试者的遗传DNA读数，靶区可以包含导致布卢姆综合征的基因。此外，CNV是指受试者的基因组中重复的区段，并且基因组中的重复数量在人口中的受试者之间有所不同。CNV是拷贝数变异事件的结果，拷贝数变异事件是影响大量碱基对的重复或缺失事件类型。通常，基因组中DNA序列的差异有助于受试者的独特性。这些差异可能会影响大多数特性，包含对疾病的易感性。由于CNV通常涵盖基因，因此CNV检测在人类疾病和药物反应两者中都具有重要作用。此外，与其它遗传变体(例如，SNP和插入缺失)相比，CNV的大小更大，并且通常可能涉及复杂的重复DNA序列。在某些情况下，CNV还涵盖整个基因，这些基因具有归因于其的特定蛋白质编码功能。出于这些原因，CNV可能更容易被误解，并且与其它遗传变体相比难以被检测到。应当理解，CNV与如遗传疾病等遗传病症有关。在人类基因组中，目前发现大多数CNV是不会直接导致疾病的良性变体。然而，存在CNV影响关键发育基因并且导致罕见疾病，例如智力障碍的若干种情况。某些报告称CNV会导致影响神经系统的神经系统病症，并且有助于帕金森氏病(Parkinson′s Disease)和阿尔茨海默氏病以及神经精神病症，如双相情感障碍和精神分裂症。人口中可能还存在数千种CNV，其由于上文讨论的各种原因和问题而未被检测到。因此，与设备一起使用的试剂盒被配置成处理遗传DNA读数以检测其中的SNV、插入缺失和CNV。随后，对SNV、插入缺失和CNV的准确且全面的检测在决策支持中得到应用，并且促进查明基因组的细胞外显子组中的靶区，所述靶区需要聚焦以用于例如通过执行基因疗法治疗由于特定的检测到的SNV、插入缺失或CNV而被鉴定出的罕见遗传病症。在一些情况下，可以采用某些SNV、插入缺失或CNV来增加法医学中的辨别能力。Furthermore, the kit can be performed as a single assay for processing the genetic material. Kits typically perform a single wet laboratory assay to process genetic material to obtain genetic DNA reads, which in turn are used to detect SNVs, indels, and CNVs in genetic DNA reads. A single assay by itself is capable of detecting SNVs, indels and CNVs in genetic DNA reads from genetic material. It is understood that SNVs occur in the exome of a cell when a single DNA base within the exome of a cell is replaced by a different DNA base. For example, if you replace 'A' with 'G', the original base pair 'A-T' is replaced with the base pair 'G-T'. In such cases, abnormalities occur in the subject's exome due to the defective base pair 'G-T'. SNVs can cause several types of genetic disorders or diseases, such as sickle cell anemia, beta-thalassemia, cystic fibrosis, and others. Notably, the severity of a subject's disease and the way the subject responds to treatment are also manifestations of genetic variation (eg, SNV). For example, single-base variants in the apolipoprotein E (APOE) gene are associated with a lower risk of Alzheimer's disease; it should be understood that UMI deduplication refers to the processing of genetic readout data The process of removing non-biological repeats. Furthermore, 'indels' refer to small genetic variations or variants associated with insertions or deletions of bases (eg, A, T, C, or G) in the genome of a subject. In one example, indels can vary in length from 1 base pair to 10,000 base pairs, contain insertion and deletion events that may be years apart, and may not be related to each other in any way. Notably, an indel may further comprise a micro-indel, such that a micro-indel corresponds to an indel that results in a length change of 1 to 50 base pairs. Indels can also lead to several types of genetic disorders or diseases, such as Bloom syndrome, a rare autosomal recessive disorder characterized by short stature, susceptibility to cancer, and genomic unstable. Notably, Bloom syndrome is mainly observed in the Jewish population and the Japanese population. Thus, to process genetic DNA reads from Jewish subjects or Japanese subjects, the target region may contain the gene that causes Bloom's syndrome. Furthermore, CNVs refer to segments that are repeated in a subject's genome, and the number of repeats in a genome varies among subjects in a population. CNVs are the result of copy number variation events, a type of duplication or deletion event that affects a large number of base pairs. Often, differences in DNA sequences in the genome contribute to a subject's uniqueness. These differences may affect most properties, including susceptibility to disease. Because CNVs often encompass genes, CNV detection has an important role in both human disease and drug response. Furthermore, CNVs are larger in size compared to other genetic variants (eg, SNPs and indels) and often may involve complex repetitive DNA sequences. In some cases, CNVs also encompass entire genes with specific protein-coding functions ascribed to them. For these reasons, CNVs can be more easily misinterpreted and harder to detect than other genetic variants. It is understood that CNVs are associated with genetic disorders such as genetic diseases. In the human genome, most CNVs are currently found to be benign variants that do not directly cause disease. However, there are several conditions in which CNVs affect key developmental genes and lead to rare diseases, such as intellectual disability. Certain reports state that CNV causes neurological disorders affecting the nervous system and contributes to Parkinson's Disease and Alzheimer's disease as well as neuropsychiatric disorders such as bipolar disorder and schizophrenia . There may also be thousands of CNVs in the population that go undetected for the various reasons and problems discussed above. Accordingly, the kits used with the device are configured to process genetic DNA reads to detect SNVs, indels and CNVs therein. Subsequently, accurate and comprehensive detection of SNVs, indels, and CNVs finds application in decision support and facilitates the identification of target regions in the cellular exome of the genome that need to be focused for e.g. by performing Gene therapy treats rare genetic disorders that have been identified due to specific detected SNVs, indels, or CNVs. In some cases, certain SNVs, indels, or CNVs can be employed to increase discrimination in forensics. 更进一步地，所述试剂盒包含软件产品，所述软件产品可在计算硬件上执行以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，术语“软件产品”是指可由计算机或其它数字系统(如计算硬件)执行的任何指令集合或指令集，以便配置计算硬件以执行作为软件产品意图的任务。另外，软件产品旨在涵盖存储在如随机存取存储器(RAM)、硬盘、光盘等存储介质中的指令，并且还旨在涵盖所谓的“固件”，即存储在ROM等上的软件。任选地，软件产品是指软件应用程序和相关联数据。此类软件产品以各种方式组织，例如软件产品包含被组织成文库的软件组件、存储在远程服务器等上的基于互联网的程序、源代码、解释代码、目标代码、直接可执行代码等。应当理解，软件产品任选地调用系统级代码或调用驻留在服务器或其它位置上的其它软件以执行某些功能，如指示计算硬件。术语“计算硬件”是指可操作以响应和处理驱动与设备一起使用的试剂盒的指令的计算元件。任选地，计算硬件包含但不限于微处理器、微控制器、复杂指令集计算(CISC)微处理器、精简指令集(RISC)微处理器、超长指令字(VLIW)微处理器或任何其它类型的处理电路。此外，术语“计算硬件”任选地是指一个或多个单独的硬件、处理装置以及与任选地由其它计算装置共享的计算装置相关联的各种元件。另外，一个或多个单独的计算装置和元件布置在各种架构中，用于在与设备一起使用时响应和处理驱动试剂盒的指令。计算硬件被配置成调用例如，作为一个或多个应用程序存储在计算硬件中的一种或多种算法。术语“算法”是指执行特定任务所需的指令集。本文中，一种或多种算法由计算硬件调用(即，执行)以执行任务，如确定对应于DNA读数数据中的一种或多种DNA序列转录物的变体的出现。通过将遗传DNA读数的部分与一种或多种DNA序列转录物进行比较，调用一种或多种算法来处理遗传DNA读数。需要对遗传DNA读数进行此类处理以确定对应于DNA读数数据中的一个或多个DNA序列转录物的变体的出现。所述一种或多种算法的实例包含但不限于基于回归的算法、基于读段深度数据的算法等。Still further, the kit includes a software product executable on computing hardware to cause the computing hardware to invoke one or more algorithms to perform a combination of the portion of the genetic DNA read with one or more of the algorithms. DNA sequence transcripts are compared to process the genetic DNA reads in order to determine the occurrence of variants corresponding to the one or more DNA sequence transcripts in the DNA read data, the term 'software product' means Any set or set of instructions executable by a computer or other digital system (eg, computing hardware) in order to configure the computing hardware to perform the tasks intended as a software product. In addition, software product is intended to cover instructions stored in storage media such as random access memory (RAM), hard disks, optical discs, etc., and is also intended to cover so-called 'firmware', ie software stored on ROM, etc. Optionally, a software product refers to a software application and associated data. Such software products are organized in various ways, eg, software products contain software components organized into libraries, Internet-based programs stored on remote servers, etc., source code, interpreted code, object code, directly executable code, and the like. It should be understood that a software product optionally invokes system-level code or other software resident on a server or other location to perform certain functions, such as instructing computing hardware. The term 'computing hardware' refers to a computing element operable to respond to and process instructions to drive a kit for use with a device. Optionally, computing hardware includes, but is not limited to, microprocessors, microcontrollers, complex instruction set computing (CISC) microprocessors, reduced instruction set (RISC) microprocessors, very long instruction word (VLIW) microprocessors, or Any other type of processing circuit. Furthermore, the term 'computing hardware' optionally refers to one or more separate hardware, processing devices, and various elements associated with a computing device that is optionally shared by other computing devices. Additionally, one or more separate computing devices and elements are arranged in various architectures for responding to and processing instructions to drive the kit when used with the device. The computing hardware is configured to invoke, for example, one or more algorithms stored in the computing hardware as one or more application programs. The term 'algorithm' refers to the set of instructions required to perform a particular task. Herein, one or more algorithms are invoked (ie, executed) by computing hardware to perform a task, such as determining the occurrence of variants corresponding to one or more DNA sequence transcripts in DNA read data. One or more algorithms are invoked to process genetic DNA reads by comparing portions of the genetic DNA reads to one or more DNA sequence transcripts. Such processing of genetic DNA reads is required to determine the occurrence of variants corresponding to one or more DNA sequence transcripts in the DNA read data. Examples of the one or more algorithms include, but are not limited to, regression-based algorithms, read depth data-based algorithms, and the like. 术语“DNA序列转录物”是指参考基因组序列，如来源于包括关于序列中存在的引起疾病的变体的经验证信息的公开可用的DNA数据库或自我处理的DNA数据库的基因变体序列。此类DNA序列转录物用作比较DNA读数数据以确定对应于DNA读数数据中的一种或多种DNA序列转录物的变体的出现的参考。The term 'DNA sequence transcript' refers to a reference genome sequence, such as a gene variant sequence derived from a publicly available DNA database or a self-processing DNA database that includes verified information about disease-causing variants present in the sequence. Such DNA sequence transcripts are used as a reference for comparing DNA read data to determine the occurrence of variants corresponding to one or more DNA sequence transcripts in the DNA read data. 根据一个实施例，所述一种或多种DNA序列转录物包含共有编码序列(CCDS)转录物。CCDS转录物是在基因组注释中在人类和小鼠参考基因组组装上进行了相同的注释的蛋白质编码区(即，外显子组)的数据集。使用自动化流水线过程生成并且通过多项质量保证检查的相同地被注释的编码区被分配稳定且被跟踪的标识符(CCDS ID)。另外，CCDS转录物数据集通过严格的质量保证测试和手动处理进行维护。遗传DNA读数与CCDS转录物序列的序列比对鉴定任何不同的潜在区。在这些区出现不同类型变体的可能性很大。在一个实例中，使用比对工具(例如，基本局部比对搜索工具(BLAST)的离线或在线版本或其它比对工具)执行序列比对。进一步地，遗传DNA读数(即，查询序列)与其它更多DNA序列转录物(即，靶序列)的序列比对提供了对特定类型的变体和对应的致病表型的透彻理解。通常使用序列覆盖率和序列相似性在查询和靶序列的每次比对中生成比对评分。序列覆盖率百分比和序列相似性指示相同的序列(即，完美匹配)，这进而表示受试者具有导致疾病的遗传变体并且得到确认。此外，执行使用与设备相关联的显示屏上渲染的GUI的分析，以检查遗传变体是显性的还是隐性的，或者遗传变体将导致表型出现的可能性有多大。According to one embodiment, the one or more DNA sequence transcripts comprise consensus coding sequence (CCDS) transcripts. CCDS transcripts are datasets of protein-coding regions (ie, exomes) that are identically annotated on both human and mouse reference genome assemblies in Genome Annotation. Identically annotated coding regions that were generated using an automated pipeline process and passed multiple quality assurance checks were assigned stable and tracked identifiers (CCDS IDs). Additionally, the CCDS transcript dataset is maintained through rigorous quality assurance testing and manual processing. Sequence alignment of the genetic DNA reads to the CCDS transcript sequence identifies any potential regions of difference. There is a high potential for different types of variants to appear in these regions. In one example, sequence alignment is performed using an alignment tool (eg, an offline or online version of the Basic Local Alignment Search Tool (BLAST) or other alignment tool). Further, sequence alignment of genetic DNA reads (ie, query sequences) with other more DNA sequence transcripts (ie, target sequences) provides a thorough understanding of specific types of variants and corresponding pathogenic phenotypes. Alignment scores are typically generated in each alignment of query and target sequences using sequence coverage and sequence similarity. The percent sequence coverage and sequence similarity indicate identical sequences (ie, perfect matches), which in turn indicate that the subject has and is confirmed to have the genetic variant that causes the disease. Additionally, an analysis using a GUI rendered on a display screen associated with the device is performed to examine whether the genetic variant is dominant or recessive, or how likely it is that the genetic variant will result in a phenotype. 根据一个实施例，一种或多种DNA序列转录物包含至少一种病态基因RefSeq转录物。病态基因RefSeq转录物是从公开可用的数据库(被称为病态基因RefSeq转录物数据库)获取的基因序列，所述数据库包括基因和遗传表型的综合集合。值得注意的是，病态基因RefSeq转录物数据库是公开可用的数据库，并且由国家医学图书馆与美国约翰霍普金斯大学的William H.Welch医学图书馆合作维护，并且定期更新。病态基因RefSeq转录物包含关于已知孟德尔病症，如镰状细胞性贫血、戴萨克斯症(Tay-Sachs disease)、囊性纤维化、色素性干皮病等的信息。病态基因RefSeq转录物包括其数据库中至少15,000个基因的信息。通常，病态基因RefSeq转录物专注于建立基因型与表型之间的关系。根据一个实施例，一种或多种DNA序列转录物包含至少4091种病态基因RefSeq转录物。病态基因RefSeq转录物数据库包括提供关于人类基因和遗传表型的信息的至少4091种病态基因RefSeq转录物。如果通过遗传DNA读数与病态基因RefSeq转录物的序列比对生成比对评分(高于指定阈值)，则指示DNA读数的一部分具有导致特定孟德尔病症的变体。According to one embodiment, the one or more DNA sequence transcripts comprise at least one pathological gene RefSeq transcript. Sick Gene RefSeq transcripts are gene sequences obtained from publicly available databases (referred to as the Sick Gene RefSeq Transcript Database) that include comprehensive collections of genes and genetic phenotypes. Notably, the Pathological Gene RefSeq Transcript Database is a publicly available database and is maintained by the National Library of Medicine in collaboration with the William H. Welch Library of Medicine at Johns Hopkins University, USA, and is regularly updated. Sick Gene RefSeq transcripts contain information on known Mendelian disorders such as sickle cell anemia, Tay-Sachs disease, cystic fibrosis, xeroderma pigmentosum, and others. The Pathological Gene RefSeq transcript includes information on at least 15,000 genes in its database. Typically, RefSeq transcripts for diseased genes focus on establishing the relationship between genotype and phenotype. According to one embodiment, the one or more DNA sequence transcripts comprise at least 4091 pathological gene RefSeq transcripts. The Pathological Gene RefSeq Transcript Database includes at least 4091 Pathological Gene RefSeq transcripts that provide information on human genes and genetic phenotypes. If an alignment score (above a specified threshold) is generated from sequence alignment of the genetic DNA reads to the RefSeq transcript of the diseased gene, it indicates that a portion of the DNA reads has a variant that causes a particular Mendelian disorder. 根据一个实施例，所述一种或多种DNA序列转录物包含至少一种胎儿异常基因转录物。胎儿异常基因转录物是从数据库中获取的基因变体序列，所述数据库包括关于人类基因组中存在的导致胎儿异常的变体的信息。胎儿异常是指胎儿中产生的遗传缺陷，所述缺陷可能会影响妊娠，使女性的分娩过程复杂化，并且可能对儿童的生命构成严重威胁。值得注意的是，胎儿异常，也被称为出生缺陷，包含由于胎儿的身体的一个或多个部位的遗传缺陷而可能产生的可能增加儿童发病和死亡的机会的结构变化。此外，胎儿异常可能导致可能会损害儿童的健康、阻碍儿童的发育并且降低儿童的生活质量的缺陷。根据一个实施例，所述一种或多种DNA序列转录物包含至少2598种胎儿异常基因转录物。胎儿异常基因转录物数据库包括提供关于导致缺陷的基因的信息的至少2598种胎儿异常基因转录物，所述缺陷如羊膜带综合征、软骨发育不全、唐氏综合征(Down syndrome)、特纳氏综合征(Turner′s syndrome)、脊柱神经管闭合不全、连体双胞胎、羊水过多、Rh血型不合、胃肠道闭锁等。试剂盒被配置成从数据库中检索任何更新的胎儿异常基因转录物数据，以便在序列比对和分析中仅使用最新的变体数据。如果通过遗传DNA读数与胎儿异常基因转录物的序列比对生成比对评分(高于指定阈值)，则指示DNA读数的一部分具有导致特定胎儿异常的变体。According to one embodiment, the one or more DNA sequence transcripts comprise at least one fetal abnormal gene transcript. A fetal abnormal gene transcript is a gene variant sequence obtained from a database that includes information about variants present in the human genome that cause fetal abnormalities. Fetal abnormalities refer to genetic defects that develop in the fetus that can affect pregnancy, complicate a woman's delivery process, and can pose a serious threat to a child's life. Notably, fetal abnormalities, also known as birth defects, contain structural changes that may arise due to genetic defects in one or more parts of the fetus' body that may increase the chance of morbidity and mortality in children. In addition, fetal abnormalities can lead to defects that can compromise the child's health, hinder the child's development, and reduce the child's quality of life. According to one embodiment, the one or more DNA sequence transcripts comprise at least 2598 fetal abnormal gene transcripts. The fetal abnormal gene transcript database includes at least 2598 fetal abnormal gene transcripts that provide information on genes causing defects such as amniotic band syndrome, achondroplasia, Down syndrome, Turner's Syndrome (Turner's syndrome), spinal neural tube insufficiency, conjoined twins, polyhydramnios, Rh incompatibility, gastrointestinal atresia, etc. The kit is configured to retrieve any updated fetal abnormal gene transcript data from the database so that only the latest variant data is used in the sequence alignment and analysis. If an alignment score (above a specified threshold) is generated from sequence alignment of the genetic DNA reads with fetal abnormal gene transcripts, it is indicative that a portion of the DNA reads has a variant that causes a particular fetal abnormality. 根据一个实施例，所述一种或多种DNA序列转录物包含至少一种癫痫异常基因转录物。癫痫异常转录物是从数据库中获取的基因变体序列，所述数据库包括与癫痫，更具体地，早期婴儿型癫痫性脑病(EIEE)相关的信息。EIEE的原因可能是遗传的，如由于儿童的基因组中的特定类型变体。癫痫异常转录物用作参考以鉴定可能导致儿童EIEE发作的此类变体的存在。可能导致EIEE的变体的鉴定任选地用于胎儿的疾病评估目的。通常，EIEE是与年龄相关的病症，其特征在于在儿童出生后的前三个月内的强直性痉挛发病，与睡眠周期无关，每天可能发生数百次，从而导致儿童精神运动障碍和死亡。因此，此类癫痫异常转录物有助于提供与EIEE相关的信息，所述信息可能有助于检测胎儿中导致EIEE的特定基因变体以进行产前筛查。According to one embodiment, the one or more DNA sequence transcripts comprise at least one epilepsy abnormality gene transcript. Epilepsy abnormal transcripts are gene variant sequences obtained from databases that include information related to epilepsy, and more specifically, early infantile epileptic encephalopathy (EIEE). The cause of EIEE may be genetic, such as due to a specific type of variant in a child's genome. Epilepsy aberrant transcripts were used as a reference to identify the presence of such variants that may lead to seizures in childhood EIEE. The identification of variants likely to cause EIEE is optionally used for disease assessment purposes in the fetus. In general, EIEE is an age-related disorder characterized by the onset of tonic spasms within the first three months of life in children, independent of sleep cycles, and can occur hundreds of times per day, resulting in psychomotor disturbances and death in children. Thus, such epilepsy aberrant transcripts can help provide EIEE-related information that may be useful in the detection of specific genetic variants in fetuses that cause EIEE for prenatal screening. 根据一个实施例，所述一种或多种DNA序列转录物包含至少5019种癫痫基因哈瓦那转录物特征。哈瓦那(人类和脊椎动物分析和注释)转录物强调如可替代地剪接的转录物和假基因等领域。哈瓦那转录物注释考虑并利用各种数据，如CpG岛(即，其中“C-G”序列频率高于其它序列的DNA短序列)、基因预测、重复和基因组特征标记。此外，哈瓦那转录物特征使用的注释软件是分布式注释系统(DAS)感知的，因此哈瓦那转录物能够链接到外部数据源。如果通过遗传DNA读数与癫痫基因哈瓦那转录物序列的序列比对生成比对评分(高于指定阈值)，则指示DNA读数的一部分具有导致特定癫痫病症的变体。According to one embodiment, the one or more DNA sequence transcripts comprise at least 5019 epilepsy gene Havana transcript signatures. Havana (Human and Vertebrate Analysis and Annotation) transcripts highlights areas such as alternatively spliced transcripts and pseudogenes. Havana transcript annotation takes into account and utilizes a variety of data such as CpG islands (ie, short sequences of DNA in which 'C-G' sequences are more frequent than other sequences), gene predictions, repeats, and genomic signatures. In addition, the annotation software used for the Havana transcript signature is Distributed Annotation System (DAS) aware, so the Havana transcript is able to link to external data sources. If an alignment score (above a specified threshold) is generated from a sequence alignment of the genetic DNA reads to the epilepsy gene Havana transcript sequence, it indicates that a portion of the DNA reads has a variant that causes a particular epilepsy disorder. 根据一个实施例，一种或多种DNA序列转录物包含至少一种ACMG 59基因RefSeq转录物。ACMG(即，美国医学遗传学和基因组学学院)59基因RefSeq转录物是包括关于目前59个基因的信息的数据库。所述数据库包括被报告为偶然发现或次要发现的基因的列表。创建ACMG 59基因RefSeq转录物的目的是通过旨在预防或显著降低人类发病率和死亡率的已建立的干预措施来鉴定和管理所选高度外显性遗传病症的风险。According to one embodiment, the one or more DNA sequence transcripts comprise at least one ACMG 59 gene RefSeq transcript. The ACMG (ie, American College of Medical Genetics and Genomics) 59-gene RefSeq transcript is a database that includes information on the current 59 genes. The database includes a list of genes reported as incidental or minor discoveries. The ACMG 59 gene RefSeq transcript was created to identify and manage the risk of selected highly penetrant genetic disorders through established interventions aimed at preventing or significantly reducing human morbidity and mortality. 根据一个实施例，所述一种或多种DNA序列转录物包含DNA序列的可能致病变体和非编码变体(ClinVar)。ClinVar是公开可用的数据库，其包括关于医学上重要的变体与表型之间的关系的信息。ClinVar数据库包含报告人类变异的信息、对此变异与人类健康关系的解释以及支持每种解释的证据。值得注意的是，ClinVar数据库中的每条记录都表示提交者、变异和表型。ClinVar数据库也可以表示对不同基因的中单一等位基因、复合杂合子、单倍型和等位基因组合的解释。应当理解，人类基因组的一部分的大部分是非编码DNA，因此，关于此类非编码DNA中的非编码变体的信息也可以呈现在ClinVar数据库中。如果通过遗传DNA读数与DNA序列的致病变体和非编码变体的序列比对产生比对评分(高于指定阈值)，则指示DNA读数的一部分具有导致特定病症的变体，如Clinvar数据库中变体的对应注释所指示的。According to one embodiment, the one or more DNA sequence transcripts comprise potentially pathogenic variants and non-coding variants (ClinVar) of the DNA sequence. ClinVar is a publicly available database that includes information on the relationship between medically important variants and phenotypes. The ClinVar database contains information on reported human variants, explanations for the relationship of this variant to human health, and evidence to support each explanation. Notably, each record in the ClinVar database represents committer, variant, and phenotype. The ClinVar database can also represent interpretations of single alleles, compound heterozygotes, haplotypes and allelic combinations in different genes. It will be appreciated that a large portion of the human genome is non-coding DNA and therefore information on non-coding variants in such non-coding DNA can also be presented in the ClinVar database. If an alignment score (above a specified threshold) is generated by sequence alignment of genetic DNA reads with pathogenic and noncoding variants of the DNA sequence, it indicates that a portion of the DNA reads has a variant that causes a particular disorder, as in the Clinvar database as indicated by the corresponding annotations for the variants in . 根据一个实施例，所述一种或多种DNA序列转录物包含至少一种样品跟踪SNP。生物样品经历了从DNA提取到测序数据的生成的许多物理步骤，由此使生物样品容易受到不准确处理的影响，例如，由于生物样品的混淆。阳性结果的鉴定是使用直系同源方法完成的，但是使用此类直系同源方法难以鉴定阴性结果。另外，生物样品混淆可能延迟结果的返回，浪费时间和试剂，这会产生财务影响。因此，一种或多种DNA序列转录物包含有助于在整个过程中跟踪生物样品，由此减少混淆的机会的至少一种样品跟踪SNP。According to one embodiment, the one or more DNA sequence transcripts comprise at least one sample tracking SNP. Biological samples undergo many physical steps from DNA extraction to the generation of sequencing data, thereby making biological samples susceptible to inaccurate processing, eg, due to confounding of biological samples. Identification of positive results was accomplished using orthologous methods, but negative results were difficult to identify using such orthologous methods. Additionally, biological sample confusion can delay the return of results and waste time and reagents, which can have financial implications. Thus, the one or more DNA sequence transcripts contain at least one sample tracking SNP that facilitates tracking the biological sample throughout the process, thereby reducing the chance of confounding. 此外，一种或多种算法包含用于在单一测定中同时检测来自遗传物质的遗传DNA读数中的SNV和CNV和任选地插入缺失的算法。可在计算硬件上执行的软件产品使计算硬件调用算法来同时检测作为来自遗传物质的遗传DNA读数中的双重变体的SNV和CNV两者。在遗传DNA读数中检测SNV和CNV使得能够鉴定由于任何检测到的SNV和CNV的组合而可能出现在受试者中的遗传疾病或病症。值得注意的是，SNV和CNV在受试者的整个基因组中共存，因此，SNV影响CNV的基因型测量，并且反之亦然。在一个实施例中，SNV和CNV的组合被检测为相同基因组区中的双重变体。在SNV基因分型期间生成的数据可以用于提取信息，如遗传DNA读数中CNV的位置。此外，一些CNV可以通过使用许多常见的SNV阵列来检测。所述算法被配置成检测遗传DNA读数中的SNV和CNV，以鉴定各种SNV和CNV的组合同时对受试者的影响。In addition, one or more algorithms comprise algorithms for the simultaneous detection of SNVs and CNVs and optionally indels in genetic DNA reads from genetic material in a single assay. A software product executable on computing hardware causes the computing hardware to invoke algorithms to simultaneously detect both SNVs and CNVs that are double variants in genetic DNA reads from genetic material. Detection of SNVs and CNVs in genetic DNA reads enables the identification of genetic diseases or disorders that may be present in a subject due to any combination of detected SNVs and CNVs. Notably, SNVs and CNVs co-exist throughout the genome of subjects, and thus, SNVs affect genotype measurements of CNVs, and vice versa. In one embodiment, the combination of SNV and CNV is detected as a double variant in the same genomic region. Data generated during SNV genotyping can be used to extract information such as the location of CNVs in genetic DNA reads. Furthermore, some CNVs can be detected by using many common SNV arrays. The algorithm is configured to detect SNVs and CNVs in genetic DNA reads to identify the simultaneous effects of various combinations of SNVs and CNVs on a subject. 此外，一种或多种算法包含用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法。在遗传DNA读数的外显子组区中检测到的CNV通常具有临床相关性。存在于受试者的遗传DNA读数的外显子组区中的CNV比存在于内含子区中的CNV的促成发病机制的概率更大。因此，假设存在于外显子组区中的CNV具有临床相关性，因为它们可能与受试者遗传病症和遗传疾病的出现有关。所述算法被配置成对在受试者的遗传DNA读数中检测到的所有CNV中的临床相关CNV进行注释。此外，可能需要鉴定导致特定遗传病症出现的特定类型的CNV。在此类情况下，算法被配置成检测具有临床相关性的特定类型的CNV并且对其进行注释。在一个实例中，临床研究需要鉴定名为“亨廷顿氏病(Huntington′s disease，HD)”的神经系统病症。所述算法然后被配置成检测亨廷顿基因中“CAG”碱基对的三核苷酸重复。“CAG”三核苷酸重复超过36次通常指示可能患上亨廷顿氏病。因此，所述算法对在遗传DNA读数中检测到的所有CNV中“CAG”三核苷酸的重复进行注释，以验证受试者是否可能患上亨廷顿氏。Additionally, one or more algorithms comprise algorithms for annotating clinically relevant CNVs present in the genetic DNA reads from the genetic material. CNVs detected in exome regions of genetic DNA reads are often clinically relevant. CNVs present in exome regions of a subject's genetic DNA reads are more likely to contribute to pathogenesis than CNVs present in intronic regions. Therefore, it is hypothesized that CNVs present in exome regions are of clinical relevance as they may be associated with the emergence of genetic disorders and diseases in subjects. The algorithm is configured to annotate clinically relevant CNVs among all CNVs detected in the subject's genetic DNA reads. In addition, it may be desirable to identify specific types of CNVs that lead to the emergence of specific genetic disorders. In such cases, the algorithm is configured to detect and annotate specific types of CNVs of clinical relevance. In one example, a clinical study entails the identification of a neurological disorder named 'Huntington's disease (HD).' The algorithm was then configured to detect trinucleotide repeats of 'CAG' base pairs in the Huntington gene. More than 36 repeats of the 'CAG' trinucleotide are generally indicative of possible Huntington's disease. Thus, the algorithm annotates repeats of the 'CAG' trinucleotide in all CNVs detected in genetic DNA reads to verify whether a subject is likely to have Huntington's disease. 此外，一种或多种算法包含根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法。遗传DNA读数的一部分中的变体可能导致受试者出现特定表型。所述算法被配置成对遗传DNA读数的此类一个或多个部分进行优先级排序，以鉴定可能有助于所关注特定表型的变体。在一个实例中，与受试者相关联的表型为：眼睛的向上倾斜形状、眼睛虹膜上的白点、扁平的鼻梁、突出的舌头、第五指的单一屈曲沟等。与上述表型相关联的遗传DNA读数的一个或多个部分优先于遗传DNA读数的其它部分。此类优先级排序使得能够容易且快速地检测遗传异常，因为结果仅限于可能导致表型并具有临床相关性的特定变体。所述算法能够鉴定可能与上述表型相关的遗传病症、综合征或疾病。Additionally, one or more algorithms comprise algorithms that prioritize the one or more portions of the genetic DNA reads from the genetic material according to the phenotype associated with the one or more portions. Variants in a portion of the genetic DNA readout may lead to a specific phenotype in a subject. The algorithm is configured to prioritize such one or more portions of genetic DNA reads to identify variants that may contribute to a particular phenotype of interest. In one example, the phenotype associated with the subject is: upward sloping shape of the eye, white spot on the iris of the eye, flat nose bridge, protruding tongue, single flexion groove of the fifth finger, and the like. One or more portions of the genetic DNA reads associated with the above phenotypes take precedence over other portions of the genetic DNA reads. Such prioritization enables easy and rapid detection of genetic abnormalities, as results are limited to specific variants that may contribute to the phenotype and are clinically relevant. The algorithm is capable of identifying genetic disorders, syndromes or diseases that may be associated with the aforementioned phenotypes. 此外，一种或多种算法包含检测药物基因组学(PGx)标志物的变体识别并且单独检测样品跟踪SNP的算法。PGx标志物有助于确定受试者的基因组中存在的各种变体之间的关系，以及由于各种变体而导致的药物对受试者的影响。应当理解，由于每个受试者中存在的变体的差异，每个受试者可能经历来自药物的不同反应。因此，药物基因组学有助于建立变体与药物之间的关系，以便根据受试者的基因组中存在的变体为每个受试者提供个性化和更好的诊断。例如，酶CYP2D6在人体内由基因“CYP2D6”编码。不同人之间产生酶CYP2D6的效率和量变化很大，取决于所述人的基因“CYP2D6”的存在、不存在、拷贝等。一些人能够快速消除由酶CYP2D6代谢的某些药物，而一些人缓慢消除由酶CYP2D6代谢的药物。应当理解，药物的快速代谢导致药物功效降低，而药物的缓慢代谢可能导致毒性。因此，需要相应地为每个人施用和个性化此类药物的剂量。所述算法被配置成检测变体识别，如针对用于药物基因组学(PGx)标志物的基因“CYP2D6”。In addition, the one or more algorithms include algorithms that detect variant identification of pharmacogenomics (PGx) markers and individually detect sample tracking SNPs. PGx markers help to determine the relationship between the various variants present in a subject's genome, and the effect of the drug on the subject due to each variant. It will be appreciated that each subject may experience a different response from a drug due to differences in the variants present in each subject. Therefore, pharmacogenomics helps to establish the relationship between variants and drugs in order to provide individualized and better diagnosis for each subject based on the variants present in the subject's genome. For example, the enzyme CYP2D6 is encoded by the gene 'CYP2D6' in humans. The efficiency and amount of production of the enzyme CYP2D6 varies widely from person to person, depending on the presence, absence, copy, etc. of the gene 'CYP2D6' in said person. Some people are able to quickly eliminate certain drugs metabolized by the enzyme CYP2D6, while some people slowly eliminate drugs metabolized by the enzyme CYP2D6. It will be appreciated that rapid metabolism of a drug results in reduced drug efficacy, while slow metabolism of a drug may lead to toxicity. Therefore, the dosage of such drugs needs to be administered and individualized accordingly for each individual. The algorithm is configured to detect variant recognition, such as for the gene 'CYP2D6' for pharmacogenomics (PGx) markers. 根据一个实施例，所述软件产品包含算法，所述算法当在所述计算硬件上执行时检测所述DNA读数数据中与所述DNA序列转录物相关的重复和缺失中的至少一种，并且其中所述试剂盒用于的所述遗传筛查包含孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用中的至少一种，并且其中使用单细胞测序对所述遗传物质进行处理。算法检测到重复和缺失，如插入缺失，以鉴定遗传病症或与之相关联的遗传疾病。例如，囊性纤维化、布鲁姆综合征等是由于遗传DNA读数中存在插入缺失而引起的。已知的是，不同的致病变体类型在长度方面具有不同的范围。例如，SNP影响单一碱基，并且插入缺失通常影响不到十个碱基，但缺失和重复跨越数百到数千个碱基。因此，与通常比(通过测序获得的)NGS短读段短得多并且因此在单一DNA读段中清晰可见且可鉴定的SNP和插入缺失不同，而超过NGS读段长度的缺失和重复需要对NGS测序数据进行适当分析。因此，基于与DNA序列转录物的比较来检测重复和缺失变体。在一个实施方案中，可能会使用探针。成功结合到基因组DNA的探针有进行扩增的能力，因此经扩增的探针的量与基因组DNA的量成正比(即，使基因组DNA的量减半的缺失将产生经扩增探针的一半，由此指示缺失)。类似地，与其它经扩增探针相比，重复增加(加倍)在特定位点处的基因组DNA的量，并且将在同一时间产生两倍多的经扩增探针。According to one embodiment, the software product comprises an algorithm that, when executed on the computing hardware, detects at least one of duplications and deletions in the DNA read data associated with the DNA sequence transcript, and wherein the genetic screening for which the kit is used comprises at least one of preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology, and wherein single-cell sequencing is used for the genetic material to be processed. Algorithms detect duplications and deletions, such as indels, to identify genetic disorders or genetic diseases associated with them. For example, cystic fibrosis, Bloom syndrome, etc. are caused by the presence of indels in genetic DNA reads. It is known that different pathogenic variant types have different ranges in length. For example, SNPs affect a single base, and indels typically affect less than ten bases, but deletions and duplications span hundreds to thousands of bases. Thus, unlike SNPs and indels, which are typically much shorter than NGS short reads (obtained by sequencing) and are therefore clearly visible and identifiable in a single DNA read, deletions and duplications that exceed the length of an NGS read require Appropriate analysis of NGS sequencing data. Therefore, duplication and deletion variants are detected based on comparison with DNA sequence transcripts. In one embodiment, probes may be used. Probes that successfully bind to genomic DNA have the ability to be amplified, so the amount of amplified probe is proportional to the amount of genomic DNA (i.e. a deletion that halved the amount of genomic DNA would result in amplified probe half of , thus indicating a deletion). Similarly, repeats increase (double) the amount of genomic DNA at a particular site compared to other amplified probes, and will yield twice as many amplified probes at the same time. 根据一个实施例，试剂盒用于孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用。孕前筛查是指允许确定给定个体(父母)是否处于怀上患有遗传病症的孩子的风险的遗传筛查。胚胎植入前遗传筛查是指允许在妊娠前确定通过体外受精(IVF)产生的胚胎中的遗传缺陷的遗传筛查。通常，在胚胎植入前遗传筛查中，对来自假定染色体正常遗传父母的胚胎进行非整倍性筛查。辅助生殖技术与帮助实现妊娠的技术和程序有关。使用单细胞测序对遗传物质进行处理，单细胞测序利用NGS技术提供来自单独细胞的测序数据(例如，外显子组或转录组)，从而提供对单独细胞的功能或基因表达的更好理解。According to one embodiment, the kit is used for preconception screening, preimplantation genetic screening or applications related to assisted reproductive technology. Preconception screening refers to genetic screening that allows to determine whether a given individual (parent) is at risk of having a child with a genetic disorder. Preimplantation genetic screening refers to genetic screening that allows the determination of genetic defects in embryos produced by in vitro fertilization (IVF) prior to pregnancy. Typically, in preimplantation genetic screening, embryos from presumed chromosomally normal parents are screened for aneuploidy. Assisted reproductive technology is concerned with techniques and procedures that help achieve pregnancy. Genetic material is processed using single-cell sequencing, which utilizes NGS technology to provide sequencing data (eg, exomes or transcriptomes) from individual cells, thereby providing a better understanding of the function or gene expression of individual cells. 根据一个实施例，操作试剂盒以检测来自所述遗传物质的遗传DNA读数中的拷贝数变异(CNV)，所述试剂盒进一步包括控制电路系统，所述控制电路系统被配置成：接收所述遗传DNA读数和多个候选CNV检测应用程序；通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述遗传DNA读数的随机选择区中的基线CNV，其中所述基线CNV是所述遗传DNA读数中预先存在的CNV，被认为是真值；组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；通过使用模拟应用程序模拟所述遗传DNA读数的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。According to one embodiment, a kit is operative to detect copy number variation (CNV) in genetic DNA reads from said genetic material, said kit further comprising control circuitry configured to: receive said Genetic DNA reads and a plurality of candidate CNV detection applications; performing a first CNV identification by using each of the plurality of candidate CNV detection applications to obtain randomly selected regions of the genetic DNA reads The baseline CNVs, wherein the baseline CNVs are pre-existing CNVs in the genetic DNA reads, are considered to be the true value; combinations obtained from each candidate CNV detection application in the plurality of candidate CNV detection applications the baseline CNVs to generate a baseline CNV set; generating a simulated genome sequence data set by simulating an artificial CNV set in at least one target region of the genetic DNA reads using a simulation application, wherein the simulated genome sequence data set includes the an artificial CNV set and the baseline CNV set; record the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence data set; by using the plurality of candidates Each candidate CNV detection application in the CNV detection application performs a second CNV identification in the simulated genome sequence dataset; eliminates the CNV identification from the second CNV identification obtained from the simulated genome sequence dataset A baseline CNV set to obtain a new set of CNVs; based on the recorded positions of the artificial CNV set, determine the position of each new CNV in the new CNV set in the simulated genome sequence data set; based on the position of the new CNV set Determining the degree of recall and degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications, based on a comparison with the positions of the artificial CNV set; the combination of the degree of recall and the degree of precision of the copy number variant, selecting one of the plurality of candidate CNV detection applications as the optimal; and identifying the genomic sequence using the selected candidate CNV detection application CNVs in the data. 根据一个实施例，所述试剂盒的所述控制电路系统被进一步配置成通过鉴定以下各项来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度：真阳性，在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下；假阳性，在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下；以及假阴性，在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下。According to one embodiment, the control circuitry of the kit is further configured to determine the CNV detection application associated with each candidate CNV detection application of the plurality of candidate CNV detection applications by identifying Degree of recall: true positives, where the positions of new CNVs in the new set of CNVs match the corresponding positions of artificial CNVs in the set of artificial CNVs; false positives, when the positions of artificial CNVs in the set of artificial CNVs match In the case of a position where a new CNV in the new set of CNVs is detected at a different position; and a false negative, in the case where no new CNV in the set of new CNVs is detected at the position of the artificial CNV in the set of artificial CNVs . 根据一个实施例，所述试剂盒的所述控制电路系统被进一步配置成测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述精确程度。According to one embodiment, the control circuitry of the kit is further configured to measure the degree of overlap between positions of new CNVs in the new set of CNVs and corresponding positions of artificial CNVs in the set of artificial CNVs to determine the degree of accuracy associated with each candidate CNV detection application in the plurality of candidate CNV detection applications. 根据一个实施例，所述试剂盒的所述控制电路系统被进一步配置成基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。According to one embodiment, the control circuitry of the kit is further configured to be based on the measured positions of the new CNVs in the new CNV set and all the artificial CNVs in the artificial CNV set The degree of overlap of the corresponding positions, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to assign the highest degree of accuracy to a first candidate CNV detection application of the plurality of candidate CNV detection applications program. 根据一个实施例，所述试剂盒的所述控制电路系统被进一步配置成设置指定阈值以确定所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的所述重叠程度。According to one embodiment, the control circuitry of the kit is further configured to set a specified threshold to determine the position of the new CNVs in the new CNV set and the artificial CNVs in the artificial CNV set the degree of overlap of the corresponding locations. 根据一个实施例，来自遗传物质的遗传DNA读数是通过全基因组测序、外显子组测序或两者产生的。According to one embodiment, genetic DNA reads from genetic material are generated by whole genome sequencing, exome sequencing, or both. 根据一个实施例，所述试剂盒的所述控制电路系统被进一步配置成生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中所述选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡，其中与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的所述平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。According to one embodiment, the control circuitry of the kit is further configured to generate a precision-recall curve relationship associated with each candidate CNV detection application of the plurality of candidate CNV detection applications, and wherein The selection of one of the plurality of candidate CNV detection applications to be optimal depends on the balance between the degree of recall and the degree of precision, wherein each candidate CNV in the plurality of candidate CNV detection applications The balance between the degree of recall and the degree of precision relevant to the detection application is indicated by the corresponding area under the precision-recall curve in the generated precision-recall curve relationship. 根据一个实施例，所述试剂盒进一步包括湿实验室，所述湿实验室被配置成在所述湿实验室布置中处理所述受试者的生物样品以至少得到所述受试者的所述基因组的所述部分，以便生成所述遗传DNA读数。According to one embodiment, the kit further comprises a wet laboratory configured to process a biological sample of the subject in the wet laboratory arrangement to obtain at least all of the subject's biological samples. said portion of said genome in order to generate said genetic DNA read. 根据一个实施例，所述软件产品包含算法，所述算法当在所述计算硬件上执行时检测存在于与所述DNA序列转录物相关的所述DNA读数数据中的一个或多个基因间变体。由变体引起的一些致病变体位于通过外显子组测定捕获的编码区之外。外显子组测定检测位于编码区之外的变体失败可能导致错过鉴定致病变体事件，由此导致对受此类一种或多种基因间变体影响的基因变体的误解。例如，基因调控元件，如顺式元件或反式元件通常是保守的，但如果由于变体而改变，会导致结合对应的转录因子失败。这进而导致基因转录和蛋白质形成的失败。产生蛋白质失败可能会导致病症。因此，为了避免任何基因变体的误解或遗漏，还基于与相关DNA序列转录物的序列比对来检测DNA读数数据中存在的基因间变体。如果发现基因间变体的相同匹配(或高于指定相似性阈值(例如，90％相似性))，则确认受试者具有特定基因间变体。According to one embodiment, the software product comprises an algorithm that, when executed on the computing hardware, detects one or more intergenic variants present in the DNA read data associated with the DNA sequence transcript body. Some of the pathogenic variants caused by the variants are located outside the coding regions captured by exome assays. Failure of exome assays to detect variants located outside the coding region may lead to missed identification of pathogenic variant events, thereby leading to misinterpretation of gene variants affected by such intergenic variant(s). For example, gene regulatory elements such as cis- or trans-elements are often conserved but, if altered due to variants, can lead to failure to bind the corresponding transcription factor. This in turn leads to failure of gene transcription and protein formation. Failure to produce the protein can lead to illness. Therefore, in order to avoid any misunderstanding or omission of gene variants, the presence of intergenic variants in the DNA read data is also detected based on sequence alignments with related DNA sequence transcripts. A subject is confirmed to have a particular intergenic variant if an identical match (or above a specified similarity threshold (eg, 90% similarity)) is found for the intergenic variant. 根据一个实施例，软件产品包含算法，所述算法当在计算硬件上执行时检测异质变体以在大量候选者中识别有助于表型(例如，疾病)的功能上最重要的线粒体变体。mtDNA数据是从测序数据(即，从sWGS和WES数据)中提取的。在一个实例中，使用“MToolBox”工具，所述工具是本领域已知的用于高通量测序中人类线粒体变体的异质性注释和优先级分析的自动化流水线。在一个实例中，映射到mtDNA上的读段被重新比对到核基因组(GRCh38/hg38)上，以丢弃核线粒体序列和扩增产物。According to one embodiment, the software product contains an algorithm that, when executed on computational hardware, detects heterogeneous variants to identify the functionally most important mitochondrial variants that contribute to a phenotype (eg, disease) among a large number of candidates body. mtDNA data were extracted from sequencing data (ie, from sWGS and WES data). In one example, the 'MToolBox' tool, an automated pipeline known in the art for heterogeneity annotation and prioritization of human mitochondrial variants in high-throughput sequencing, is used. In one example, reads mapped to mtDNA were re-aligned to the nuclear genome (GRCh38/hg38) to discard nuclear mitochondrial sequences and amplification products. 根据一个实施例，软件产品包含算法，所述算法当在计算硬件上执行时提供使用图形用户界面(GUI)实施的可视化布置，以可视地传送遗传DNA读数中SNV和CNV的检测结果、对遗传DNA读数中存在的临床相关CNV进行的注释、根据与一个或多个部分相关联的表型对来自遗传物质的遗传DNA读数的一个或多个部分进行的优先级排序以及对药物基因组学(PGx)标志物的变体识别和样品跟踪SNP的检测。可视化布置是指用于结果的可视化表示的一个或多个组件的集合。在一个实例中，可视化布置是膝上型计算机、个人计算机、医疗监测器等。“GUI”是指在可视化布置(如显示屏)上渲染的结构化用户界面元素集。任选地，在可视化布置上渲染的GUI由可由相关联的数字系统执行的任何指令集合或指令集生成。另外，GUI可操作用于与用户交互以传达图形和/或文本信息并且接收来自用户的输入。此外，GUI元素是指在GUI中具有大小和位置的可视对象。用户界面元素可能是可见的，尽管有时用户界面元素可能是隐藏的。用户界面控件被认为是用户界面元素。文本块、标签、文本框、列表框、线和图像窗口、对话框、框架、面板、菜单、按钮、图标等是用户界面元素的实例。除了大小和位置之外，用户界面元素还可以具有其它性质，如边距、间距等。所述算法被配置成与GUI通信以可视地表示检测到的变体、对遗传DNA读数中存在的临床相关CNV进行的注释、根据与一个或多个部分相关联的表型对来自遗传物质的遗传DNA读数的一个或多个部分进行的优先级排序以及对药物基因组学(PGx)标志物的变体识别和样品跟踪SNP的检测。根据另一个实施例，所述算法被配置成与GUI通信以可视地表示DNA读数数据中相对于DNA序列转录物的重复和缺失、DNA读数数据中存在的相对于DNA序列转录物的基因间变体以及通过基因遗传模式进行的组合的SNV和CNV过滤和解释。According to one embodiment, a software product contains an algorithm that, when executed on computing hardware, provides a visual arrangement implemented using a graphical user interface (GUI) to visually communicate the detection results of SNVs and CNVs in genetic DNA reads, to Annotation of clinically relevant CNVs present in genetic DNA reads, prioritization of one or more portions of genetic DNA reads from genetic material based on the phenotype associated with one or more portions, and pharmacogenomics ( Variant identification of PGx) markers and detection of sample tracking SNPs. A visual arrangement refers to a collection of one or more components for a visual representation of a result. In one example, the visualization arrangement is a laptop computer, personal computer, medical monitor, or the like. 'GUI' refers to a structured set of user interface elements rendered on a visual arrangement, such as a display screen. Optionally, the GUI rendered on the visual arrangement is generated by any instruction set or instruction sets executable by the associated digital system. Additionally, the GUI is operable to interact with the user to communicate graphical and/or textual information and to receive input from the user. Furthermore, GUI elements refer to visual objects that have size and position in the GUI. User interface elements may be visible, although sometimes user interface elements may be hidden. User interface controls are considered user interface elements. Text blocks, labels, text boxes, list boxes, line and image windows, dialog boxes, frames, panels, menus, buttons, icons, etc. are examples of user interface elements. In addition to size and position, user interface elements can have other properties, such as margins, spacing, and so on. The algorithm is configured to communicate with the GUI to visually represent detected variants, annotations of clinically relevant CNVs present in genetic DNA reads, pairs derived from genetic material according to phenotypes associated with one or more parts Prioritization of one or more portions of genetic DNA reads and detection of variant calling and sample tracking SNPs for pharmacogenomics (PGx) markers. According to another embodiment, the algorithm is configured to communicate with the GUI to visually represent duplications and deletions in DNA read data relative to DNA sequence transcripts, intergenic relative to DNA sequence transcripts present in DNA read data Variants and combined SNV and CNV filtering and interpretation by genetic inheritance patterns. 根据一个实施例，在多个阶段的第四可视化阶段中，GUI被渲染以基于多个定义的设置与第三数据处理流水线阶段中的检测结果进行通信和交互。多个定义的设置(以下称为预设设置)、知识库和面板以交互方式通过所渲染的GUI(即，可视界面)被选择和应用。换句话说，在GUI上渲染各种数据处理操作的结果以供进一步分析。此外，数据处理是基于通过渲染的可视界面选择和应用的预设设置、知识库和面板执行的。第三数据处理阶段和第四可视化阶段彼此同步执行。在一个实施方案中，多个预设设置中的第一预设设置(预设1)允许预加载主要基因面板和相关联数据(例如，前述产前模块或前述EIEE模块面板)。在主要面板基于预定义规则没有检测到可鉴定的致病变体的情况下，应用多个预设设置中的第二预设设置(预设2)。在第二预设设置中，孟德尔遗传(例如，OMIM或MORBID)数据和HPO数据被预加载并且与预加载的主要基因面板和相关联数据一起渲染。According to one embodiment, in a fourth visualization stage of the plurality of stages, a GUI is rendered to communicate and interact with detection results in the third data processing pipeline stage based on the plurality of defined settings. A number of defined settings (hereafter referred to as presets), knowledge bases, and panels are interactively selected and applied through the rendered GUI (ie, the visual interface). In other words, the results of various data processing operations are rendered on the GUI for further analysis. Furthermore, data processing is performed based on preset settings, knowledge bases and panels selected and applied through the rendered visual interface. The third data processing stage and the fourth visualization stage are executed synchronously with each other. In one embodiment, a first preset of the plurality of presets (Preset 1 ) allows preloading of the primary genetic panel and associated data (eg, the aforementioned prenatal module or the aforementioned EIEE module panel). In the event that the primary panel detects no identifiable pathogenic variants based on predefined rules, a second preset setting of the plurality of preset settings (Preset 2) is applied. In a second preset, Mendelian genetics (eg, OMIM or MORBID) data and HPO data are preloaded and rendered with the preloaded primary gene panel and associated data. 根据一个实施例，所述软件产品包含算法，所述算法当在所述计算硬件上执行时通过基因遗传模式提供组合的SNV和CNV过滤和解释，其中所述基因遗传模式包含存在隐性基因的可能性。基因遗传模式(也被简称为遗传模式(MOI))是指遗传特性或遗传病症从一代传给下一代的方式。例如，遗传模式可以是常染色体显性基因遗传模式、常染色体隐性基因遗传模式、X连锁显性基因遗传模式、X连锁隐性基因遗传模式、多因子基因遗传模式、线粒体基因遗传模式等。组合的SNV和CNV过滤过程任选地通过例如使用基因遗传模式来执行。在一个实例中，某人具有与色盲相关的携带者基因，即，所述人不是色盲，但携带色盲的隐性基因。所述人的基因组中的变体被过滤掉，以鉴定与色盲相关的携带者基因的存在。此类鉴定有助于鉴定所述人的后代出现色盲的概率。在亲代中需要至少一个显性携带者基因才能表现为表型，并且因此过滤有助于避免与后代发展表型的概率相关的任何误解。组合的SNV和CNV过滤过程任选地还包括，例如，选择被识别为存在于遗传DNA读数中的确信变体，以及消除可能已被错误鉴定的变体。此类过滤使得能够准确检测遗传DNA读数中的变体。此外，任选地执行对SNV和CNV的过滤以提取变体子集、组合来自若干个外显子组测定的变体等。与和湿实验室处理和可视化不连贯并且使用单独的系统和装置并且有时甚至操作实体(例如，实验室、诊所、研究中心)进行操作的现有分析方法相比，所公开的试剂盒被设计成作为定制的临床外显子组测定，专门用于根据实体的应用领域更有效的实体，并且使得不仅能够检测，还能够进一步可视化，并且进一步使用单一测定同时分析导致个体的罕见疾病的包含双重变体或三重变体的多种变体类型，由于在处理来源于一个或多个细胞外显子组的遗传物质时采用不连贯的方法，以及对从此类经处理的遗传物质中获得的遗传DNA读数进行单独或不连贯的分析，所述多种变体类型目前被忽略(例如，忽略同一基因组区中的双重变体CNV和SNV)。由于所公开的试剂盒允许在单一测定中同时检测SNV和CNV(即，SNV和CNV的组合)作为来自遗传物质的遗传DNA读数中的双重变体，因此所述试剂盒以集成方式提供了对组合SNV和CNV进行过滤和解释的能力，其中至少通过使用组合的SNV和CNV过滤和解释，此类双重变体的临床意义很容易辨别。进一步地，此类过滤允许鉴定人的后代中临床显著(或相关)表型(例如，遗传病症)的出现概率，这在孕前筛查、胚胎植入前遗传筛查和/或与辅助生殖技术相关的应用中具有实际意义。According to one embodiment, the software product includes an algorithm that, when executed on the computing hardware, provides combined SNV and CNV filtering and interpretation by genetic inheritance patterns that include the presence of recessive genes possibility. A genetic pattern of inheritance (also referred to simply as a pattern of inheritance (MOI)) refers to the way in which an inherited trait or genetic disorder is passed from one generation to the next. For example, the inheritance pattern can be an autosomal dominant gene inheritance pattern, an autosomal recessive gene inheritance pattern, an X-linked dominant gene inheritance pattern, an X-linked recessive gene inheritance pattern, a multifactorial gene inheritance pattern, a mitochondrial gene inheritance pattern, and the like. A combined SNV and CNV filtering process is optionally performed, eg, by using genetic patterns of inheritance. In one example, a person has a carrier gene associated with color blindness, ie, the person is not color blind, but carries a recessive gene for color blindness. Variants in the human genome were filtered to identify the presence of carrier genes associated with color blindness. Such identification helps to identify the probability of color blindness in the offspring of said person. At least one dominant carrier gene is required in the parent to manifest the phenotype, and thus filtering helps to avoid any misunderstandings related to the probability of the offspring developing the phenotype. The combined SNV and CNV filtering process optionally also includes, for example, selection of confident variants identified as being present in genetic DNA reads, and elimination of variants that may have been misidentified. Such filtering enables accurate detection of variants in genetic DNA reads. In addition, filtering of SNVs and CNVs is optionally performed to extract subsets of variants, combine variants from several exome assays, and the like. In contrast to existing analytical methods that are incoherent with wet laboratory processing and visualization and operate using separate systems and devices and sometimes even operating entities (eg, laboratories, clinics, research centers), the disclosed kits are designed Become a customized clinical exome assay, specifically for entities that are more efficient according to their application area, and enable not only detection, but also further visualization, and further simultaneous analysis of rare diseases that cause individuals containing doublets using a single assay Multiple variant types of variants or triple variants due to incoherent methods in the processing of genetic material derived from one or more exomes of a cell, as well as on genetic material obtained from such processed genetic material DNA reads are analyzed individually or disjointly, and the multiple variant types are currently ignored (eg, double variant CNVs and SNVs in the same genomic region are ignored). Since the disclosed kits allow the simultaneous detection of SNVs and CNVs (ie, combinations of SNVs and CNVs) in a single assay as dual variants in genetic DNA reads from genetic material, the kits provide an integrated approach to The ability to combine SNVs and CNVs for filtering and interpretation, where the clinical significance of such double variants is readily discernible, at least by using combined SNV and CNV filtering and interpretation. Further, such filtering allows identification of the probability of occurrence of a clinically significant (or relevant) phenotype (eg, a genetic disorder) in a person's offspring, which is relevant in preconception screening, preimplantation genetic screening and/or in relation to assisted reproductive technology practical application. 根据一个实施例，确定DNA读数数据中变体的出现进一步包括检测遗传DNA读数数据中的短串联重复序列(STR)和VNTR(可变数量串联重复序列)。STR通常是在DNA链上连续重复多次的1个到13个碱基对的单元。任选地，1个到6个重复碱基对形成STR。值得注意的是，STR是人类基因组中的高突变序列。在用于法医学、人口遗传学等各种应用的遗传DNA读数中检测到STR。可以在基因间区以及多种不同基因的非编码区和编码区两者中找到VNTR。由于长且高度多态的串联重复序列引起的疾病是重复扩增疾病。基因组的编码序列中的串联重复序列可能导致有毒或功能失常的蛋白质的产生，而非编码区中的串联重复序列可能导致染色体脆性的产生、染色体脆性所在基因的沉默、转录的调节和翻译、涉及如剪接和细胞结构等过程的蛋白质的隔离等。According to one embodiment, determining the occurrence of the variant in the DNA read data further comprises detecting short tandem repeats (STRs) and VNTRs (variable number tandem repeats) in the genetic DNA read data. STRs are usually units of 1 to 13 base pairs that are repeated multiple times in succession on a DNA strand. Optionally, 1 to 6 repeating base pairs form the STR. Notably, STRs are highly mutated sequences in the human genome. STRs are detected in genetic DNA reads used in various applications such as forensics, population genetics, etc. VNTRs can be found in intergenic regions as well as in both noncoding and coding regions of a variety of different genes. Diseases caused by long and highly polymorphic tandem repeats are repeat expansion diseases. Tandem repeats in coding sequences of the genome may lead to the production of toxic or dysfunctional proteins, while tandem repeats in non-coding regions may lead to the development of chromosomal fragility, silencing of genes responsible for chromosomal fragility, regulation of transcription and translation, involvement of Sequestration of proteins for processes such as splicing and cellular structure. DNA读数数据中变体出现的确定进一步包括检测遗传DNA读数数据中的镶嵌变体。镶嵌现象是指在一个生物体(如受试者)中存在两个或多个发现具有遗传差异的细胞群，并且通常是由于在发展期间获取体细胞变体。通常，体细胞变体在癌细胞中很常见。在一个实施方案中，“MuTect”工具用于鉴定镶嵌变体。在一个实例中，与其它类型的变体相比，父母/受影响的孩子三重数据的队列可能用于此类为低频率变体的镶嵌变体检测。Determination of the occurrence of variants in the DNA read data further includes detecting mosaic variants in the genetic DNA read data. Mosaicism refers to the presence of two or more cell populations found to be genetically different in an organism (eg, a subject), and is usually due to the acquisition of somatic variants during development. Often, somatic variants are common in cancer cells. In one embodiment, the 'MuTect' tool is used to identify mosaic variants. In one example, a cohort of parent/affected child triple data may be used for such mosaic variant detection, which are low frequency variants compared to other types of variants. 根据一个实施例，根据遗传DNA读数数据上对应位点处的变体类型对识别出的不同变体(重复和缺失变体，包含进一步的CNV识别、SNV、插入缺失、STR和VNTR)进行标记。对符合基因遗传模式(MOI)(即，观察到的基因MO1)和家族中的预期MOI的变体进行标记(或注释)。遗传模式(MOI)是遗传特性或病症从一代传给下一代的方式。例如，常染色体显性遗传、常染色体隐性遗传、X连锁显性遗传、X连锁隐性遗传、多因子遗传和线粒体遗传是从一代传给下一代的遗传特性或病症。由于隐性-显性等位基因的各种组合，每种遗传模式都会导致受影响和未受影响的家庭成员的特性模式。According to one embodiment, the different variants identified (duplication and deletion variants, including further CNV identification, SNVs, indels, STRs and VNTRs) are marked according to the variant type at the corresponding site on the genetic DNA read data . Variants matching the gene's pattern of inheritance (MOI) (ie, the observed gene MO1) and the expected MOI in the family are marked (or annotated). Mode of inheritance (MOI) is the way in which an inherited trait or condition is passed from one generation to the next. For example, autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, multifactorial, and mitochondrial inheritance are inherited traits or conditions that are passed from one generation to the next. Each inheritance pattern results in a pattern of traits in affected and unaffected family members due to various combinations of recessive-dominant alleles. 根据一个实施例，软件产品当在计算硬件上执行时确定变体是遗传变体还是从头变体。由父母之一传给后代的变体被称为遗传变体，而由于父母之一的生殖细胞(卵子或精子)中的变体或在早期胚胎发生期间受精卵本身出现的变体而在后代中首次出现的遗传变异被称为从头变体。从头变体可能导致许多严重的早发性遗传病症，如智力残疾、自闭症谱系障碍、发育疾病等。因此，在第三数据处理流水线阶段，检测到的变体被确定为是遗传变体还是从头变体，因为这两种变体的影响在个体中有所不同。According to one embodiment, the software product, when executed on computing hardware, determines whether the variant is a genetic variant or a de novo variant. Variants that are passed from one parent to offspring are called genetic variants, and occur in offspring as a result of a variant in one of the parents' germ cells (egg or sperm) or a variant present in the fertilized egg itself during early embryogenesis Genetic variants that first appear in are called de novo variants. De novo variants can cause many serious early-onset genetic disorders such as intellectual disability, autism spectrum disorders, developmental disorders, and more. Therefore, in the third data processing pipeline stage, the detected variants are determined as genetic or de novo variants, as the effects of these two variants differ among individuals. 根据一个实施方案，将检测到的变体在主要基因面板上进行分类(即，执行变体分层)。此外，基于所关注基因对所有检测到的变体执行变体优先级排序。此外，当所述检测到的变体与从定义基因变异和对应病症的指定数据源获取的预存储变体序列匹配时，自动填充证据代码。例如，在检测到的变体与ACMG提供的变体序列匹配的情况下，会自动填充ACMG证据代码。ACMG表示美国医学遗传学和基因组学学院，其已发布针对报告某些基因的外显子中的偶然发现的建议(通常规定了59个基因)。例如，最近的版本推荐是ACMG SF v2.0(可在PubMed 27854360中获得)，其指示每个基因变异和具有临床意义(例如，可能致病的)的对应病症的综合列表和相关数据。如上文所讨论的，在第三数据处理阶段执行的各种数据处理操作的结果被渲染在GUI(即，可视界面)上以供进一步分析，并且基于预设设置、知识库和通过渲染的可视界面选择和应用的面板执行数据处理。因此，除了第一和第二预设设置之外，可通过GUI选择第三预设设置。第三预设设置与面板无关，并且用于配置可以用于疾病评估的决策支持的报告模板。例如，在可视界面上渲染了携带者筛查面板报告和计算的贝叶斯携带者风险(Bayes carrier risk)。贝叶斯携带者风险是指受试者的孩子受到一种或预选的一组孟德尔病状影响的概率。贝叶斯载体风险是使用贝叶斯定理计算的，在所述定理中，当满足给定数量的预定义条件时，会根据给定条件总数中实际满足多少条件来计算概率评分。满足条件的数量越多，受试者具有将疾病传给孩子的风险(即，处于高贝叶斯携带者风险)的概率就越大。贝叶斯定理被实施为使用状态表来满足的条件，所述状态表定义所述条件并且检查在给定时间满足多少条件以计算贝叶斯携带者风险。According to one embodiment, the detected variants are classified on a major gene panel (ie, variant stratification is performed). Additionally, variant prioritization is performed on all detected variants based on the gene of interest. In addition, evidence codes are automatically populated when the detected variants match pre-stored variant sequences obtained from designated data sources that define genetic variants and corresponding conditions. For example, ACMG evidence codes are automatically populated in cases where a detected variant matches the variant sequence provided by ACMG. ACMG stands for the American College of Medical Genetics and Genomics, which has issued recommendations for reporting incidental findings in the exons of certain genes (59 genes are generally specified). For example, the most recent version recommendation is ACMG SF v2.0 (available in PubMed 27854360), which indicates a comprehensive list and associated data for each gene variant and corresponding conditions of clinical significance (eg, potentially pathogenic). As discussed above, the results of the various data processing operations performed in the third data processing stage are rendered on the GUI (ie, the visual interface) for further analysis, and are based on preset settings, knowledge bases, and A panel of visual interface selection and application performs data processing. Therefore, in addition to the first and second preset settings, a third preset setting can be selected through the GUI. The third preset is panel independent and is used to configure report templates that can be used for decision support for disease assessment. For example, the carrier screening panel reports and calculated Bayes carrier risk are rendered on a visual interface. Bayesian carrier risk is the probability that a subject's child will be affected by one or a preselected set of Mendelian conditions. Bayesian carrier risk is calculated using Bayes' theorem, where a probability score is calculated based on how many of a given total number of conditions are actually met when a given number of predefined conditions are met. The greater the number of conditions met, the greater the probability that the subject is at risk of passing the disease to a child (ie, at high Bayesian carrier risk). Bayes' theorem is implemented as a condition that is satisfied using a state table that defines the condition and checks how many conditions are satisfied at a given time to calculate Bayesian carrier risk. 根据一个实施例，可选择其它研究预设选项用于可视分析。多个已定义设置的第四预设设置可通过GUI选择。第四预设设置允许基于共享等位基因(例如，由多个检测算法共享和检测的变体)执行队列分析和过滤。还可通过GUI选择第五预设设置。第五预设设置允许基于共享等位基因同时执行多个谱系的STR、NTR、SNP连锁分析。According to one embodiment, other study preset options may be selected for visual analysis. A fourth preset of several defined settings is selectable via the GUI. A fourth preset allows cohort analysis and filtering to be performed based on shared alleles (eg, variants shared and detected by multiple detection algorithms). A fifth preset setting can also be selected through the GUI. The fifth preset allows simultaneous STR, NTR, SNP linkage analysis of multiple lineages based on shared alleles. 本公开还涉及如上文所描述的方法。上文所公开的各种实施例和变体加以必要的变更应用于所述方法。The present disclosure also relates to the method as described above. The various embodiments and variants disclosed above apply mutatis mutandis to the method. 根据一个实施例，所述方法的特征在于所述方法用于在多个阶段中实施所述测定，其中在所述多个阶段中的第一选择阶段中，所述方法允许从可使用所述试剂盒进行配置的多个特征中选择一组所关注特征，其中所述多个特征包含外显子组测序偏好和多个自定义变体鉴定模块。According to one embodiment, the method is characterized in that the method is used for carrying out the assay in a plurality of stages, wherein in a first selection stage of the plurality of stages, the method allows the use of the A set of features of interest is selected from a plurality of features configured by the kit, wherein the plurality of features includes exome sequencing preferences and a plurality of custom variant identification modules. 根据一个实施例，所述方法的特征在于所述方法用于在多个阶段中实施所述测定，其中在所述多个阶段中的第二湿实验室阶段中，所述方法允许根据在所述第一选择阶段中所选择的一组所关注特征使用所述试剂盒处理所述遗传物质，以从所述遗传物质中获得所述遗传DNA读数数据，其中所述遗传DNA读数数据对应于测序数据，并且其中所述试剂盒用于孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用中的至少一种，并且其中使用单细胞测序对所述遗传物质进行处理。According to one embodiment, the method is characterized in that the method is used for carrying out the assay in a plurality of stages, wherein in a second wet laboratory stage of the plurality of stages, the method allows according to the A set of features of interest selected in the first selection stage is used to process the genetic material using the kit to obtain the genetic DNA read data from the genetic material, wherein the genetic DNA read data corresponds to sequencing data, and wherein the kit is used for at least one of preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology, and wherein the genetic material is processed using single-cell sequencing. 根据一个实施例，所述方法的特征在于所述方法用于在多个阶段中实施所述测定，其中在所述多个阶段中的第三数据处理流水线阶段中，所述方法允许根据在所述第一选择阶段中所选择的一组所关注特征来确定所述DNA读数数据中变体的出现，其中所述确定所述DNA读数数据中变体的出现进一步包括：According to one embodiment, the method is characterized in that the method is used for carrying out the determination in a plurality of stages, wherein in a third data processing pipeline stage of the plurality of stages, the method allows according to the determining the occurrence of a variant in the DNA read data using a set of features of interest selected in the first selection stage, wherein the determining the occurrence of a variant in the DNA read data further comprises: -根据在所述第一选择阶段中所选择的一组所关注特征来触发特定处理流水线；- triggering a particular processing pipeline according to a set of features of interest selected in said first selection stage; -对所述遗传DNA读数数据执行唯一分子标识符(UMI)解复用；- performing Unique Molecular Identifier (UMI) demultiplexing on said genetic DNA read data; -执行线粒体(mtDNA)流水线以测量所述遗传DNA读数数据中的异质变体；- performing a mitochondrial (mtDNA) pipeline to measure heterogeneous variants in said genetic DNA read data; -检测所述遗传DNA读数数据中的短串联重复序列(STR)和VNTR(可变数量串联重复序列)；- detection of short tandem repeats (STRs) and VNTRs (variable number of tandem repeats) in said genetic DNA read data; -检测所述遗传DNA读数数据中的镶嵌变体；- detecting mosaic variants in said genetic DNA read data; -使用家族中的预期遗传模式(MOI)对检测到的符合基因MOI的变体进行标记；- tagging of detected variants that match the MOI of the gene using the expected mode of inheritance (MOI) in the family; -确定检测到的变体是遗传变体还是从头变体；以及- determine whether the detected variant is a genetic or de novo variant; and -当所述检测到的变体与从定义基因变异和对应病症的指定数据源获取的预存储变体序列匹配时，自动填充证据代码。- Automatically populate evidence codes when said detected variants match pre-stored variant sequences obtained from specified data sources defining genetic variants and corresponding conditions. 根据一个实施例，所述方法的特征进一步在于所述方法用于在多个阶段中实施所述测定，其中在所述多个阶段中的第四可视化阶段中，所述方法允许渲染图形用户界面，以基于多个定义的设置传送所述第三数据处理流水线阶段中的检测的结果并且与所述结果进行交互。According to one embodiment, the method is further characterized in that the method is for carrying out the assay in a plurality of stages, wherein in a fourth visualization stage of the plurality of stages, the method allows rendering of a graphical user interface , to communicate and interact with the results of detections in the third data processing pipeline stage based on a plurality of defined settings. 根据一个实施例，所述对遗传物质进行处理包括以下中的一项、多项或全部：According to one embodiment, the processing of the genetic material includes one, more or all of the following: (a)从取自受试者的样品中提取所述遗传物质；(a) extracting the genetic material from a sample taken from the subject; (b)优选地通过测量所提取的遗传物质的UV吸光度来评估其纯度；(b) assessing the purity of the extracted genetic material, preferably by measuring its UV absorbance; (c)在所述遗传物质为RNA的情况下，对所述RNA进行逆转录以获得cDNA；(c) in the case that the genetic material is RNA, reverse transcription of the RNA to obtain cDNA; (d)在所述遗传物质为DNA或cDNA的情况下，对所述遗传物质进行剪切或消化以获得片段；(d) where the genetic material is DNA or cDNA, shearing or digesting the genetic material to obtain fragments; (e)优选地通过与互补寡核苷酸杂交来富集蛋白质编码区；以及(e) enrichment of protein-coding regions, preferably by hybridization to complementary oligonucleotides; and (f)将在(d)中获得的所述片段连接到衔接子，并且将连接产物粘接到如载玻片等固体载体上。(f) The fragment obtained in (d) is ligated to an adaptor, and the ligation product is attached to a solid support such as a glass slide. 根据一个实施例，所述样品选自组织、活组织检查、胎儿样品和体液，所述体液优选地为血液、咽拭子、痰、外科引流液或羊水。According to one embodiment, the sample is selected from tissue, biopsy, fetal sample and body fluid, preferably blood, throat swab, sputum, surgical drainage fluid or amniotic fluid. 根据一个实施例，所述遗传物质是DNA或RNA，优选地DNA。According to one embodiment, the genetic material is DNA or RNA, preferably DNA. 另一方面，本公开的实施例提供了一种获取和处理基因组序列数据以检测其中的拷贝数变体(CNV)的系统，所述系统包括：In another aspect, embodiments of the present disclosure provide a system for acquiring and processing genomic sequence data to detect copy number variants (CNVs) therein, the system comprising: -被配置成处理受试者的基因组的至少一部分以生成原始基因组序列数据集的设备；以及- a device configured to process at least a portion of a subject's genome to generate a raw genome sequence data set; and -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -从所述设备中获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining the raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in the data storage device from the device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 另一方面，本公开的实施例提供了一种处理原始基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的系统，所述系统包括：In another aspect, embodiments of the present disclosure provide a system for processing a raw genome sequence data set to detect one or more copy number variants (CNVs) therein, the system comprising: -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said data storage device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 另一方面，本公开的实施例提供了一种用于获取和处理基因组序列数据以检测其中的拷贝数变体(CNV)的方法，其中所述方法使用包括设备和计算布置的系统来实施，其中所述方法包括：In another aspect, embodiments of the present disclosure provide a method for acquiring and processing genomic sequence data to detect copy number variants (CNVs) therein, wherein the method is implemented using a system comprising an apparatus and a computing arrangement, wherein the method includes: -通过使用所述设备处理受试者的基因组的至少一部分以生成原始基因组序列数据集；- by processing at least a portion of the subject's genome using the device to generate a raw genome sequence data set; -通过使用所述计算布置的控制电路系统，从所述设备中获取所述原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining from said apparatus said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said computationally arranged data memory means by using said computationally arranged control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating an artificial set of CNVs in at least one target region of said original genome sequence dataset by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 又另一方面，本公开的实施例提供了一种计算机程序产品，其包括其上存储有计算机可读指令的非暂时性计算机可读存储介质，所述计算机可读指令可由包括处理硬件的计算机化装置执行以上述方法。In yet another aspect, embodiments of the present disclosure provide a computer program product comprising a non-transitory computer readable storage medium having computer readable instructions stored thereon, the computer readable instructions being executable by a computer comprising processing hardware The chemical device performs the method described above. 又另一方面，本公开的实施例提供了一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括计算布置的系统来实施，其中所述方法包括：In yet another aspect, embodiments of the present disclosure provide a method for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method uses a The system is implemented, wherein the method includes: -通过使用所述计算布置的控制电路系统，获取原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining a raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in a data memory device of the computing arrangement by using the control circuitry of the computing arrangement; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating an artificial set of CNVs in at least one target region of said original genome sequence dataset by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 本公开提供了获取和处理基因组序列数据以检测CNV的系统和方法。所述系统包括控制电路系统，所述控制电路系统被配置成确定与用于检测基因组序列数据中的CNV的多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度。进一步地，控制电路系统基于与多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度来比较多个候选CNV检测应用程序。控制电路系统基于用于识别所述基因组序列数据中的所述CNV的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优。利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。此类所选候选CNV检测应用程序考虑了由于使用各种捕获测定试剂盒和用于生成基因组序列数据的测序技术类型而引入系统中的偏差的影响。值得注意的是，控制电路系统被配置成针对特定基因组序列数据选择最佳CNV检测应用程序以检测CNV。针对特定基因组序列数据的所选最佳CNV检测应用程序消除了在特定基因组序列数据中引入的偏差的影响，并且由此使得能够有效处理特定基因组序列数据以准确检测其中存在的新CNV。针对每个基因组序列数据的最佳CNV检测应用程序选择允许准确检测每个基因组序列数据中的CNV。因此，获取和处理基因组序列数据的系统可靠地检测任何给定基因组序列数据的CNV。所述系统能够检测导致个体罕见疾病的CNV。例如，一些检测到的CNV可能会导致疾病或异常，如目前由于基因组序列数据的处理和电子分析中的错误而被忽视的亨廷顿氏病。The present disclosure provides systems and methods for acquiring and processing genomic sequence data to detect CNVs. The system includes control circuitry configured to determine a degree of recall associated with each candidate CNV detection application of a plurality of candidate CNV detection applications for detecting CNVs in genomic sequence data and degree of precision. Further, the control circuitry compares the plurality of candidate CNV detection applications based on a degree of recall and a degree of precision associated with each of the plurality of candidate CNV detection applications. Control circuitry selects one of the plurality of candidate CNV detection applications as the optimal based on the combination of the degree of recall and the degree of precision for identifying the CNV in the genomic sequence data. CNVs in the genomic sequence data are identified using a selected candidate CNV detection application. Such selected candidate CNV detection applications take into account the effects of bias introduced into the system due to the use of various capture assay kits and the type of sequencing technology used to generate genomic sequence data. Notably, the control circuitry is configured to select the best CNV detection application for the specific genome sequence data to detect CNVs. The selected optimal CNV detection application for specific genome sequence data removes the effects of biases introduced in specific genome sequence data, and thereby enables efficient processing of specific genome sequence data to accurately detect new CNVs present therein. The selection of optimal CNV detection applications for each genome sequence data allows accurate detection of CNVs in each genome sequence data. Thus, systems that acquire and process genomic sequence data reliably detect CNVs for any given genomic sequence data. The system is capable of detecting CNVs that cause rare diseases in individuals. For example, some detected CNVs may contribute to diseases or abnormalities such as Huntington's disease, which is currently overlooked due to errors in the processing and electronic analysis of genome sequence data. 上述系统获取和处理基因组序列数据集以检测其中的CNV。所述系统包括被配置成处理受试者的基因组的至少一部分以生成原始基因组序列数据集的设备。术语“拷贝数变体”或CNV是指个体的基因组中重复的区段，并且基因组中的重复数量在人口中的个体之间有所不同。“拷贝数变体”是拷贝数变异事件的结果，拷贝数变异事件是影响大量碱基对的重复或缺失事件类型。通常，基因组中DNA序列的差异有助于个体的独特性。这些差异可能会影响大多数特性，包含对疾病的易感性。由于CNV通常涵盖基因，因此CNV检测在人类疾病和药物反应两者中都具有重要作用。此外，与其它遗传变体(例如，SNP)相比，CNV的大小更大，并且通常可能涉及复杂的重复DNA序列。在某些情况下，CNV还涵盖整个基因，这些基因具有归因于其的特定蛋白质编码功能。出于这些原因，CNV可能更容易被误解，并且与其它遗传变体相比难以被检测到。The systems described above acquire and process genomic sequence data sets to detect CNVs therein. The system includes a device configured to process at least a portion of a subject's genome to generate a raw genome sequence data set. The term 'copy number variant' or CNV refers to a segment that is repeated in an individual's genome, and the number of repetitions in a genome varies among individuals in a population. A 'copy number variant' is the result of a copy number variation event, a type of duplication or deletion event affecting a large number of base pairs. Often, differences in DNA sequences in the genome contribute to an individual's uniqueness. These differences may affect most properties, including susceptibility to disease. Because CNVs often encompass genes, CNV detection has an important role in both human disease and drug response. Furthermore, CNVs are larger in size compared to other genetic variants (eg, SNPs) and often may involve complex repetitive DNA sequences. In some cases, CNVs also encompass entire genes with specific protein-coding functions ascribed to them. For these reasons, CNVs can be more easily misinterpreted and harder to detect than other genetic variants. 应当理解，CNV与如遗传疾病等遗传病症有关。在人类基因组中，目前发现大多数CNV是不会直接导致疾病的良性变体。然而，存在CNV影响关键发育基因并且导致罕见疾病。例如，某些报告称CNV会影响神经系统，并且导致帕金森氏病和阿尔茨海默氏病。人口中可能还存在数千种CNV，其由于上文讨论的各种原因和问题而未被检测到。因此，所述系统被配置成处理基因组序列数据集以检测其中的CNV。随后，对CNV的准确且全面的检测在决策支持中得到应用，并且促进查明基因组中的靶区，所述靶区需要聚焦以用于例如通过执行基因疗法治疗由于特定的检测到的CNV而被鉴定出的罕见遗传病症。在一些情况下，可以采用某些CNV来增加法医学中的辨别能力。It is understood that CNVs are associated with genetic disorders such as genetic diseases. In the human genome, most CNVs are currently found to be benign variants that do not directly cause disease. However, there are CNVs that affect key developmental genes and cause rare diseases. For example, some reports state that CNV affects the nervous system and contributes to Parkinson's disease and Alzheimer's disease. There may also be thousands of CNVs in the population that go undetected for the various reasons and problems discussed above. Accordingly, the system is configured to process genomic sequence data sets to detect CNVs therein. Subsequently, accurate and comprehensive detection of CNVs finds application in decision support and facilitates the identification of target regions in the genome that need to be focused for, for example, by performing gene therapy for treatment of disease due to specific detected CNVs Rare genetic disorder identified. In some cases, certain CNVs may be employed to increase discrimination in forensic science. 贯穿本公开，术语“设备”是指被配置成获取和处理受试者(例如，人)的生物样品，具体地，受试者的基因组的一部分的机器或硬件平台。在一个实例中，所述设备可以是脱氧核糖核酸(DNA)读数设备，如测序平台。测序平台可以是大型测序仪或紧凑型台式测序仪。进一步地，贯穿本公开，术语“基因组的一部分”是指具有受试者的给定基因组序列的基因组的段。Throughout this disclosure, the term 'device' refers to a machine or hardware platform configured to acquire and process a biological sample of a subject (eg, a human), in particular, a portion of the subject's genome. In one example, the device may be a deoxyribonucleic acid (DNA) reading device, such as a sequencing platform. The sequencing platform can be a large sequencer or a compact benchtop sequencer. Further, throughout this disclosure, the term 'portion of a genome' refers to a segment of the genome having a given genomic sequence of a subject. 根据一个实施例，所述系统进一步包括湿实验室布置，并且其中所述湿实验室布置被配置成在所述湿实验室布置中处理所述受试者的生物样品以至少得到所述受试者的所述基因组的所述部分，以便生成所述原始基因组序列数据集。如本文所使用的，术语“湿实验窒布置”是指设施、诊所和/或以下的设置：仪器、设备和/或装置，所述仪器、设备和/或装置用于体液样品的提取(侵入性或非侵入性)、采集、处理和分析；遗传物质的收集、处理和分析；遗传物质的扩增、富集和处理；以及从经扩增的遗传物质接收的遗传信息的分析，以得到受试者的基因组的至少一部分，以生成原始基因组序列数据集。本文中，仪器、设备和/或装置可以包含但不限于离心机、ELISA、分光光度计、PCR、RT-PCR、高通量筛查(HTS)系统、下一代测序系统、微阵列系统、超声、基因分析仪、脱氧核糖核酸(DNA)测序仪和SNP分析仪。值得注意的是，执行对生物样品的体外处理以得到受试者的基因组的至少一部分，以生成原始基因组序列数据集。通常，在测序中执行标准流水线过程，以处理从湿实验室布置中的受试者体外提取的生物样品，以制备包括多个互补脱氧核糖核酸(cDNA)片段分子的测序文库。此外，受试者的生物样品是指通过在受控环境下采样而优选地非侵入性地采集的实验室样本，即，医学受试者的组织、液体或来源于受试者的其它材料的收集物质。生物样品的实例包含但不限于血液、咽拭子、痰、手术引流液、组织活检、羊水或胎儿样品。According to one embodiment, the system further comprises a wet lab arrangement, and wherein the wet lab arrangement is configured to process a biological sample of the subject in the wet lab arrangement to obtain at least the subject said portion of said genome of the person in order to generate said raw genome sequence data set. As used herein, the term 'wet laboratory setup' refers to a facility, clinic and/or setting of instruments, equipment and/or devices used for the extraction of bodily fluid samples (invasive invasive or non-invasive), collection, processing, and analysis; collection, processing, and analysis of genetic material; amplification, enrichment, and processing of genetic material; and analysis of genetic information received from amplified genetic material to obtain at least a portion of the subject's genome to generate a raw genome sequence dataset. Herein, instruments, devices and/or devices may include, but are not limited to, centrifuges, ELISAs, spectrophotometers, PCR, RT-PCR, high-throughput screening (HTS) systems, next-generation sequencing systems, microarray systems, ultrasound , genetic analyzers, deoxyribonucleic acid (DNA) sequencers and SNP analyzers. Notably, in vitro processing of the biological sample is performed to obtain at least a portion of the subject's genome to generate a raw genome sequence dataset. Typically, standard pipeline processes are performed in sequencing to process biological samples extracted in vitro from subjects in wet lab settings to prepare sequencing libraries comprising multiple complementary deoxyribonucleic acid (cDNA) fragment molecules. Furthermore, a biological sample of a subject refers to a laboratory sample that is preferably collected non-invasively by sampling in a controlled environment, ie a medical subject's tissue, fluid or other material derived from the subject Collect material. Examples of biological samples include, but are not limited to, blood, throat swabs, sputum, surgical drainage, tissue biopsies, amniotic fluid, or fetal samples. 根据一个实施例，湿实验室布置处理受试者的生物样品以分离DNA(或RNA)，确定其中无细胞DNA(cfDNA)片段的存在，以制备测序文库并且进一步对分离的遗传物质进行测序。术语“无细胞DNA”是指不在细胞内的DNA。本文中，湿实验室布置提取生物样品中存在的无细胞DNA(cfDNA)并且获得DNA片段。在一个实例中，为了执行下一代测序(NGS)，从受试者中分离输入样品，如受试者的DNA的样品。例如，在对血液采样后，从采样的血液中分离出少量DNA。分离的DNA的数量不足以进行测序文库制备。因此，输入样品然后被分割成短区段。这些区段的长度任选地相同，例如，少于250个碱基对，任选地在100个到250个碱基对的范围内。长度任选地还取决于所使用的测序机器的类型或要进行的实验的类型。在DNA区段长度相对较长，例如，超过250个碱基对的一些情况下，片段与通用衔接子(即位于读段末端的小片段已知DNA)连接并且使用衔接子粘接到载玻片(例如，在基于Illumina的测序中)。在一些情况下，例如在外显子组测序中分离出对应于功能性基因的编码区的mRNA转录物。According to one embodiment, a wet lab arrangement processes a subject's biological sample to isolate DNA (or RNA), determine the presence of cell-free DNA (cfDNA) fragments therein, to prepare a sequencing library and further sequence the isolated genetic material. The term 'cell-free DNA' refers to DNA that is not within cells. Herein, a wet laboratory setup extracts cell-free DNA (cfDNA) present in biological samples and obtains DNA fragments. In one example, to perform next generation sequencing (NGS), an input sample, such as a sample of the subject's DNA, is isolated from a subject. For example, after sampling blood, small amounts of DNA are isolated from the sampled blood. The amount of DNA isolated is insufficient for sequencing library preparation. Therefore, the input sample is then segmented into short segments. The lengths of these segments are optionally the same, eg, less than 250 base pairs, optionally in the range of 100 to 250 base pairs. The length optionally also depends on the type of sequencing machine used or the type of experiment to be performed. In some cases where DNA segments are relatively long in length, eg, in excess of 250 base pairs, the fragments are ligated with universal adaptors (ie, small fragments of known DNA at the ends of the reads) and attached to the glass slide using the adaptors Slices (eg, in Illumina-based sequencing). In some cases, mRNA transcripts corresponding to coding regions of functional genes are isolated, eg, in exome sequencing. 根据一个实施例，所述设备被进一步配置成在下一代测序(NGS)过程中同时执行对多个互补脱氧核糖核酸(cDNA)片段分子的测序以生成原始基因组序列数据集。值得注意的是，测序(例如，DNA测序)是确定给定DNA区段中核苷酸序列的过程。下文描述了NGS过程的一个实例。According to one embodiment, the apparatus is further configured to simultaneously perform sequencing of multiple complementary deoxyribonucleic acid (cDNA) fragment molecules in a next-generation sequencing (NGS) process to generate a raw genome sequence dataset. Notably, sequencing (eg, DNA sequencing) is the process of determining the sequence of nucleotides in a given segment of DNA. An example of an NGS process is described below. 在一个实例中，在NGS中，大量的短读段(例如，多个cDNA片段分子)在单一运行中被测序。在制备好测序文库后，进行PCR以扩增每个读段，从而创建具有相同读段的多个拷贝的点。然后通过变性将经扩增的拷贝分离成单链用于后续测序。在NSG中，测序是使用边合成边测序的并行方式完成的，以产生由数百万个短测序读段构成的并发数据的集合。因此，载玻片上覆盖着大量的核苷酸和DNA聚合酶。此类核苷酸被荧光标记，具有独特的碱基颜色(例如，不同的核酸碱基，即，A、T、C和C，颜色不同)。荧光标记的碱基具有终止子，使得一次仅添加一个碱基。由于一次添加一个碱基，这使得能够捕获载玻片的图像。每个读段位置中的荧光信号指示最近添加的特定碱基。然后为下一个循环准备载玻片。终止子被自动移除，从而允许添加下一个碱基，并且荧光信号被移除，从而防止信号污染下一个图像。重复所述过程，一次添加一个核苷酸并且在其之间成像。然后采用计算装置，如计算布置，检测每个图像中每个读段位置位点的碱基，然后将所述碱基用于构建序列。由所述设备获得的序列读数对应于原始基因组序列数据集(或读数)。通常，来源于生物样品的原始基因组序列数据集包含偏差(或随机数据错误)。有益地，本文中所描述的系统提供了显著准确的结果，尽管原始基因组序列数据集中存在偏差。作为NGS的替代方案，长读段测序也可以适用。In one example, in NGS, a large number of short reads (eg, multiple cDNA fragment molecules) are sequenced in a single run. After the sequencing library is prepared, PCR is performed to amplify each read, creating spots with multiple copies of the same read. The amplified copies are then separated into single strands by denaturation for subsequent sequencing. In NSG, sequencing is done using a parallel sequencing-by-synthesis approach to generate a collection of concurrent data consisting of millions of short sequencing reads. Therefore, the slides are covered with a large amount of nucleotides and DNA polymerases. Such nucleotides are fluorescently labeled with unique base colors (eg, different nucleic acid bases, ie, A, T, C, and C, are colored differently). Fluorescently labeled bases have terminators so that only one base is added at a time. This enables the capture of images of the slide as one base is added at a time. The fluorescent signal in each read position indicates the most recent addition of a specific base. Slides are then prepared for the next cycle. The terminator is automatically removed, allowing the next base to be added, and the fluorescent signal is removed, preventing the signal from contaminating the next image. The process is repeated, adding one nucleotide at a time and imaging in between. A computational device, such as a computational arrangement, is then used to detect the bases at each read position site in each image, which are then used to construct the sequence. The sequence reads obtained by the device correspond to the original genome sequence dataset (or reads). Often, raw genome sequence datasets derived from biological samples contain bias (or random data errors). Beneficially, the system described herein provides remarkably accurate results despite bias in the original genome sequence dataset. As an alternative to NGS, long-read sequencing is also applicable. 根据一个实施例，所述设备被配置成执行外显子组测序或全基因组测序(WGS)中的至少一个，以生成原始基因组序列数据集。所述设备是测序平台，用于执行外显子组测序，以生成原始基因组序列数据集。术语“外显子组”是指基因组中蛋白质编码基因中的所有外显子的完整序列。可替代地，取决于用户偏好，可以执行WGS以生成原始基因组序列数据集。在一个实例中，WGS利用大的全基因组(例如，人类基因组)来生成原始测序数据集。任选地，所述设备可能用于执行小的全基因组测序(例如，微生物)、靶向基因测序(扩增子、基因小组)、全转录组测序、使用mRNA测序的基因表达谱或靶向基因表达谱。According to one embodiment, the apparatus is configured to perform at least one of exome sequencing or whole genome sequencing (WGS) to generate a raw genome sequence dataset. The device is a sequencing platform for performing exome sequencing to generate a raw genome sequence dataset. The term 'exome' refers to the complete sequence of all exons in a protein-coding gene in a genome. Alternatively, depending on user preference, WGS can be performed to generate raw genome sequence datasets. In one example, WGS utilizes large whole genomes (eg, the human genome) to generate raw sequencing datasets. Optionally, the device may be used to perform small whole-genome sequencing (eg, microorganisms), targeted gene sequencing (amplicons, panels), whole-transcriptome sequencing, gene expression profiling using mRNA sequencing, or targeted gene expression profiling. 此外，所述系统包括计算布置，所述计算布置包括数据存储器装置和控制电路系统。值得注意的是，术语“计算布置”是指包含可编程和/或非可编程组件的结构和/或硬件模块，所述组件被配置成存储、处理和/或共享生物信息，如与受试者的基因组有关的原始序列数据集。此外，应当理解，计算布置任选地实施为单一硬件计算装置，如服务器，或者以并行或分布式架构操作的多个硬件计算装置。在一个实例中，计算布置任选地包含如数据存储器装置、处理器、显示器、网络接口等组件，以存储、处理和/或与其它计算组件(如用户装置/用户设备)共享信息。计算布置的实例包含但不限于医疗系统、服务器、电子装置、专用计算生物学设备或其它计算装置。任选地，计算布置是机器的一部分(即，集成到设备中)。如本文所使用的，术语“数据存储器装置”是指存储数据的非暂时性计算机可读存储介质。在一个实例中，数据存储器装置是易失性数据存储器。在另一个实例中，数据存储装置是快速存取存储器(例如，固态数据存储器)与持久性存储器(例如，光盘驱动器、磁性硬盘数据存储器)的组合，用于存储当前正在由计算布置使用的数据。数据存储器装置的实例包含但不限于随机存取存储器(RAM)、同步动态随机存取存储器(SDRAM)、动态RAM(DRAM)、双列直插式存储器模块(DIMM)、视频随机存取存储器(VRAM)、图形双倍数据速率(GDDR)RAM、ROM等。Furthermore, the system includes a computing arrangement including a data memory device and control circuitry. Notably, the term 'computing arrangement' refers to a structure and/or hardware module comprising programmable and/or non-programmable components configured to store, process and/or share biological information, such as with a subject The original sequence data set related to the genome of the individual. Furthermore, it should be understood that the computing arrangement is optionally implemented as a single hardware computing device, such as a server, or multiple hardware computing devices operating in a parallel or distributed architecture. In one example, a computing arrangement optionally includes components such as data memory devices, processors, displays, network interfaces, etc., to store, process, and/or share information with other computing components (eg, user devices/user equipment). Examples of computing arrangements include, but are not limited to, medical systems, servers, electronic devices, specialized computational biology equipment, or other computing devices. Optionally, the computing arrangement is part of the machine (ie, integrated into the device). As used herein, the term 'data storage device' refers to a non-transitory computer-readable storage medium that stores data. In one example, the data storage device is volatile data storage. In another example, the data storage device is a combination of fast access memory (eg, solid state data storage) and persistent storage (eg, optical disk drive, magnetic hard disk data storage) for storing data currently being used by the computing arrangement . Examples of data memory devices include, but are not limited to, random access memory (RAM), synchronous dynamic random access memory (SDRAM), dynamic RAM (DRAM), dual inline memory modules (DIMMs), video random access memory ( VRAM), Graphics Double Data Rate (GDDR) RAM, ROM, etc. 此外，术语“控制电路系统”是指可操作以响应和处理驱动上述系统的指令的计算元件。任选地，控制电路系统包含但不限于微处理器、微控制器、复杂指令集计算(CISC)微处理器、专用集成电路(ASIC)、精简指令集(RISC)微处理器、超长指令字(VLIW)微处理器或任何其它类型的处理或控制电路系统。此外，控制电路系统可以指一个或多个单独的处理器、处理装置、作为机器的一部分的处理单元以及与系统相关联的各种元件。任选地，控制电路系统和数据存储器装置彼此通信地耦接。Furthermore, the term 'control circuitry' refers to computing elements operable to respond to and process the instructions that drive the systems described above. Optionally, control circuitry includes, but is not limited to, microprocessors, microcontrollers, complex instruction set computing (CISC) microprocessors, application specific integrated circuits (ASIC), reduced instruction set (RISC) microprocessors, very long instructions Word (VLIW) microprocessor or any other type of processing or control circuitry. Additionally, control circuitry may refer to one or more individual processors, processing devices, processing units that are part of a machine, and various elements associated with the system. Optionally, the control circuitry and the data memory device are communicatively coupled to each other. 此外，控制电路系统被配置成从所述设备中获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序。控制电路系统通信地耦接到所述设备以获取由所述设备生成的原始基因组序列数据集。术语“多个候选CNV检测应用程序”是指可能检测CNV但在精确和召回方面的性能有所不同的不同应用程序。在一个实例中，不同应用程序是不同的软件应用程序、算法或多个可执行代码。多个候选CNV检测应用程序的实例包含但不限于基于回归的CNV检测应用程序、基于读段深度数据的CNV检测应用程序等。CNV检测应用程序的一些实例包含“CANOES”、“DragenTM”、“ExomeDepth”、“Sentieon”等。CANOES是通过使用负二项分布和使用基于回归的方法估计读段序列的方差来检测CNV的CNV检测应用程序，所述基于回归的方法基于给定基因组序列数据集中的所选参考样品。DragenTM是映射、对齐、分类和复制CNV的CNV检测应用程序。ExomeDepth是使用读段深度数据从外显子组测序实验中识别CNV的CNV检测应用程序。Additionally, control circuitry is configured to obtain from the apparatus the raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in the data memory device. Control circuitry is communicatively coupled to the device to obtain a raw genome sequence data set generated by the device. The term 'multiple candidate CNV detection applications' refers to different applications that may detect CNVs but differ in performance in terms of precision and recall. In one example, the different applications are different software applications, algorithms or multiple executable codes. Examples of multiple candidate CNV detection applications include, but are not limited to, regression-based CNV detection applications, read depth data-based CNV detection applications, and the like. Some examples of CNV detection applications include 'CANOES', 'Dragen ™ ', 'ExomeDepth', 'Sentieon', and the like. CANOES is a CNV detection application that detects CNVs by using a negative binomial distribution and estimating the variance of read sequences using regression-based methods based on selected reference samples in a given genomic sequence dataset. Dragen TM is a CNV detection application that maps, aligns, classifies and replicates CNVs. ExomeDepth is a CNV detection application that uses read depth data to identify CNVs from exome sequencing experiments. 不同的CNV检测应用程序作为候选应用程序(即，多个候选CNV检测应用程序)存储在数据存储器装置中，所述数据存储器装置由控制电路系统检索以处理从设备获取的原始基因组序列数据集。在一个实例中，控制电路系统被配置成一次一个地检索存储在数据存储器装置中的多个候选CNV检测应用程序。在另一个实例中，控制电路系统被配置成一次检索多个候选CNV检测应用程序中的所有候选CNV检测应用程序(即，并发/并行处理)，并且然后使用检索到的多个候选CNV检测应用程序中的每个候选CNV检测应用程序来处理原始基因组序列数据集。The different CNV detection applications are stored as candidate applications (ie, multiple candidate CNV detection applications) in a data memory device that is retrieved by the control circuitry to process the raw genome sequence dataset obtained from the device. In one example, the control circuitry is configured to retrieve a plurality of candidate CNV detection applications stored in the data memory device one at a time. In another example, the control circuitry is configured to retrieve all candidate CNV detection applications of the plurality of candidate CNV detection applications at once (ie, concurrent/parallel processing), and then use the retrieved plurality of candidate CNV detection applications Each candidate CNV detection application in the program is used to process the raw genome sequence dataset. 此外，控制电路系统被配置成通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值。本文中使用的术语“CNV识别”是指从原始基因组序列数据集中鉴定拷贝数变体的过程。任选地，CNV识别分多个步骤进行。在第一步骤中，由设备执行外显子组测序或WGS以创建FASTQ格式的文件。FASTQ(也被称为Fastq)是用于存储下一代测序(NGS)数据的常用格式。在第二步骤中，将在第一步骤中获得的序列与参考基因组进行比对，以创建二进制比对映射(BAM)文件格式的文件。在第三步骤中，对来自参考基因组的比对读段的差异进行鉴定。第三步骤促进进一步处理以鉴定原始基因组序列数据集中的拷贝数变体。出于全面检测CNV的目的，第一CNV识别用于原始基因组序列数据集的下游处理。基线CNV是指已知存在于原始基因组序列数据集中并且从多个候选CNV检测应用程序中识别处的天然存在的CNV。由于已知基线CNV存在，因此基线CNV被认为是真值，用于比较多个候选CNV检测应用程序的性能。控制电路系统利用多个候选CNV检测应用程序中的每个候选CNV检测应用程序在原始基因组序列数据集的随机选择区中执行第一CNV识别，以从多个候选CNV检测应用程序中的每个候选CNV检测应用程序获得基线CNV。值得注意的是，从多个候选CNV检测应用程序中的每个候选CNV检测应用程序获得的基线CNV可以相同或可以不同。Furthermore, the control circuitry is configured to perform a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline in a randomly selected region of the raw genome sequence data set CNVs, where the baseline CNVs are pre-existing CNVs in the original genome sequence dataset, are considered ground truths. The term 'CNV identification' as used herein refers to the process of identifying copy number variants from a raw genome sequence data set. Optionally, CNV identification is performed in multiple steps. In the first step, exome sequencing or WGS is performed by the device to create a file in FASTQ format. FASTQ (also known as Fastq) is a common format for storing next-generation sequencing (NGS) data. In the second step, the sequences obtained in the first step are aligned with the reference genome to create a file in the binary alignment map (BAM) file format. In a third step, differences in the aligned reads from the reference genome are identified. The third step facilitates further processing to identify copy number variants in the original genome sequence dataset. For the purpose of comprehensive CNV detection, the first CNV identification was used for downstream processing of the original genome sequence dataset. Baseline CNVs refer to naturally occurring CNVs that are known to be present in the original genome sequence dataset and identified from multiple candidate CNV detection applications. Since baseline CNVs are known to exist, baseline CNVs are considered ground truth for comparing the performance of multiple candidate CNV detection applications. The control circuitry utilizes each of the plurality of candidate CNV detection applications to perform a first CNV identification in a randomly selected region of the raw genome sequence data set to select from each of the plurality of candidate CNV detection applications Candidate CNV detection applications obtain baseline CNVs. Notably, the baseline CNV obtained from each of the multiple candidate CNV detection applications may or may not be the same. 此外，控制电路系统被配置成组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集。从多个候选CNV检测应用程序中的每个候选CNV检测应用程序获得的基线CNV在数量和/或其在原始基因组序列数据集的随机选择区中的相应位置方面可能不同。控制电路系统组合从每个候选CNV检测应用程序获得的结果以形成基线CNV集(即，从所有多个候选CNV检测应用程序获得的基线CNV的集合)，使得每个获得的基线CNV在所述基线CNV集中仅出现一次。例如，从第一候选CNV检测应用程序获得的基线CNV为CNV1、CNV2和CNV3。从第二候选CNV检测应用程序获得的基线CNV为CNV1、CNV2、CNV3和CNV4。从第三候选CNV检测应用程序获得的基线CNV为CNV1和CNV3。控制电路系统组合所获得的基线CNV CNV1、CNV2、CNV3和CNV4，以获得被认为是真值的基线CNV集。Additionally, control circuitry is configured to combine the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set. Baseline CNVs obtained from each of the multiple candidate CNV detection applications may vary in number and/or their corresponding positions in randomly selected regions of the original genome sequence dataset. Control circuitry combines the results obtained from each candidate CNV detection application to form a baseline CNV set (i.e., a set of baseline CNVs obtained from all multiple candidate CNV detection applications) such that each obtained baseline CNV is There was only one occurrence in the baseline CNV set. For example, the baseline CNVs obtained from the first candidate CNV detection application are CNV1, CNV2, and CNV3. The baseline CNVs obtained from the second candidate CNV detection application were CNV1, CNV2, CNV3 and CNV4. The baseline CNVs obtained from the third candidate CNV detection application were CNV1 and CNV3. The control circuitry combines the obtained baseline CNVs CNV1, CNV2, CNV3, and CNV4 to obtain a set of baseline CNVs that are considered ground truth. 此外，控制电路系统被配置成通过使用预存储在数据存储器装置中的模拟应用程序模拟原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集。模拟的基因组序列数据集包括人工CNV集和基线CNV集。原始基因组序列数据集的“靶区”是指在原始基因组序列数据集中用于测序的一个或多个所关注区(例如，焦点基因小组)。参考本公开，靶区可以是其中由于CNV而存在的异常可能导致发病机制的区。例如，靶区可以是对应于原始基因组序列数据集中的外显子的区，即，基因组中的某些所关注编码区。关于受试者的基因组的靶区中存在的一种或多种CNV的信息可能用于决策支持，以便帮助鉴定由于鉴定出的一种或多种CNV导致的受试者的罕见遗传病症的出现。因此，控制电路系统模拟原始基因组序列数据集的至少一个靶区中的人工CNV集，用于鉴定可能导致罕见遗传病症出现的CNV。术语“模拟应用程序”是指被配置成运行和模拟人工CNV集以评估多个候选CNV检测应用程序的框架。控制电路系统利用预存储在数据存储器装置中的模拟应用程序来模拟人工CNV集，使得在原始基因组序列数据集的靶区中生成人工CNV。由于人工CNV集是在原始基因组序列数据集中模拟的，原始基因组序列数据集包括被识别的基线CNVS集合，因此，模拟基因组序列数据集包括由模拟应用程序模拟的人工CNV集和在由控制电路系统进行第一CNV识别期间识别的基线CNV集。值得注意的是，原始基因组序列数据集的靶区可能与原始基因组序列数据集的随机选择区重叠。Furthermore, the control circuitry is configured to generate a simulated genome sequence dataset by simulating the artificial CNV set in at least one target region of the original genome sequence dataset using a simulation application program pre-stored in the data memory device. The simulated genome sequence dataset includes an artificial CNV set and a baseline CNV set. A 'target region' of a raw genome sequence data set refers to one or more regions of interest (eg, focus groups) in the raw genome sequence data set for sequencing. With reference to the present disclosure, a target region may be a region in which an abnormality due to a CNV may lead to pathogenesis. For example, a target region may be a region corresponding to an exon in the original genome sequence data set, ie, some coding region of interest in the genome. Information about the presence of one or more CNVs in a target region of a subject's genome may be used for decision support to help identify the occurrence of a rare genetic disorder in the subject due to the identified one or more CNVs . Thus, the control circuitry mimics an artificial set of CNVs in at least one target region of the original genome sequence dataset for the identification of CNVs that may contribute to the emergence of rare genetic disorders. The term 'simulation application' refers to a framework configured to run and simulate artificial CNV sets to evaluate multiple candidate CNV detection applications. The control circuitry utilizes a simulation application pre-stored in the data memory device to simulate a set of artificial CNVs such that artificial CNVs are generated in target regions of the original genome sequence data set. Since the artificial CNV set is simulated in the original genome sequence dataset, which includes the identified baseline CNVS set, the simulated genome sequence dataset includes the artificial CNV set simulated by the simulation application and the set of artificial CNVs simulated by the simulation application Baseline set of CNVs identified during the first CNV identification. Notably, the target regions of the original genome sequence dataset may overlap with randomly selected regions of the original genome sequence dataset. 任选地，模拟应用程序是“Ximmer”工具。“Ximmer”工具是可自动配置和运行各种CNV检测应用程序的分析流水线。“Ximmer”工具充当可以在测序数据中创建人工CNV的模拟应用程序。“Ximmer”工具可能用作可以结合来自多个CNV检测应用程序的结果并且允许用户检查多个CNV检测应用程序连同相关注释的可视化和处理工具。Optionally, the simulation application is the 'Ximmer' tool. The 'Ximmer' tool is an analysis pipeline that automatically configures and runs various CNV detection applications. The 'Ximmer' tool acts as a simulation application that can create artificial CNVs in sequencing data. The 'Ximmer' tool may serve as a visualization and processing tool that can combine results from multiple CNV detection applications and allow the user to examine multiple CNV detection applications along with associated annotations. 此外，控制电路系统被配置成在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置。模拟基因组序列数据集中每个人工CNV和每个基线CNV的位置由控制电路系统记录，所述控制电路系统用作在稍后阶段测量多个候选CNV检测应用程序的性能的参考。基线CNV集的每个基线CNV的位置是已知的，并且因此可以可靠地将每个基线CNV的位置用作参考。进一步地，在预定义的靶区处模拟人工CNV，所述预定义的靶区的位置对于模拟应用程序是已知的。模拟基因组序列数据集中的人工CNV集中的每个人工CNV和基线CNV集中的每个基线CNV的位置存储在数据库中。值得注意的是，所述数据库是数据存储器装置的一部分。Furthermore, control circuitry is configured to record the location of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset. The location of each artificial CNV and each baseline CNV in the simulated genome sequence dataset was recorded by control circuitry that was used as a reference to measure the performance of multiple candidate CNV detection applications at a later stage. The location of each baseline CNV of the baseline CNV set is known, and thus the location of each baseline CNV can be reliably used as a reference. Further, artificial CNVs are simulated at predefined target regions whose locations are known to the simulation application. The location of each artificial CNV in the artificial CNV set in the simulated genome sequence dataset and each baseline CNV in the baseline CNV set is stored in the database. Notably, the database is part of a data storage device. 此外，控制电路系统被配置成通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别。控制电路系统利用多个候选CNV检测应用程序中的每个候选CNV检测应用程序在模拟基因组序列数据集中执行第二CNV识别以获得CNV，如存在于模拟基因组序列数据集中的基线CNV集和人工CNV集。值得注意的是，从多个候选CNV检测应用程序中的每个候选CNV检测应用程序获得的基线CNV集和人工CNV集可以相同也可以不同。应当理解，在执行第二CNV识别期间识别的CNV可以包括一个或多个基线CNV，所述基线CNV在执行第一CNV识别期间可能未被检测到。应当进一步理解，在执行第二CNV识别期间识别的CNV可以包括不同于存在于人工CNV集中的模拟人工CNV的一个或多个CNV。Additionally, control circuitry is configured to perform a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications. The control circuitry utilizes each of the plurality of candidate CNV detection applications to perform a second CNV identification in the simulated genome sequence dataset to obtain CNVs, such as the baseline CNV set and the artificial CNVs present in the simulated genome sequence dataset set. Notably, the baseline and artificial CNV sets obtained from each of the multiple candidate CNV detection applications can be the same or different. It should be understood that the CNVs identified during the performance of the second CNV identification may include one or more baseline CNVs that may not have been detected during the performance of the first CNV identification. It should be further understood that the CNVs identified during the performance of the second CNV identification may include one or more CNVs different from the simulated artificial CNVs present in the artificial CNV set. 此外，控制电路系统被配置成从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集。从模拟基因组序列数据集中的第二CNV识别获得的新CNV集可以包括人工CNV集和在消除所述基线CNV集之后除了模拟人工CNV之外的一个或多个CNV。Furthermore, control circuitry is configured to eliminate the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs. The new set of CNVs obtained from the identification of the second CNV in the simulated genomic sequence data set may include the set of artificial CNVs and one or more CNVs in addition to the simulated artificial CNVs after eliminating the set of baseline CNVs. 此外，控制电路系统被配置成基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置。将模拟基因组序列数据集中的新CNV集中的新CNV的序列与人工CNV集的每个人工CNV的序列进行比较以确定模拟基因组序列数据集中新CNV集中的新CNV的位置。类似地，执行新CNV集中的每个新CNV的序列与已知位置的每个人工CNV的序列的比较以确定新CNV集的位置。Furthermore, control circuitry is configured to determine the location of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded locations of the artificial CNV set. The sequences of the new CNVs in the new set of CNVs in the simulated genome sequence data set are compared to the sequence of each artificial CNV in the set of artificial CNVs to determine the location of the new CNVs in the new set of CNVs in the simulated genome sequence data set. Similarly, a comparison of the sequence of each new CNV in the new CNV set with the sequence of each artificial CNV of known position is performed to determine the position of the new CNV set. 此外，控制电路系统被配置成基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度。控制电路系统比较多个候选CNV检测应用程序中的每个候选CNV检测应用程序在确定模拟基因组序列数据集中的新CNV集的准确位置方面的性能。进一步地，基于所述性能，控制电路系统确定与多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度。Additionally, control circuitry is configured to determine a CNV detection application associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on the comparison of the position of the new CNV set with the position of the artificial CNV set Recall and precision. The control circuitry compares the performance of each of the plurality of candidate CNV detection applications in determining the exact location of the new set of CNVs in the simulated genome sequence data set. Further, based on the performance, the control circuitry determines a degree of recall and a degree of precision associated with each candidate CNV detection application of the plurality of candidate CNV detection applications. 根据一个实施例，控制电路系统被进一步配置成在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下，通过真阳性鉴定来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度。如果新CNV的位置与模拟基因组序列数据集中人工CNV的对应位置相同(或几乎相同)，则认为检测到的新CNV为真阳性。在一个实例中，候选CNV检测应用程序执行第二CNV识别以获得新CNV。在此类情况下，假设人工CNV的序列可以是模拟基因组序列数据集中位置L1处的“ATTCGAC”。如果新CNV的序列“ATTCGAC”的位置与人工CNV的序列“ATTCGAC”的位置L1匹配，则控制电路系统鉴定出真阳性。According to one embodiment, the control circuitry is further configured to determine, by a true positive identification, a match with the artificial CNV in the new set of CNVs if the position of the new CNV matches the corresponding position of the artificial CNV in the artificial CNV set The recall degree associated with each candidate CNV detection application of the plurality of candidate CNV detection applications. A detected new CNV was considered a true positive if the location of the new CNV was identical (or nearly identical) to the corresponding location of the artificial CNV in the simulated genome sequence dataset. In one example, the candidate CNV detection application performs a second CNV identification to obtain new CNVs. In such cases, it is assumed that the sequence of the artificial CNV may be 'ATTCGAC' at position L1 in the simulated genomic sequence dataset. The control circuitry identifies a true positive if the position of the sequence 'ATTCGAC' of the new CNV matches position L1 of the sequence 'ATTCGAC' of the artificial CNV. 控制电路系统被进一步配置成在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下，通过假阳性鉴定来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度。如果在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置，则认为检测到的新CNV为假阳性。在一个实例中，候选CNV检测应用程序执行第二CNV识别以获得新CNV。在此类情况下，假设人工CNV的序列可以是模拟基因组序列数据集中位置L1处的“TCCGAACTG”。如果在与人工CNV集中的人工CNV的序列“TCCGAACTG”的位置L1不同的位置(例如，位置L2)处检测到具有序列“TCCGAACTG”的新CNV的位置，则控制电路系统鉴定出假阳性。The control circuitry is further configured to determine, by false positive identification, a relationship to the plurality of CNVs in the event that a location of a new CNV in the new set of CNVs is detected at a location different from the location of the artificial CNV in the set of artificial CNVs. The recall degree associated with each candidate CNV detection application in the candidate CNV detection applications. A detected new CNV is considered a false positive if the location of the new CNV in the new set of CNVs is detected at a different location than the location of the artificial CNVs in the set of artificial CNVs. In one example, the candidate CNV detection application performs a second CNV identification to obtain new CNVs. In such cases, it is assumed that the sequence of the artificial CNV may be 'TCCGAACTG' at position L1 in the simulated genomic sequence dataset. The control circuitry identifies a false positive if a position of a new CNV with the sequence 'TCCGAACTG' is detected at a position (eg, position L2) different from position L1 of the sequence 'TCCGAACTG' of the artificial CNVs in the set of artificial CNVs. 控制电路系统被进一步配置成在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下，通过假阴性鉴定来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度。换句话说，如果在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV，则检测到的新CNV被认为是假阴性。应当理解，由候选CNV检测应用程序在模拟基因组序列数据集中检测到的CNV的总数等于与候选CNV检测应用程序相关联的真阳性和假阴性。控制电路系统被进一步配置成确定与具有较多数量的真阳性的候选CNV检测应用程序而不是具有较少数量的真阳性的候选CNV检测应用程序相关联的更高的召回程度。在一个实例中，三个候选CNV检测应用程序A、B和C用于识别基因组序列数据集中的CNV。候选CNV检测应用程序A在基因组序列数据集中鉴定出5个CNV，因此，它被分配了5个真阳性。候选CNV检测应用程序B在基因组序列数据集中鉴定出8个CNV，因此，它被分配了8个真阳性。候选CNV检测应用程序C在基因组序列数据集中鉴定出3个CNV，因此，它被分配了3个真阳性。因此，控制电路系统确定与候选CNV检测应用程序B相关联的召回程度最高，并且控制电路系统确定与候选CNV检测应用程序C相关联的召回程度是三个候选CNV检测应用程序中最低的。The control circuitry is further configured to determine, by false negative identification, a correlation with the plurality of candidate CNV detection applications in the event that no new CNVs in the new set of CNVs are detected at locations of the artificial CNVs in the set of artificial CNVs The recall degree associated with each candidate CNV detection application. In other words, a detected new CNV is considered a false negative if no new CNV in the new CNV set is detected at the location of the artificial CNV in the artificial CNV set. It should be understood that the total number of CNVs detected by the candidate CNV detection application in the simulated genome sequence dataset is equal to the true positives and false negatives associated with the candidate CNV detection application. The control circuitry is further configured to determine a higher degree of recall associated with candidate CNV detection applications having a higher number of true positives than candidate CNV detection applications having a lower number of true positives. In one example, three candidate CNV detection applications A, B, and C were used to identify CNVs in a genome sequence dataset. Candidate CNV detection application A identified 5 CNVs in the genome sequence dataset, therefore, it was assigned 5 true positives. Candidate CNV detection application B identified 8 CNVs in the genome sequence dataset, therefore, it was assigned 8 true positives. Candidate CNV detection application C identified 3 CNVs in the genome sequence dataset, and as such, it was assigned 3 true positives. Accordingly, the control circuitry determines that the degree of recall associated with candidate CNV detection application B is the highest, and the control circuitry determines that the degree of recall associated with candidate CNV detection application C is the lowest of the three candidate CNV detection applications. 根据一个实施例，所述控制电路系统被进一步配置成测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述精确程度。换句话说，与多个候选CNV检测应用程序相关联的精确程度是新CNV的确定位置相对于人工CNV的对应位置的精确度的度量。例如，新CNV集中的检测到的新CNV的序列可以为“AGGTCCAGC”。如果候选CNV检测应用程序检测到具有序列“AGGTCCAGC”的新CNV的位置与具有序列“AGGTCCAGC”的人工CNV的位置精确重叠，则控制电路系统确定与多个候选CNV检测应用程序相关联的精确程度为高。According to one embodiment, the control circuitry is further configured to measure the degree of overlap of the positions of the new CNVs in the new set of CNVs with corresponding positions of the artificial CNVs in the set of artificial CNVs to determine the degree of overlap with the plurality of candidate CNVs The degree of accuracy associated with each candidate CNV detection application in the detection application. In other words, the degree of accuracy associated with multiple candidate CNV detection applications is a measure of the accuracy of the determined locations of new CNVs relative to the corresponding locations of artificial CNVs. For example, the sequence of a detected novel CNV in the novel CNV set may be 'AGGTCCAGC'. If the candidate CNV detection application detects that the location of the new CNV with the sequence 'AGGTCCAGC' exactly overlaps the location of the artificial CNV with the sequence 'AGGTCCAGC', the control circuitry determines the degree of accuracy associated with the multiple candidate CNV detection applications to high. 根据一个实施例，所述控制电路系统被进一步配置成设置指定阈值用于确定所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度。特定阈值是新CNV集中的新CNV的位置与人工CNV集中的人工CNV的对应位置的最小重叠程度的度量，使得如果新CNV的位置的重叠程度大于指定阈值，则称新CNV的位置与人工CNV的对应位置相匹配。任选地，指定阈值50％被设置用于确定新CNV集中的新CNV的位置与人工CNV集中的人工CNV的对应位置的重叠程度。在此类情况下，如果候选CNV检测应用程序检测到新CNV的位置与人工CNV的对应位置的重叠程度为50％(即，50％匹配或重叠)或更多，则称新CNV与人工CNV的对应位置相匹配。According to one embodiment, the control circuitry is further configured to set a specified threshold for determining the degree of overlap of the positions of new CNVs in the new set of CNVs with corresponding positions of artificial CNVs in the set of artificial CNVs. The specific threshold is a measure of the minimum degree of overlap between the position of the new CNV in the new CNV set and the corresponding position of the artificial CNV in the artificial CNV set, such that if the overlapping degree of the position of the new CNV is greater than the specified threshold, the position of the new CNV is said to be the same as the artificial CNV. match the corresponding positions. Optionally, a specified threshold of 50% is set for determining the degree of overlap of the positions of the new CNVs in the new CNV set with the corresponding positions of the artificial CNVs in the artificial CNV set. In such cases, a new CNV is said to be identical to an artificial CNV if the candidate CNV detection application detects a location that overlaps the corresponding location of the artificial CNV by 50% (i.e., 50% match or overlap) or more match the corresponding positions. 根据一个实施例，所述控制电路系统被进一步配置成基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。值得注意的是，候选CNV检测应用程序检测到的重叠程度越大，与之相关联的精确程度就越高。在一个实例中，由第一候选CNV检测应用程序测得的重叠程度为80％，由第二候选CNV检测应用程序测得的重叠程度为67％，并且由第三候选CNV检测应用程序测得的重叠程度为70％。因此，与第一候选CNV检测应用程序相关联的精确程度最高，并且与第二候选CNV检测应用程序相关联的精确程度最低。According to one embodiment, the control circuitry is further configured to be based on a measured overlap of the positions of the new CNVs in the new set of CNVs with the corresponding positions of the artificial CNVs in the set of artificial CNVs degree, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to assign the highest degree of accuracy to a first candidate CNV detection application of the plurality of candidate CNV detection applications. Notably, the greater the degree of overlap detected by the candidate CNV detection application, the higher the degree of precision associated with it. In one example, the degree of overlap measured by the first candidate CNV detection application is 80%, the degree of overlap measured by the second candidate CNV detection application is 67%, and the degree of overlap measured by the third candidate CNV detection application The degree of overlap is 70%. Therefore, the highest degree of accuracy is associated with the first candidate CNV detection application, and the lowest degree of accuracy is associated with the second candidate CNV detection application. 此外，控制电路系统被配置成基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优。多个候选CNV检测应用程序中的候选CNV检测应用程序被选择为最优的，具有最高召回程度和与之相关联的最高精确程度。然而，最优候选CNV检测应用程序也可以基于取决于其在各种应用中的使用的召回程度与精确程度之间的折衷来选择。选择用于特定基因组序列数据的最佳候选CNV检测应用程序以用于识别此基因组序列数据中的拷贝数变体，以提供最优结果，即，促进基因组序列数据中拷贝数变体的最佳识别。Additionally, control circuitry is configured to select one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data as the best. The candidate CNV detection application of the multiple candidate CNV detection applications was selected as the optimal one with the highest recall and the highest precision associated with it. However, the optimal candidate CNV detection application can also be selected based on a trade-off between degree of recall and degree of precision depending on its use in various applications. Select the best candidate CNV detection application for a particular genome sequence data for use in identifying copy number variants in this genome sequence data to provide the best results, i.e., promote the best possible copy number variants in the genome sequence data identify. 根据一个实施例，控制电路系统被进一步配置成生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡。与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。可以对新CNV的检测进行评分并且用于创建精确-召回曲线关系。任选地，精确-召回曲线关系显示为图形精确-召回曲线图。精确-召回曲线关系是每个候选CNV检测应用程序性能的度量。精确-召回曲线关系描绘了与候选CNV检测应用相关联的召回程度和精确程度的变化以及与之相关联的灵敏度测量的变化。利用此类精确-召回曲线关系，精确-召回曲线可以方便且准确地鉴定出最优候选CNV检测应用程序。通过选择具有最大精确-召回曲线下面积的精确-召回曲线来选择最优候选CNV检测应用程序。可替代地，一些需要CNV检测的应用程序可能会优先考虑精确程度而不是召回程度，或反之亦然。因此，最优候选CNV检测应用程序的选择过程是通过基于使用候选CNV检测应用程序的应用程序的精确程度和召回程度的差分加权来执行的。According to one embodiment, the control circuitry is further configured to generate a precision-recall curve relationship associated with each candidate CNV detection application of the plurality of candidate CNV detection applications, and wherein the plurality of candidate CNV detection applications are selected Which one of the detection applications is optimal depends on the balance between the degree of recall and the degree of precision. The balance between the degree of recall and the degree of precision associated with each candidate CNV detection application of the plurality of candidate CNV detection applications is determined by a corresponding precision-recall curve in the generated precision-recall curve relationship Area indicated below. Detection of new CNVs can be scored and used to create a precision-recall curve relationship. Optionally, the precision-recall curve relationship is displayed as a graphical precision-recall curve graph. The precision-recall curve relationship is a measure of the performance of each candidate CNV detection application. The precision-recall curve relationship depicts changes in recall and precision associated with candidate CNV detection applications and changes in sensitivity measures associated with them. Using such precision-recall curve relationships, the precision-recall curve can easily and accurately identify optimal candidate CNV detection applications. The optimal candidate CNV detection application was selected by selecting the precision-recall curve with the largest area under the precision-recall curve. Alternatively, some applications requiring CNV detection may prioritize precision over recall, or vice versa. Therefore, the selection process of the optimal candidate CNV detection application is performed by differential weighting based on the precision and recall of the application using the candidate CNV detection application. 此外，控制电路系统被配置成利用所选候选CNV检测应用程序识别基因组序列数据中的CNV。控制电路系统被配置成利用最优候选CNV检测应用程序准确识别基因组序列数据中的CNV。由系统的控制电路系统对CNV的准确检测提供了决策支持，使得能够识别个体基因组序列数据中的疾病或异常。此外，疾病或异常的识别有助于随后例如，通过执行基因疗法对所鉴定出的疾病或异常的治疗。Additionally, the control circuitry is configured to identify CNVs in the genomic sequence data using the selected candidate CNV detection application. The control circuitry is configured to accurately identify CNVs in the genomic sequence data using the optimal candidate CNV detection application. Accurate detection of CNVs by the system's control circuitry provides decision support, enabling the identification of diseases or abnormalities in individual genomic sequence data. Furthermore, identification of a disease or abnormality facilitates subsequent treatment of the identified disease or abnormality, eg, by performing gene therapy. 本公开还涉及如上文所描述的方法。上文所公开的各种实施例和变体加以必要的变更应用于所述方法。The present disclosure also relates to the method as described above. The various embodiments and variants disclosed above apply mutatis mutandis to the method. 根据一个实施例，所述方法进一步包括由所述控制电路系统通过鉴定以下各项来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度：According to one embodiment, the method further includes determining, by the control circuitry, a degree of recall associated with each candidate CNV detection application of the plurality of candidate CNV detection applications by identifying: -真阳性，在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下；- true positives, where the positions of the new CNVs in the set of new CNVs match the corresponding positions of the artificial CNVs in the set of artificial CNVs; -假阳性，在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下；以及- false positives, where the position of a new CNV in the new set of CNVs is detected at a different position than the position of the artificial CNVs in the set of artificial CNVs; and -假阴性，在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下。- False negatives, where no new CNVs in the new set of CNVs are detected at the positions of the artificial CNVs in the set of artificial CNVs. 根据一个实施例，所述方法进一步包括通过使用所述控制电路系统，测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确程度。According to one embodiment, the method further includes, using the control circuitry, measuring the degree of overlap between the positions of the new CNVs in the new set of CNVs and the corresponding positions of the artificial CNVs in the set of artificial CNVs to determine the degree of overlap with the The degree of accuracy associated with each of the multiple candidate CNV detection applications. 根据一个实施例，所述方法进一步包括通过使用所述控制电路系统，基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。According to one embodiment, the method further comprises using the control circuitry based on the measured location of the new CNVs in the new CNV set and the artificial CNVs in the artificial CNV set Corresponding to the degree of overlap of the positions, assigning the highest degree of accuracy to the first candidate CNV detection application of the plurality of candidate CNV detection applications by using each candidate CNV detection application of the plurality of candidate CNV detection applications . 根据一个实施例，所述方法进一步包括通过使用所述控制电路系统，设置指定阈值以确定所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的所述重叠程度。According to one embodiment, the method further includes, using the control circuitry, setting a specified threshold to determine the location of the new CNVs in the new set of CNVs and the location of the artificial CNVs in the set of artificial CNVs the degree of overlap of the corresponding positions. 根据一个实施例，所述方法进一步包括通过使用所述控制电路系统，生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中所述选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡，其中与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的所述平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。According to one embodiment, the method further includes generating, using the control circuitry, a precision-recall curve relationship associated with each candidate CNV detection application of the plurality of candidate CNV detection applications, and wherein the The selection of one of the plurality of candidate CNV detection applications to be optimal depends on the balance between the degree of recall and the degree of precision, wherein each candidate CNV detection application in the plurality of candidate CNV detection applications The balance between the degree of recall and the degree of precision that is application dependent is indicated by the corresponding area under the precision-recall curve in the generated precision-recall curve relationship. 附图详细描述Detailed Description of the Drawings 参考图1A，示出了根据本公开的实施例的在设备102中使用的试剂盒104的框图100A。试剂盒104当在操作中时执行湿实验室测定。所述测定包含处理来源于一个或多个细胞外显子组的遗传物质。所述测定检测来自遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变体(CNV)。试剂盒104可作为处理遗传物质的单一测定来执行以获得遗传DNA读数。试剂盒104包含软件产品(未示出)，所述软件产品可在计算硬件(未示出)上执行以使所述计算硬件调用算法，通过将所述遗传DNA读数的部分与一个或多个DNA序列转录物进行比较来处理所述遗传DNA读数，以确定对应于所述DNA读数数据中的所述一个或多个DNA序列转录物的变体的出现。Referring to FIG. 1A , there is shown a block diagram 100A of a kit 104 for use in a device 102 according to an embodiment of the present disclosure. The kit 104 performs wet lab assays when in operation. The assay comprises processing genetic material derived from one or more cellular exomes. The assay detects single nucleotide variants (SNVs), indels and copy number variants (CNVs) in genetic DNA reads from genetic material. Kit 104 may be performed as a single assay for processing genetic material to obtain genetic DNA reads. Kit 104 contains a software product (not shown) executable on computing hardware (not shown) to cause the computing hardware to invoke an algorithm by combining portions of the genetic DNA reads with one or more The DNA sequence transcripts are compared to process the genetic DNA reads to determine the occurrence of variants corresponding to the one or more DNA sequence transcripts in the DNA read data. 由计算硬件调用的算法包含用于检测来自遗传物质的遗传DNA读数中的SNV和CNV两者以及任选地插入缺失的算法。计算硬件进一步调用用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法。计算硬件进一步调用根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法。此外，计算硬件进一步调用检测药物基因组学(PGx)标志物的变体识别和样品跟踪SNP的算法。The algorithms invoked by the computing hardware include algorithms for detecting both SNVs and CNVs, and optionally indels, in genetic DNA reads from genetic material. Computing hardware further invokes an algorithm for annotating clinically relevant CNVs present in the genetic DNA reads from the genetic material. Computing hardware further invokes an algorithm that prioritizes the one or more portions of the genetic DNA reads from the genetic material according to the phenotype associated with the one or more portions. In addition, computational hardware further invokes algorithms for variant calling and sample tracking SNPs that detect pharmacogenomics (PGx) markers. 参考图1B，示出了根据本公开的实施例的在设备102中使用的试剂盒104的框图100B。在本实施例中，所述设备进一步包含计算硬件106。试剂盒104进一步包含软件产品108和遗传物质处理布置110。Referring to FIG. 1B , a block diagram 100B of a kit 104 for use in the device 102 according to an embodiment of the present disclosure is shown. In this embodiment, the apparatus further includes computing hardware 106 . The kit 104 further includes a software product 108 and a genetic material processing arrangement 110 . 试剂盒104当在操作中时执行湿实验室测定。所述测定包含处理来源于细胞外显子组的遗传物质(例如，通过单细胞测序)。试剂盒104在孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用中得到应用。在此实施例中，遗传物质处理布置110用于处理遗传物质以获得遗传DNA读数。所述测定检测来自遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变体(CNV)。试剂盒104可作为处理遗传物质的单一测定来执行以获得遗传DNA读数。试剂盒104的软件产品108可在计算硬件106上执行以使计算硬件106通过将遗传DNA读数的部分与DNA序列转录物进行比较来处理所述遗传DNA读数，以确定与DNA读数数据中的DNA序列转录物相对应的变体的出现。The kit 104 performs wet lab assays when in operation. The assay comprises processing genetic material derived from the cell's exome (eg, by single-cell sequencing). Kit 104 finds use in preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology. In this embodiment, the genetic material processing arrangement 110 is used to process the genetic material to obtain genetic DNA reads. The assay detects single nucleotide variants (SNVs), indels and copy number variants (CNVs) in genetic DNA reads from genetic material. Kit 104 may be performed as a single assay for processing genetic material to obtain genetic DNA reads. The software product 108 of the kit 104 may be executed on the computing hardware 106 to cause the computing hardware 106 to process the genetic DNA reads by comparing portions of the genetic DNA reads to the DNA sequence transcripts to determine the DNA in the DNA read data. Occurrence of variants corresponding to sequence transcripts. 试剂盒104的软件产品108可在计算硬件106上执行，以使计算硬件106检测来自遗传物质的遗传DNA读数中的SNV和CNV两者；对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释；根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序；并且检测药物基因组学(PGx)标志物的变体识别和样品跟踪SNP。The software product 108 of the kit 104 can be executed on the computing hardware 106 to cause the computing hardware 106 to detect both SNVs and CNVs in genetic DNA reads from genetic material; annotate the clinically relevant CNVs of the Variant identification and sample tracking SNPs for PGx) markers. 本技术领域的技术人员应当理解，图1A和1B仅出于清楚起见包含系统100A和100B的简化图解，其不应过度限制本文中权利要求的范围。本领域技术人员将认识到本公开的实施例的许多变型、替代方案和修改。Those skilled in the art will appreciate that FIGS. 1A and 1B contain simplified illustrations of systems 100A and 100B for clarity only and should not unduly limit the scope of the claims herein. Those skilled in the art will recognize many variations, alternatives, and modifications to the embodiments of the present disclosure. 参考图2，示出了根据本公开的实施例的用于实施示例性试剂盒以执行定制湿实验室测定的示例性场景200。示例性场景200包含四个顺序阶段，即，第一选择阶段202A、第二湿实验室阶段202B、第三数据处理阶段202C和第四可视化阶段202D。Referring to FIG. 2, an exemplary scenario 200 for implementing an exemplary kit to perform a custom wet lab assay is shown in accordance with an embodiment of the present disclosure. The example scenario 200 includes four sequential stages, namely, a first selection stage 202A, a second wet lab stage 202B, a third data processing stage 202C, and a fourth visualization stage 202D. 第一选择阶段202A是指使用试剂盒的实体能够根据定制要求选择所关注特征集的选择阶段(即，可根据特定供应商、实体或最终用户的要求进行配置的定制临床外显子组测定)。第二湿实验室阶段202B是指遗传物质处理阶段，使用试剂盒根据第一选择阶段202A中所选的所关注特征集从遗传物质中获得遗传DNA读数。第三数据处理阶段202C是指数据处理流水线，其中根据在第一选择阶段202A中所选的所关注特征集处理来自第二湿实验室阶段202B的输出(即，遗传DNA读数)。第四可视化阶段202D是指渲染图形用户界面以用于可视化和进一步分析在第三数据处理阶段202C处理的数据的可视化阶段。The first selection stage 202A refers to the selection stage in which the entity using the kit is able to select the set of features of interest according to custom requirements (ie, a custom clinical exome assay that can be configured according to the requirements of a particular vendor, entity or end user) . The second wet lab stage 202B refers to the genetic material processing stage, where the kits are used to obtain genetic DNA reads from the genetic material according to the set of features of interest selected in the first selection stage 202A. The third data processing stage 202C refers to a data processing pipeline in which the output from the second wet lab stage 202B (ie, genetic DNA reads) is processed according to the set of features of interest selected in the first selection stage 202A. The fourth visualization stage 202D refers to the visualization stage in which the graphical user interface is rendered for visualization and further analysis of the data processed in the third data processing stage 202C. 在第一选择阶段202A中，当(购买中或任选地购买试剂盒后的)用户具有根据要求选择所关注特征的选项。试剂盒允许数据处理、变体过滤、变体优先级排序和经处理数据的可视化。在此示例性场景200中，在步骤204A处，数据处理特征和可视化特征是可配置的，并且可根据需要提供给试剂盒的所有者。在此实施例中，令牌提供对某些所选特征(或模块)的访问或激活某些所选特征(或模块)。在步骤204B处，选择外显子组测序偏好，即，全外显子组测序(WES)、浅全基因组测序(sWGS)或其组合(即，WES±sWGS或sWGS±WES)。在步骤204C处，选择外显子组加分析特征。除了外显子组测序偏好外，还可根据选择来选择(即，允许选择加入或选择退出)以下特征：i)产前模块204D；ii)早期婴儿型癫痫性脑病(EIEE)神经医学模块204E；和携带者筛查面板模块204F。In the first selection stage 202A, when the user (in the process of purchasing or optionally after purchasing the kit) has the option to select the feature of interest as required. The kit allows data processing, variant filtering, variant prioritization, and visualization of processed data. In this exemplary scenario 200, at step 204A, the data processing features and visualization features are configurable and provided to the owner of the kit as needed. In this embodiment, the token provides access to or activates certain selected features (or modules). At step 204B, an exome sequencing preference is selected, ie, whole exome sequencing (WES), shallow whole genome sequencing (sWGS), or a combination thereof (ie, WES±sWGS or sWGS±WES). At step 204C, exome plus analysis features are selected. In addition to exome sequencing preferences, the following features may be selected (ie, allow opt-in or opt-out) upon selection: i) prenatal module 204D; ii) early infantile epileptic encephalopathy (EIEE) neuromedical module 204E ; and Carrier Screening Panel Module 204F. 在第二湿实验室阶段202B中，在步骤206处，本地提取DNA样品。在步骤208A处，所选样品跟踪测定(即，根据在第一选择阶段202A中执行的选择)也在本地运行。在步骤208B处，DNA样品被剪切(酶剪切或声剪切)。在步骤210A处，剪切后的片段化DNA样品用于制备sWGS(浅-低水平)文库，在第一选择阶段202A中在序列偏好中选择了sWGS特征的情况下，所述文库并入唯一分子标识符(UMI)和对应样品的索引(即，样品索引)。在步骤210B处，剪切后的片段化DNA样品用于WES文库制备，所述文库还包含UMI和样品索引，以防在第一选择阶段202A中在序列偏好中选择了WES特征。在步骤212处，合并sWGS和WES文库(即，将sWGS与WES文库结合)进行高覆盖率的双末端外显子组测序(这使得能够进行全外显子组加下游分析)。In the second wet lab stage 202B, at step 206, a DNA sample is extracted locally. At step 208A, the selected sample tracking assay (ie, according to the selection performed in the first selection stage 202A) is also run locally. At step 208B, the DNA sample is sheared (enzymatically or sonicated). At step 210A, the sheared fragmented DNA sample is used to prepare a sWGS (shallow-low level) library that incorporates unique sWGS features in the sequence preference selected in the first selection stage 202A The molecular identifier (UMI) and the index of the corresponding sample (ie, the sample index). At step 210B, the sheared fragmented DNA samples are used for WES library preparation, which also contains UMIs and sample indexes in case WES features were selected in the sequence preference in the first selection stage 202A. At step 212, the sWGS and WES libraries are combined (ie, the sWGS and WES libraries are combined) for high coverage paired-end exome sequencing (which enables whole exome plus downstream analysis). 在步骤214处，执行对汇集的文库的测序。在此情况下，使用定义数量的碱基对(bp)配对末端读段(通过下一代测序(NGS)的短读段)进行测序。可以应用长读段测序作为替代方案。在步骤216处，将从测序中获得的测序数据上传到通信地耦接到试剂盒的基于云的序列分析和可视化平台。本此实施例中，上传的测序数据为BCL、FASTQ、BAM、VCF或BED格式。测序数据与指示在第一选择阶段202A中提供对所选模块(即，特征)的访问的所选令牌的解释请求(IR)一起上传。在步骤218处，包含用于在步骤208A处执行的跟踪的SNP数据的样品跟踪测定的输出也被上传到基于云的序列分析和可视化平台中。At step 214, sequencing of the pooled library is performed. In this case, sequencing was performed using a defined number of base pairs (bp) paired-end reads (short reads by next-generation sequencing (NGS)). Long-read sequencing can be applied as an alternative. At step 216, the sequencing data obtained from the sequencing is uploaded to a cloud-based sequence analysis and visualization platform communicatively coupled to the kit. In this embodiment, the uploaded sequencing data is in BCL, FASTQ, BAM, VCF or BED format. The sequencing data is uploaded with an Interpretation Request (IR) indicating the selected token providing access to the selected module (ie, feature) in the first selection stage 202A. At step 218, the output of the sample tracking assay containing the SNP data for the tracking performed at step 208A is also uploaded into the cloud-based sequence analysis and visualization platform. 在第三数据处理阶段202C中，数据处理流水线阶段开始，其中处理上传的测序数据。在步骤220处，根据在第一选择阶段202A中选择的特征(即，以令牌形式选择的模块)触发特定处理流水线。在步骤222处，测序数据的初始比对与参考基因组数据集一起执行。测序数据与最新版本的基因组构建组装比对(在此情况下，使用GRCh38/hg38人类基因组构建组装)。此比对使得能够鉴定个体的基因组序列中有意义的变异，以区分什么是健康的和什么是潜在病态的。在步骤224A处，使用在步骤222处的比对数据或上传的原始测序数据，生成有质量控制的样品跟踪SNP。SNPS和在一些情况下短串联重复序列标志物用于遗传样品跟踪以避免样品混淆。在步骤226A处，对测序数据(即，对上传的原始测序数据或在步骤222处获得的比对数据)执行UMI解复用。在步骤228A处，使用在步骤222处的比对数据或原始测序数据，执行线粒体(mtDNA)流水线以测量异质性(即，异质变体)并且在大量候选者中识别有助于表型(例如，疾病)的功能上最重要的线粒体变体。mtDNA数据是从测序数据(即，从sWGS和WES数据)中提取的。在一个实施方案中，步骤224A、226A和228A同时执行。在另一个实施方案中，步骤224A、226A和228A以任何定义的顺序依次执行。In the third data processing stage 202C, the data processing pipeline stage begins, wherein the uploaded sequencing data is processed. At step 220, a particular processing pipeline is triggered according to the features selected in the first selection stage 202A (ie, the modules selected in the form of tokens). At step 222, an initial alignment of the sequencing data is performed with the reference genome dataset. The sequencing data were aligned to the latest version of the genome build assembly (in this case, the GRCh38/hg38 human genome build assembly was used). This alignment enables the identification of meaningful variations in an individual's genome sequence to distinguish between what is healthy and what is potentially pathological. At step 224A, quality controlled sample tracking SNPs are generated using the alignment data at step 222 or the uploaded raw sequencing data. SNPS and in some cases short tandem repeat markers are used for genetic sample tracking to avoid sample confusion. At step 226A, UMI demultiplexing is performed on the sequencing data (ie, on the uploaded raw sequencing data or the alignment data obtained at step 222). At step 228A, using the alignment data or raw sequencing data at step 222, a mitochondrial (mtDNA) pipeline is performed to measure heterogeneity (ie, heterogeneous variants) and identify among a large number of candidates contributing to phenotype (eg, disease) the most functionally important mitochondrial variants. mtDNA data were extracted from sequencing data (ie, from sWGS and WES data). In one embodiment, steps 224A, 226A and 228A are performed concurrently. In another embodiment, steps 224A, 226A and 228A are performed sequentially in any defined order. 在步骤224B处，在第四可视化阶段202D中，将在步骤222A处生成的有质量控制的样品跟踪SNP渲染在GUI(即，可视界面)上。GUI在设备(未示出)上渲染。在步骤226B处，GUI允许设置配置以控制在第三数据处理阶段202C处的数据处理操作。在第三数据处理阶段202C处执行的各种数据处理操作的结果被渲染在GUI上以供进一步分析，并且基于多个定义的设置(即，预设设置)、指定的知识库和通过渲染的GUI选择和应用的面板执行数据处理。第三数据处理阶段202C和第四可视化阶段202D彼此同步执行。在此示例性场景200中，多个预设设置(预设1)中的第一预设设置250A在被选择时允许预加载主要基因面板和相关联数据(例如，产前模块204D或EIEE模块面板204E)。在主要面板基于预定义规则没有检测到可鉴定的致病变体的情况下，应用多个预设设置中的第二预设设置250B(预设2)。在第二预设设置250B中，孟德尔遗传(例如，OMIM或MORBID)数据和HPO数据被预加载并且与预加载的主要基因面板和相关联数据一起渲染。At step 224B, in a fourth visualization stage 202D, the quality-controlled sample tracking SNPs generated at step 222A are rendered on a GUI (ie, a visual interface). The GUI is rendered on a device (not shown). At step 226B, the GUI allows configuration to be set to control the data processing operations at the third data processing stage 202C. The results of the various data processing operations performed at the third data processing stage 202C are rendered on the GUI for further analysis, and are based on a number of defined settings (ie, preset settings), specified knowledge bases, and GUI selection and application panels perform data processing. The third data processing stage 202C and the fourth visualization stage 202D are executed in synchronization with each other. In this exemplary scenario 200, a first preset setting 250A of a plurality of preset settings (Preset 1), when selected, allows preloading of the primary genetic panel and associated data (eg, prenatal module 204D or EIEE module) panel 204E). In the event that the primary panel detects no identifiable pathogenic variants based on predefined rules, a second preset setting 250B of the plurality of preset settings (Preset 2) is applied. In the second preset setting 250B, Mendelian genetics (eg, OMIM or MORBID) data and HPO data are preloaded and rendered with the preloaded primary gene panel and associated data. 现在返回参考第三数据处理阶段202C，在步骤230处，对DNA读数数据中的重复和缺失变体进行检测。在步骤232处，执行拷贝数变异(CNV)识别。可替代地，使用算法在遗传DNA读数中同时检测SNV和CNV两者。另外，还执行了对药物基因组学(PGx)标志物的变体识别。在步骤234处，执行SNV和插入缺失识别。在步骤236处，执行STR和VNTR识别。在步骤238处，检测镶嵌变体。在步骤240处，根据遗传DNA读数数据上对应位点处的变体类型对识别出的不同变体(重复和缺失变体，包含进一步的CNV识别、SNV、插入缺失、STR和VNTR)进行标记并且通过GUI可视化。对符合基因遗传模式(MOI)(即，观察到的基因MOI)和家族中的预期MOI的变体进行标记(或注释)。在步骤242处，确定变体是遗传变体还是从头变体。在步骤244处，将检测到的变体在主要基因面板上进行分类(即，执行变体分层)。在步骤246处，基于所关注基因对所有检测到的变体执行变体优先级排序。在步骤248处，在检测到的变体与ACMG提供的变体序列匹配的情况下，会自动填充ACMG证据代码。ACMG表示美国医学遗传学和基因组学学院，其已发布针对报告某些基因的外显子中的偶然发现的建议(通常规定了59个基因)。Referring now back to the third data processing stage 202C, at step 230, duplicate and deletion variants in the DNA read data are detected. At step 232, copy number variation (CNV) identification is performed. Alternatively, algorithms are used to simultaneously detect both SNVs and CNVs in genetic DNA reads. Additionally, variant calling for pharmacogenomics (PGx) markers was also performed. At step 234, SNV and indel identification is performed. At step 236, STR and VNTR identification is performed. At step 238, mosaic variants are detected. At step 240, the different variants identified (duplication and deletion variants, including further CNV calls, SNVs, indels, STRs and VNTRs) are marked according to the variant type at the corresponding locus on the genetic DNA read data And visualized via GUI. Variants that conform to the gene's pattern of inheritance (MOI) (ie, the observed gene MOI) and the expected MOI in the family are marked (or annotated). At step 242, it is determined whether the variant is a genetic variant or a de novo variant. At step 244, the detected variants are classified on the main gene panel (ie, variant stratification is performed). At step 246, variant prioritization is performed on all detected variants based on the gene of interest. At step 248, where the detected variant matches the ACMG-provided variant sequence, the ACMG evidence code is automatically populated. ACMG stands for the American College of Medical Genetics and Genomics, which has issued recommendations for reporting incidental findings in the exons of certain genes (59 genes are generally specified). 在第四可视化阶段202D中，如上文所讨论的，在第三数据处理阶段202C处执行的各种数据处理操作的结果被渲染在GUI(即，可视界面)上以供进一步分析，并且基于预设设置、知识库和通过渲染的GUI选择和应用的面板执行数据处理。因此，除了第一预设设置250A和第二预设设置250B之外，提供了第三预设设置250C并且可通过GUI选择所述第三预设设置。第三预设250C设置与面板无关，并且用于配置用于疾病评估的决策支持的报告模板。还提供了其它研究预设选项250D，并且可选择用于可视分析。第四预设设置250E可通过GUI选择，所述第四预设设置允许基于在不同步骤中检测到的共享等位基因来执行队列分析和过滤。第五预设设置250F可通过GUI选择，所述第五预设设置允许基于在不同步骤中检测到的共享等位基因同时执行对多个谱系的STR、NTR、SNP连锁分析，并且在序列比对中通过GUI可视化。In the fourth visualization stage 202D, as discussed above, the results of the various data processing operations performed at the third data processing stage 202C are rendered on a GUI (ie, visual interface) for further analysis, and based on Preset settings, knowledge base and panels to perform data processing via rendered GUI selection and application. Therefore, in addition to the first preset setting 250A and the second preset setting 250B, a third preset setting 250C is provided and can be selected through the GUI. The third preset 250C settings are panel independent and are used to configure report templates for decision support for disease assessment. Additional study preset options 250D are also provided and can be selected for visual analysis. A fourth preset 250E, selectable through the GUI, allows cohort analysis and filtering to be performed based on shared alleles detected in different steps. A fifth preset 250F, selectable via the GUI, allows for simultaneous STR, NTR, SNP linkage analysis of multiple lineages based on shared alleles detected in different steps, and in sequence comparison. Alignment is visualized via GUI. 参考图3，示出了描绘根据本公开的实施例的使用执行湿实验室测定的试剂盒的方法的步骤的流程图300。所述方法是使用试剂盒实施的。所述试剂盒在使用时执行湿实验室测定。如图所示，在步骤302处，所述测定处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)。在步骤304处，将试剂盒作为处理所述遗传物质的单一测定进行应用。在步骤306处，在计算硬件上执行所述试剂盒的软件产品，以使所述计算硬件调用一种或多种算法，通过将所述遗传DNA读数的部分与一个或多个DNA序列转录物进行比较来处理所述遗传DNA读数，以确定对应于所述DNA读数数据中的所述一个或多个DNA序列转录物的变体的出现。此外，在步骤306处，算法被配置成检测来自遗传物质的遗传DNA读数中的SNV和CNV两者。进一步地，算法被配置成对来自遗传物质的遗传DNA读数中存在的临床相关CNV进行注释。此外，算法被配置成根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序。此外，算法被配置成检测药物基因组学(PGx)标志物的变体识别和样品跟踪SNP。Referring to FIG. 3, a flowchart 300 depicting the steps of a method of using a kit for performing a wet lab assay in accordance with an embodiment of the present disclosure is shown. The method is carried out using a kit. The kits perform wet lab assays when in use. As shown, at step 302, the assay processes genetic material derived from one or more cellular exomes, wherein the assay detects single nucleotide changes in genetic DNA reads from the genetic material body (SNV), indel and copy number variation (CNV). At step 304, the kit is applied as a single assay for processing the genetic material. At step 306, the software product of the kit is executed on computing hardware, such that the computing hardware invokes one or more algorithms by comparing the portion of the genetic DNA read with one or more DNA sequence transcripts A comparison is made to process the genetic DNA reads to determine the occurrence of variants corresponding to the one or more DNA sequence transcripts in the DNA read data. Furthermore, at step 306, the algorithm is configured to detect both SNVs and CNVs in the genetic DNA reads from the genetic material. Further, the algorithm is configured to annotate clinically relevant CNVs present in the genetic DNA reads from the genetic material. Furthermore, the algorithm is configured to prioritize the one or more portions of the genetic DNA reads from the genetic material according to the phenotype associated with the one or more portions. Additionally, the algorithm is configured to detect variant calling and sample tracking SNPs for pharmacogenomics (PGx) markers. 步骤302、304和306仅为说明性的，并且在不脱离本文权利要求的范围的情况下，还可以提供其它替代方案，其中添加一个或多个步骤、删除一个或多个步骤或者以不同顺序提供一个或多个步骤。Steps 302, 304 and 306 are illustrative only and other alternatives may be provided in which one or more steps are added, one or more steps are deleted, or in a different order without departing from the scope of the claims herein Provide one or more steps. 参考图4，示出了描绘根据本公开的另一个实施例的使用执行湿实验室测定的试剂盒的方法的步骤的流程图400。如图所示，在步骤402处，处理来源于受试者的细胞外显子组的遗传物质。在步骤404处，试剂盒当与设备一起使用时作为处理上述步骤得到的遗传物质的单一测定进行应用。在步骤406处，在来自遗传物质的遗传DNA读数中检测SNV和CNV。在步骤408处，对遗传物质的遗传DNA读数中存在的临床相关CNVS进行注释。在步骤410处，根据与遗传DNA读数的部分相关联的表型，从遗传物质对遗传DNA读数的部分进行优先级排序。在步骤412处，检测药物基因组学(PGx)标志物的变体识别并且单独检测样品跟踪SNP。Referring to FIG. 4, a flowchart 400 depicting the steps of a method of using a kit for performing a wet lab assay according to another embodiment of the present disclosure is shown. As shown, at step 402, genetic material derived from the subject's cellular exome is processed. At step 404, the kit, when used with the device, is applied as a single assay for processing the genetic material obtained from the above steps. At step 406, SNVs and CNVs are detected in the genetic DNA reads from the genetic material. At step 408, clinically relevant CNVS present in the genetic DNA reads of the genetic material are annotated. At step 410, the portion of the genetic DNA read is prioritized from the genetic material according to the phenotype associated with the portion of the genetic DNA read. At step 412, a pharmacogenomics (PGx) marker is detected for variant identification and sample tracking SNPs are detected individually. 步骤402、404、406、408、410和412仅为说明性的，并且在不脱离本文权利要求的范围的情况下，还可以提供其它替代方案，其中添加一个或多个步骤、删除一个或多个步骤或者以不同顺序提供一个或多个步骤。Steps 402, 404, 406, 408, 410 and 412 are illustrative only, and other alternatives may be provided in which one or more steps are added, one or more steps are deleted, and other alternatives may be provided without departing from the scope of the claims herein. steps or provide one or more steps in a different order. 参考图5A，示出了根据本公开的实施例的获取和处理基因组序列数据集以检测拷贝数变体(CNV)的系统500A的框图。如图所示，系统500A包括设备502和计算布置504。设备502被配置成处理受试者的基因组的至少一部分以生成原始基因组序列数据集。此外，计算布置504包括数据存储器装置506和控制电路系统508。控制电路系统508被配置成从所述设备502中获取所述原始基因组序列数据集以及预存储在所述数据存储器装置506中的多个候选CNV检测应用程序。此外，控制电路系统508被配置成通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序执行第一CNV识别以获得原始基因组序列数据集的随机选择区中的基线CNV。值得注意的是，基线CNV是原始基因组序列数据集中预先存在的CNV，被认为是真值。此外，控制电路系统508被配置成组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集。此外，控制电路系统508被配置成通过使用预存储在数据存储器装置506中的模拟应用程序(例如，zimmer工具)模拟原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集。值得注意的是，模拟的基因组序列数据集包括人工CNV集和基线CNV集。此外，控制电路系统508被配置成在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置。此外，控制电路系统508被配置成通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别。此外，控制电路系统508被配置成从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集。此外，控制电路系统508被配置成基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置。此外，控制电路系统508被配置成基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度。此外，控制电路系统508被配置成基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优。此外，控制电路系统508被配置成利用所选候选CNV检测应用程序识别基因组序列数据中的CNV。Referring to FIG. 5A, a block diagram of a system 500A for acquiring and processing a genomic sequence data set to detect copy number variants (CNVs) according to an embodiment of the present disclosure is shown. As shown, system 500A includes device 502 and computing arrangement 504 . Device 502 is configured to process at least a portion of the subject's genome to generate a raw genome sequence dataset. Additionally, computing arrangement 504 includes data memory device 506 and control circuitry 508 . Control circuitry 508 is configured to obtain from the apparatus 502 the raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in the data storage device 506 . Furthermore, control circuitry 508 is configured to perform a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the raw genome sequence data set. Notably, the baseline CNVs were pre-existing CNVs in the original genome sequence dataset and were considered ground truth. Furthermore, control circuitry 508 is configured to combine the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a set of baseline CNVs. Additionally, control circuitry 508 is configured to generate a simulated genome sequence by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application (eg, a zimmer tool) pre-stored in data memory device 506 data set. Notably, the simulated genome sequence dataset includes both an artificial CNV set and a baseline CNV set. Additionally, control circuitry 508 is configured to record the location of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence data set. Additionally, control circuitry 508 is configured to perform a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications. Additionally, control circuitry 508 is configured to eliminate the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genomic sequence dataset to obtain a new set of CNVs. Furthermore, control circuitry 508 is configured to determine the location of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded locations of the artificial CNV set. Further, control circuitry 508 is configured to determine to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new CNV set with the position of the artificial CNV set degree of recall and precision. Furthermore, control circuitry 508 is configured to select one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data One is the best. Additionally, control circuitry 508 is configured to identify CNVs in the genomic sequence data using the selected candidate CNV detection application. 参考图5B，示出了根据本公开的另一个实施例的获取和处理基因组序列数据集以检测一个或多个拷贝数变体(CNV)的系统500B的网络环境的图解。结合来自图5A的元素描述图5B。如图所示，在系统500B中，设备502和计算布置504通过数据通信网络510通信地耦接。计算布置504包括数据存储器装置506和控制电路系统508。数据通信网络510是有线或无线通信网络。进一步示出了通信地耦接到计算布置504和设备502的湿实验室布置512。湿实验室布置512被配置成处理受试者的生物样品以得到受试者的基因组的至少一部分以生成原始基因组序列数据集。Referring to Figure 5B, an illustration of the network environment of a system 500B for acquiring and processing genomic sequence data sets to detect one or more copy number variants (CNVs) is shown in accordance with another embodiment of the present disclosure. Figure 5B is described in conjunction with elements from Figure 5A. As shown, in system 500B, device 502 and computing arrangement 504 are communicatively coupled through a data communications network 510 . Computing arrangement 504 includes data memory device 506 and control circuitry 508 . Data communication network 510 is a wired or wireless communication network. Further shown is a wet lab arrangement 512 communicatively coupled to computing arrangement 504 and device 502 . The wet lab arrangement 512 is configured to process the subject's biological sample to obtain at least a portion of the subject's genome to generate a raw genome sequence data set. 本技术领域的技术人员应当理解，图1A和1B仅出于清楚起见包含系统500A和500B的简化图解，其不应过度限制本文中权利要求的范围。本领域技术人员将认识到本公开的实施例的许多变型、替代方案和修改。Those skilled in the art will appreciate that FIGS. 1A and 1B contain simplified illustrations of systems 500A and 500B for clarity only and should not unduly limit the scope of the claims herein. Those skilled in the art will recognize many variations, alternatives, and modifications to the embodiments of the present disclosure. 参考图6A和6B，示出了描绘根据本公开的实施例的用于获取和处理基因组序列数据集以检测一个或多个拷贝数变体(CNV)的方法的步骤的流程图600。所述方法是使用包括设备和计算布置的系统来实施的。Referring to Figures 6A and 6B, a flowchart 600 depicting the steps of a method for obtaining and processing a genomic sequence data set to detect one or more copy number variants (CNVs) according to embodiments of the present disclosure is shown. The method is implemented using a system including a device and a computing arrangement. 在步骤602处，通过使用设备处理受试者的基因组的至少一部分以生成原始基因组序列数据集。在步骤604处，通过使用计算布置的控制电路系统获取来自设备的原始基因组序列数据集和预存储在计算布置的数据存储器装置中的多个候选CNV检测应用程序。在步骤606处，通过使用多个候选CNV检测应用程序中的每个候选CNV检测应用程序执行第一CNV识别以获得原始基因组序列数据集的随机选择区中的基线CNV。此外，基线CNV是原始基因组序列数据集中预先存在的CNV，被认为是真值。在步骤608处，通过使用控制电路系统，组合从多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的基线CNV以生成基线CNV集。在步骤610处，通过使用预存储在数据存储器装置中的模拟应用程序模拟原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集。值得注意的是，模拟的基因组序列数据集包括人工CNV集和基线CNV集。在步骤612处，在模拟基因组序列数据集中记录人工CNV集中的每个人工CNV和基线CNV集中的每个基线CNV的位置。在步骤614处，通过使用多个候选CNV检测应用程序中的每个候选CNV检测应用程序在模拟基因组序列数据集中执行第二CNV识别。在步骤616处，从获得自模拟基因组序列数据集中的第二CNV识别的CNV中消除基线CNV集，以获得新CNV集。在步骤618处，基于记录的人工CNV集的位置，确定模拟基因组序列数据集中新CNV集中的每个新CNV的位置。在步骤620处，基于新CNV集的位置与人工CNV集的位置的比较，确定与多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度。在步骤622处，基于用于识别基因组序列数据中的拷贝数变体的召回程度和精确程度的组合，选择多个候选CNV检测应用程序之一作为最优。在步骤624处，通过使用控制电路系统，利用所选候选CNV检测应用程序识别基因组序列数据中的CNV。At step 602, at least a portion of the subject's genome is processed by using the device to generate a raw genome sequence dataset. At step 604, the raw genome sequence data set from the device and a plurality of candidate CNV detection applications pre-stored in the computationally arranged data memory device are obtained by using the computationally arranged control circuitry. At step 606, a first CNV identification is performed by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set. Furthermore, baseline CNVs are pre-existing CNVs in the original genome sequence dataset and are considered ground truth. At step 608, using control circuitry, the baseline CNVs obtained from each of the plurality of candidate CNV detection applications are combined to generate a baseline CNV set. At step 610, a simulated genome sequence dataset is generated by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device. Notably, the simulated genome sequence dataset includes both an artificial CNV set and a baseline CNV set. At step 612, the location of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set is recorded in the simulated genome sequence dataset. At step 614, a second CNV identification is performed in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications. At step 616, the baseline set of CNVs is eliminated from the CNVs identified by the second CNV obtained from the simulated genomic sequence dataset to obtain a new set of CNVs. At step 618, based on the recorded positions of the artificial CNV set, the position of each new CNV in the new set of CNVs in the simulated genome sequence data set is determined. At step 620, a degree of recall and degree of precision associated with each candidate CNV detection application of the plurality of candidate CNV detection applications is determined based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set. At step 622, one of the multiple candidate CNV detection applications is selected as the best based on a combination of recall and precision for identifying copy number variants in the genomic sequence data. At step 624, CNVs in the genomic sequence data are identified using the selected candidate CNV detection application using the control circuitry. 步骤602、604、606、608、610、612、614、616、618、620、622和624仅为说明性的，并且在不脱离本文权利要求的范围的情况下，还可以提供其它替代方案，其中添加一个或多个步骤、删除一个或多个步骤或者以不同顺序提供一个或多个步骤。Steps 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622 and 624 are illustrative only and other alternatives may be provided without departing from the scope of the claims herein, Wherein one or more steps are added, one or more steps are deleted, or one or more steps are provided in a different order. 在不脱离如所附权利要求所限定的本公开的范围的情况下，可以对之前描述的本公开的实施例进行修改。用于描述本公开并且要求保护本公开的表达，如“包含(including)”、“包括(comprising)”、“并入(incorporating)”、“具有(have)”、“是(is)”旨在以非排他性的方式进行解释，即允许也存在未明确描述的项、组分或元件。提及单数也应被解释为涉及复数。Modifications may be made to the previously described embodiments of the disclosure without departing from the scope of the disclosure as defined by the appended claims. Expressions used to describe and claim the disclosure, such as 'including', 'comprising', 'incorporating', 'have', 'is' mean Items, components or elements not expressly described are also permitted to be present when interpreted in a non-exclusive manner. Reference to the singular should also be construed as referring to the plural.

### Claims

Claims (48) Translated from Chinese 1.一种用于在设备中使用的用于遗传筛查的试剂盒，其中所述试剂盒在操作时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，1. A kit for genetic screening for use in a device, wherein the kit performs a wet laboratory assay when in operation, wherein the assay comprises processing exons derived from one or more cells a set of genetic material, wherein the assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from the genetic material, 所述试剂盒的特征在于，The kit is characterized in that, 所述试剂盒可作为处理所述遗传物质的单一测定来执行；并且The kit can be performed as a single assay for processing the genetic material; and 所述试剂盒包含软件产品，所述软件产品可在计算硬件上执行以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，The kit includes a software product executable on computing hardware to cause the computing hardware to invoke one or more algorithms to transcribe portions of the genetic DNA reads with one or more DNA sequences processing said genetic DNA reads in order to determine the occurrence of variants corresponding to said one or more DNA sequence transcripts in said DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (i)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(i) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (ii)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(ii) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (iii)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；(iii) an algorithm for prioritizing said one or more portions of said genetic DNA reads from said genetic material according to a phenotype associated with said one or more portions; (iv)检测药物基因组学(PGx)标志物的变体识别的算法；(iv) algorithms to detect variant recognition of pharmacogenomics (PGx) markers; (V)被配置成在所述单一测定中样品跟踪SNP的算法。(V) An algorithm configured to sample track SNPs in the single assay. 2.根据权利要求1所述的试剂盒，其特征在于，所述软件产品包含算法，所述算法当在所述计算硬件上执行时提供使用图形用户界面(GUI)实施的可视化布置，以可视地传送(i)到(iv)中的检测的结果。2. The kit of claim 1, wherein the software product includes an algorithm that, when executed on the computing hardware, provides a visual arrangement implemented using a graphical user interface (GUI) to enable Visually transmit the results of the detection in (i) to (iv). 3.根据权利要求1或2所述的试剂盒，其特征在于，所述软件产品包含算法，所述算法当在所述计算硬件上执行时检测所述DNA读数数据中与所述DNA序列转录物相关的重复和缺失中的至少一种，并且其中所述试剂盒用于的所述遗传筛查包含孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用中的至少一种，并且其中使用单细胞测序对所述遗传物质进行处理。3. The kit of claim 1 or 2, wherein the software product comprises an algorithm that, when executed on the computing hardware, detects that the DNA read data is transcribed with the DNA sequence at least one of gene-associated duplications and deletions, and wherein the genetic screening for which the kit is used comprises at least one of preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology species, and wherein the genetic material is processed using single-cell sequencing. 4.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述软件产品包含算法，所述算法当在所述计算硬件上执行时检测存在于与所述DNA序列转录物相关的所述DNA读数数据中的一个或多个基因间变体。4. The kit of any one of the preceding claims, wherein the software product comprises an algorithm that, when executed on the computing hardware, detects the presence of a transcript associated with the DNA sequence one or more intergenic variants in said DNA read data. 5.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述软件产品包含算法，所述算法当在所述计算硬件上执行时通过基因遗传模式提供组合的SNV和CNV过滤和解释，其中所述基因遗传模式包含存在隐性基因的可能性。5. The kit of any one of the preceding claims, wherein the software product comprises an algorithm that provides combined SNV and CNV filtering by genetic inheritance patterns when executed on the computing hardware and explanation, wherein the genetic pattern of inheritance includes the possibility of the presence of recessive genes. 6.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含共有编码序列(CCDS)转录物。6. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise consensus coding sequence (CCDS) transcripts. 7.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少一种病态基因RefSeq转录物。7. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise at least one pathological gene RefSeq transcript. 8.根据权利要求7所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少4091种病态基因RefSeq转录物。8. The kit of claim 7, wherein the one or more DNA sequence transcripts comprise at least 4091 pathological gene RefSeq transcripts. 9.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少一种胎儿异常基因转录物。9. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise at least one fetal abnormal gene transcript. 10.根据权利要求9所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少2598种胎儿异常基因转录物。10. The kit of claim 9, wherein the one or more DNA sequence transcripts comprise at least 2598 fetal abnormal gene transcripts. 11.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少一种癫痫异常基因转录物。11. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise at least one epilepsy abnormality gene transcript. 12.根据权利要求11所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少5019种癫痫基因哈瓦那转录物特征。12. The kit of claim 11, wherein the one or more DNA sequence transcripts comprise at least 5019 epilepsy gene Havana transcript signatures. 13.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少一种ACMG59基因RefSeq转录物。13. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise at least one ACMG59 gene RefSeq transcript. 14.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含DNA序列的可能致病变体和非编码变体(ClinVar)。14. The kit according to any of the preceding claims, wherein the one or more DNA sequence transcripts comprise potentially pathogenic variants and non-coding variants (ClinVar) of the DNA sequence. 15.根据前述权利要求中任一项所述的试剂盒，其特征在于，所述一种或多种DNA序列转录物包含至少一种样品跟踪SNV。15. The kit of any preceding claim, wherein the one or more DNA sequence transcripts comprise at least one sample tracking SNV. 16.一种使用根据权利要求1所述的试剂盒的方法，其中所述试剂盒在使用时执行湿实验室测定，其中所述测定包含处理来源于一个或多个细胞外显子组的遗传物质，其中所述测定检测来自所述遗传物质的遗传DNA读数中的单核苷酸变体(SNV)、插入缺失和拷贝数变异(CNV)，所述方法的特征在于，所述方法包含：16. A method of using the kit of claim 1, wherein the kit, in use, performs a wet laboratory assay, wherein the assay comprises processing genetic data derived from one or more cellular exomes A substance, wherein the assay detects single nucleotide variants (SNVs), indels and copy number variations (CNVs) in genetic DNA reads from the genetic material, the method characterized in that the method comprises: (i)将所述试剂盒作为处理所述遗传物质的单一测定应用；以及(i) applying the kit as a single assay for processing the genetic material; and (ii)在计算硬件上执行所述试剂盒的软件产品，以使所述计算硬件调用一种或多种算法以通过将所述遗传DNA读数的部分与一种或多种DNA序列转录物进行比较来处理所述遗传DNA读数，以便确定对应于所述DNA读数数据中的所述一种或多种DNA序列转录物的变体的出现，(ii) executing the software product of the kit on computing hardware such that the computing hardware invokes one or more algorithms to perform analysis by comparing portions of the genetic DNA reads with one or more DNA sequence transcripts comparing said genetic DNA reads to determine the occurrence of variants corresponding to said one or more DNA sequence transcripts in said DNA read data, 其中所述一种或多种算法包含：wherein the one or more algorithms include: (a)用于在所述单一测定中同时检测来自所述遗传物质的所述遗传DNA读数中的SNV、插入缺失和CNV的算法；(a) an algorithm for the simultaneous detection of SNVs, indels and CNVs in said genetic DNA reads from said genetic material in said single assay; (b)用于对来自所述遗传物质的所述遗传DNA读数中存在的临床相关CNV进行注释的算法；(b) an algorithm for annotating clinically relevant CNVs present in said genetic DNA reads from said genetic material; (c)根据与一个或多个部分相关联的表型对来自所述遗传物质的所述遗传DNA读数的所述一个或多个部分进行优先级排序的算法；(c) an algorithm for prioritizing said one or more portions of said genetic DNA reads from said genetic material according to a phenotype associated with one or more portions; (d)检测药物基因组学(PGx)标志物的变体识别的算法；以及(d) algorithms to detect variant recognition of pharmacogenomics (PGx) markers; and (e)被配置成样品跟踪SNP的算法。(e) Algorithm configured to sample tracking SNPs. 17.根据权利要求16所述的方法，其特征在于，所述方法用于17. The method of claim 16, wherein the method is used for 在多个阶段中实施所述测定，其中在所述多个阶段中的第一选择阶段中，所述方法允许从可使用所述试剂盒进行配置的多个特征中选择一组所关注特征，其中所述多个特征包含外显子组测序偏好和多个自定义变体鉴定模块。The assay is performed in a plurality of stages, wherein in a first selection stage of the plurality of stages, the method allows selection of a set of features of interest from a plurality of features configurable using the kit, wherein the plurality of features comprise exome sequencing bias and a plurality of custom variant identification modules. 18.根据权利要求17所述的方法，其特征在于，所述方法用于在所述多个阶段中实施所述测定，其中在所述多个阶段中的第二湿实验室阶段中，所述方法允许根据在所述第一选择阶段中所选择的一组所关注特征使用所述试剂盒处理所述遗传物质，以从所述遗传物质中获得所述遗传DNA读数数据，其中所述遗传DNA读数数据对应于测序数据，并且其中所述试剂盒用于孕前筛查、胚胎植入前遗传筛查或与辅助生殖技术相关的应用中的至少一种，并且其中使用单细胞测序对所述遗传物质进行处理。18. The method of claim 17, wherein the method is for performing the assay in the plurality of stages, wherein in a second wet laboratory stage of the plurality of stages, the The method allows processing of the genetic material using the kit according to a set of characteristics of interest selected in the first selection stage to obtain the genetic DNA read data from the genetic material, wherein the genetic The DNA read data corresponds to sequencing data, and wherein the kit is used for at least one of preconception screening, preimplantation genetic screening, or applications related to assisted reproductive technology, and wherein single cell sequencing is used for the Genetic material is processed. 19.根据权利要求17或18所述的方法，其特征在于，所述方法用于在所述多个阶段中实施所述测定，其中在所述多个阶段中的第三数据处理流水线阶段中，所述方法允许根据在所述第一选择阶段中所选择的一组所关注特征来确定所述DNA读数数据中所述变体的出现，其中所述确定所述DNA读数数据中所述变体的出现进一步包括：19. The method of claim 17 or 18, wherein the method is for performing the assay in the plurality of stages, wherein in a third data processing pipeline stage of the plurality of stages , the method allows determining the occurrence of the variant in the DNA read data based on a set of features of interest selected in the first selection stage, wherein the determining the variant in the DNA read data The appearance of the body further includes: -根据在所述第一选择阶段中所选择的一组所关注特征来触发特定处理流水线；- triggering a particular processing pipeline according to a set of features of interest selected in said first selection stage; -对所述遗传DNA读数数据执行唯一分子标识符(UMI)解复用；- performing Unique Molecular Identifier (UMI) demultiplexing on said genetic DNA read data; -执行线粒体(mtDNA)流水线以测量所述遗传DNA读数数据中的异质变体；- performing a mitochondrial (mtDNA) pipeline to measure heterogeneous variants in said genetic DNA read data; -检测所述遗传DNA读数数据中的短串联重复序列(STR)和VNTR(可变数量串联重复序列)；- detection of short tandem repeats (STRs) and VNTRs (variable number of tandem repeats) in said genetic DNA read data; -检测所述遗传DNA读数数据中的镶嵌变体；- detecting mosaic variants in said genetic DNA read data; -使用家族中的预期遗传模式(MOI)对检测到的符合基因MOI的变体进行标记；- tagging of detected variants that match the MOI of the gene using the expected mode of inheritance (MOI) in the family; -确定检测到的变体是遗传变体还是从头变体；以及- determine whether the detected variant is a genetic or de novo variant; and -当所述检测到的变体与从定义基因变异和对应病症的指定数据源获取的预存储变体序列匹配时，自动填充证据代码。- Automatically populate evidence codes when said detected variants match pre-stored variant sequences obtained from specified data sources defining genetic variants and corresponding conditions. 20.根据权利要求16所述的方法，其特征在于，所述方法用于在多个阶段中实施所述测定，其中在所述多个阶段中的第四可视化阶段中，所述方法允许渲染图形用户界面，以基于多个定义的设置传送所述第三数据处理流水线阶段中的检测的结果并且与所述结果进行交互。20. The method of claim 16, wherein the method is for performing the assay in a plurality of stages, wherein in a fourth visualization stage of the plurality of stages, the method allows rendering A graphical user interface to communicate and interact with results of detections in the third data processing pipeline stage based on a plurality of defined settings. 21.根据权利要求16到20中任一项所述的方法，其中所述对遗传物质进行处理包括以下中的一项、多项或全部：21. The method of any one of claims 16 to 20, wherein the processing of genetic material comprises one, more or all of the following: (a)从取自受试者的样品中提取所述遗传物质；(a) extracting the genetic material from a sample taken from the subject; (b)优选地通过测量所提取的遗传物质的UV吸光度来评估其纯度；(b) assessing the purity of the extracted genetic material, preferably by measuring its UV absorbance; (c)在所述遗传物质为RNA的情况下，对所述RNA进行逆转录以获得cDNA；(c) in the case that the genetic material is RNA, reverse transcription of the RNA to obtain cDNA; (d)在所述遗传物质为DNA或cDNA的情况下，对所述遗传物质进行剪切或消化以获得片段；(d) where the genetic material is DNA or cDNA, shearing or digesting the genetic material to obtain fragments; (e)优选地通过与互补寡核苷酸杂交来富集蛋白质编码区；以及(e) enrichment of protein-coding regions, preferably by hybridization to complementary oligonucleotides; and (f)将在(d)中获得的所述片段连接到衔接子，并且将连接产物粘接到如载玻片等固体载体上。(f) The fragment obtained in (d) is ligated to an adaptor, and the ligation product is attached to a solid support such as a glass slide. 22.根据权利要求21所述的方法，其中所述样品选自组织、活组织检查、胎儿样品和体液，所述体液优选地为血液、咽拭子、痰、外科引流液或羊水。22. The method according to claim 21, wherein the sample is selected from tissue, biopsy, fetal sample and body fluid, preferably blood, throat swab, sputum, surgical drainage fluid or amniotic fluid. 23.根据权利要求21或22所述的方法，其中所述遗传物质为DNA或RNA，优选地DNA。23. The method of claim 21 or 22, wherein the genetic material is DNA or RNA, preferably DNA. 24.一种获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的系统，所述系统包括：24. A system for acquiring and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, the system comprising: -被配置成处理受试者的基因组的至少一部分以生成原始基因组序列数据集的设备；以及- a device configured to process at least a portion of a subject's genome to generate a raw genome sequence data set; and -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -从所述设备中获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining the raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in the data storage device from the device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 25.根据权利要求24所述的系统，其中所述控制电路系统被进一步配置成通过鉴定以下各项来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度：25. The system of claim 24, wherein the control circuitry is further configured to determine a CNV detection application associated with each candidate CNV detection application of the plurality of candidate CNV detection applications by identifying The degree of recall: -真阳性，在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下；- true positives, where the positions of the new CNVs in the set of new CNVs match the corresponding positions of the artificial CNVs in the set of artificial CNVs; -假阳性，在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下；以及- false positives, where the position of a new CNV in the new set of CNVs is detected at a different position than the position of the artificial CNVs in the set of artificial CNVs; and -假阴性，在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下。- False negatives, where no new CNVs in the new set of CNVs are detected at the positions of the artificial CNVs in the set of artificial CNVs. 26.根据权利要求24所述的系统，其中所述控制电路系统被进一步配置成测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述精确程度。26. The system of claim 24, wherein the control circuitry is further configured to measure the degree of overlap between positions of new CNVs in the new set of CNVs and corresponding positions of artificial CNVs in the set of artificial CNVs to determine The degree of accuracy associated with each candidate CNV detection application of the plurality of candidate CNV detection applications. 27.根据权利要求25所述的系统，其中所述控制电路系统被进一步配置成基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。27. The system of claim 25, wherein the control circuitry is further configured to be based on the measured locations of the new CNVs in the new CNV set and the artificial CNVs in the artificial CNV set the degree of overlap of the corresponding positions, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to assign the highest degree of accuracy to the first candidate CNV of the plurality of candidate CNV detection applications Detect applications. 28.根据权利要求25所述的系统，其中所述控制电路系统被进一步配置成设置指定阈值以确定所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的所述重叠程度。28. The system of claim 25, wherein the control circuitry is further configured to set a specified threshold to determine the location of the new CNV in the new CNV set and the artificial CNV in the artificial CNV set the degree of overlap of the corresponding positions of the CNVs. 29.根据权利要求24所述的系统，其中所述设备被配置成执行全基因组测序、外显子组测序中的至少一项以生成所述原始基因组序列数据集。29. The system of claim 24, wherein the apparatus is configured to perform at least one of whole genome sequencing, exome sequencing to generate the raw genome sequence dataset. 30.根据权利要求24所述的系统，其中所述控制电路系统被进一步配置成生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中所述选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡，其中与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的所述平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。30. The system of claim 24, wherein the control circuitry is further configured to generate a precision-recall curve relationship associated with each candidate CNV detection application in the plurality of candidate CNV detection applications, and wherein said selecting one of said plurality of candidate CNV detection applications to be optimal depends on the balance between said degree of recall and said degree of precision, wherein with each of said plurality of candidate CNV detection applications The balance between the degree of recall and the degree of precision relative to the candidate CNV detection application is indicated by the corresponding area under the precision-recall curve in the generated precision-recall curve relationship. 31.根据权利要求24所述的系统，其中所述系统进一步包括湿实验室布置，并且其中所述湿实验室布置被配置成在所述湿实验室布置中处理所述受试者的生物样品以至少得到所述受试者的所述基因组的所述部分，以便生成所述原始基因组序列数据集。31. The system of claim 24, wherein the system further comprises a wet lab arrangement, and wherein the wet lab arrangement is configured to process a biological sample of the subject in the wet lab arrangement to obtain at least the portion of the genome of the subject in order to generate the raw genome sequence data set. 32.一种处理原始基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的系统，所述系统包括：32. A system for processing a raw genome sequence data set to detect one or more copy number variants (CNVs) therein, the system comprising: -计算布置，所述计算布置包括数据存储器装置和控制电路系统，其中所述控制电路系统被配置成：- a computing arrangement comprising data memory means and control circuitry, wherein the control circuitry is configured to: -获取所述原始基因组序列数据集和预存储在所述数据存储器装置中的多个候选CNV检测应用程序；- obtaining said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said data storage device; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the original genome sequence data set, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset and is considered a true value; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence dataset by simulating a set of artificial CNVs in at least one target region of the original genome sequence dataset using a simulation application pre-stored in the data storage device, wherein the simulated genome sequence dataset including the artificial CNV set and the baseline CNV set; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 33.一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括设备和计算布置的系统来实施，其中所述方法包括：33. A method for obtaining and processing a genome sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method is implemented using a system comprising a device and a computing arrangement, wherein the method include: -通过使用所述设备处理受试者的基因组的至少一部分以生成原始基因组序列数据集；- by processing at least a portion of the subject's genome using the device to generate a raw genome sequence data set; -通过使用所述计算布置的控制电路系统，从所述设备中获取所述原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining from said apparatus said raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in said computationally arranged data memory means by using said computationally arranged control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence data set by simulating an artificial CNV set in at least one target region of said original genome sequence data set by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 34.根据权利要求33所述的方法，其中所述方法包括由所述控制电路系统通过鉴定以下各项来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度：34. The method of claim 33, wherein the method comprises determining, by the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications by identifying The recall degree of: -真阳性，在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下；- true positives, where the positions of the new CNVs in the set of new CNVs match the corresponding positions of the artificial CNVs in the set of artificial CNVs; -假阳性，在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下；以及- false positives, where the position of a new CNV in the new set of CNVs is detected at a different position than the position of the artificial CNVs in the set of artificial CNVs; and -假阴性，在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下。- False negatives, where no new CNVs in the new set of CNVs are detected at the positions of the artificial CNVs in the set of artificial CNVs. 35.根据权利要求33所述的方法，其中所述方法包括通过使用所述控制电路系统，测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述精确程度。35. The method of claim 33, wherein the method comprises, by using the control circuitry, measuring the degree of overlap between the positions of the new CNVs in the new CNV set and the corresponding positions of the artificial CNVs in the artificial CNV set to determine the degree of accuracy associated with each candidate CNV detection application of the plurality of candidate CNV detection applications. 36.根据权利要求35所述的方法，其中所述方法进一步包括通过使用所述控制电路系统，基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。36. The method of claim 35, wherein the method further comprises using the control circuitry, based on the measured location of the new CNVs in the new CNV set and the artificial CNV set The degree of overlap of the corresponding positions of the artificial CNVs by using each candidate CNV detection application of the plurality of candidate CNV detection applications to assign the highest degree of accuracy to one of the plurality of candidate CNV detection applications; The first candidate CNV detection application. 37.根据权利要求35所述的方法，其中所述方法进一步包括通过使用所述控制电路系统，设置指定阈值以确定所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的所述重叠程度。37. The method of claim 35, wherein the method further comprises, by using the control circuitry, setting a specified threshold to determine the location of the new CNV in the new CNV set and the artificial CNV set The degree of overlap of the corresponding positions of the artificial CNVs. 38.根据权利要求33所述的方法，其中所述方法包括通过使用所述控制电路系统，生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中所述选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡，其中与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的所述平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。38. The method of claim 33, wherein the method comprises, by using the control circuitry, generating a precision-recall associated with each candidate CNV detection application in the plurality of candidate CNV detection applications curvilinear relationship, and wherein said selecting one of said plurality of candidate CNV detection applications to be optimal depends on the balance between said degree of recall and said degree of precision, wherein compared with said plurality of candidate CNV detection applications The balance between the degree of recall and the degree of precision associated with each candidate CNV detection application of is indicated by the corresponding area under the precision-recall curve in the generated precision-recall curve relationship. 39.一种计算机程序产品，其包括其上存储有计算机可读指令的非暂时性计算机可读存储介质，所述计算机可读指令可由包括处理硬件的计算机化装置执行以执行根据权利要求33所述的方法。39. A computer program product comprising a non-transitory computer-readable storage medium having stored thereon computer-readable instructions executable by a computerized apparatus including processing hardware to perform the method described in claim 33. method described. 40.一种用于获取和处理基因组序列数据集以检测其中的一个或多个拷贝数变体(CNV)的方法，其中所述方法使用包括计算布置的系统来实施，其中所述方法包括：40. A method for obtaining and processing a genomic sequence data set to detect one or more copy number variants (CNVs) therein, wherein the method is implemented using a system comprising a computational arrangement, wherein the method comprises: -通过使用所述计算布置的控制电路系统，获取原始基因组序列数据集和预存储在所述计算布置的数据存储器装置中的多个候选CNV检测应用程序；- obtaining a raw genome sequence data set and a plurality of candidate CNV detection applications pre-stored in a data memory device of the computing arrangement by using the control circuitry of the computing arrangement; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述原始基因组序列数据集的随机选择区中的基线CNV，其中所述基线CNV是所述原始基因组序列数据集中预先存在的CNV，被认为是真值；- by using the control circuitry, by using each candidate CNV detection application of the plurality of candidate CNV detection applications to perform a first CNV identification to obtain a CNV in a randomly selected region of the original genome sequence data set A baseline CNV, wherein the baseline CNV is a pre-existing CNV in the original genome sequence dataset, considered to be the true value; -通过使用所述控制电路系统，组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each candidate CNV detection application of the plurality of candidate CNV detection applications to generate a set of baseline CNVs by using the control circuitry; -通过使用所述控制电路系统，通过使用预存储在所述数据存储器装置中的模拟应用程序模拟所述原始基因组序列数据集的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence data set by simulating an artificial CNV set in at least one target region of said original genome sequence data set by using a simulation application pre-stored in said data memory device using said control circuitry, wherein the simulated genome sequence data set includes the artificial CNV set and the baseline CNV set; -通过使用所述控制电路系统，在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset by using the control circuitry; -通过使用所述控制电路系统，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- by using the control circuitry, performing a second CNV identification in the simulated genome sequence data set by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -通过使用所述控制电路系统，从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence data set to obtain a new set of CNVs by using the control circuitry; -通过使用所述控制电路系统，基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence data set based on the recorded positions of the set of artificial CNVs by using the control circuitry; -通过使用所述控制电路系统，基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining, using the control circuitry, to be associated with each candidate CNV detection application of the plurality of candidate CNV detection applications based on a comparison of the position of the new set of CNVs with the position of the artificial CNV set degree of recall and precision; -通过使用所述控制电路系统，基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting, by using the control circuitry, one of the plurality of candidate CNV detection applications based on a combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data one is optimal; and -通过使用所述控制电路系统，利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data with the selected candidate CNV detection application using the control circuitry. 41.根据权利要求1到15中任一项所述的试剂盒，其中对来自所述遗传物质的所述遗传DNA读数中的所述拷贝数变异(CNV)的检测进一步包括控制电路系统，所述控制电路系统被配置成：41. The kit of any one of claims 1 to 15, wherein the detection of the copy number variation (CNV) in the genetic DNA reads from the genetic material further comprises control circuitry, the The control circuitry is configured to: -接收所述遗传DNA读数和多个候选CNV检测应用程序；- receiving said genetic DNA reads and multiple candidate CNV detection applications; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序来执行第一CNV识别以获得所述遗传DNA读数的随机选择区中的基线CNV，其中所述基线CNV是所述遗传DNA读数中预先存在的CNV，被认为是真值；- performing a first CNV identification by using each candidate CNV detection application of the plurality of candidate CNV detection applications to obtain a baseline CNV in a randomly selected region of the genetic DNA reads, wherein the baseline CNV is all pre-existing CNVs in the genetic DNA reads described above are considered true values; -组合从所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序中获得的所述基线CNV以生成基线CNV集；- combining the baseline CNVs obtained from each of the plurality of candidate CNV detection applications to generate a baseline CNV set; -通过使用模拟应用程序模拟所述遗传DNA读数的至少一个靶区中的人工CNV集来生成模拟基因组序列数据集，其中所述模拟基因组序列数据集包括所述人工CNV集和所述基线CNV集；- generating a simulated genome sequence data set by simulating an artificial CNV set in at least one target region of said genetic DNA reads using a simulation application, wherein said simulated genome sequence data set includes said artificial CNV set and said baseline CNV set ; -在所述模拟基因组序列数据集中记录所述人工CNV集中的每个人工CNV和所述基线CNV集中的每个基线CNV的位置；- recording the position of each artificial CNV in the artificial CNV set and each baseline CNV in the baseline CNV set in the simulated genome sequence dataset; -通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序在所述模拟基因组序列数据集中执行第二CNV识别；- performing a second CNV identification in the simulated genome sequence dataset by using each candidate CNV detection application of the plurality of candidate CNV detection applications; -从获得自所述模拟基因组序列数据集中的所述第二CNV识别的CNV中消除所述基线CNV集，以获得新CNV集；- eliminating the baseline set of CNVs from the CNVs identified by the second CNV obtained from the simulated genome sequence dataset to obtain a new set of CNVs; -基于记录的所述人工CNV集的位置，确定所述模拟基因组序列数据集中所述新CNV集中的每个新CNV的位置；- determining the position of each new CNV in the new set of CNVs in the simulated genome sequence dataset based on the recorded positions of the set of artificial CNVs; -基于所述新CNV集的位置与所述人工CNV集的位置的比较，确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的召回程度和精确程度；- determining a degree of recall and a degree of precision associated with each candidate CNV detection application in the plurality of candidate CNV detection applications based on a comparison of the positions of the new CNV set with the positions of the artificial CNV set; -基于用于识别所述基因组序列数据中的所述拷贝数变体的所述召回程度和所述精确程度的组合，选择所述多个候选CNV检测应用程序之一作为最优；以及- selecting one of the plurality of candidate CNV detection applications as the best based on the combination of the degree of recall and the degree of precision for identifying the copy number variant in the genomic sequence data; and -利用所选候选CNV检测应用程序识别所述基因组序列数据中的CNV。- Identifying CNVs in the genomic sequence data using the selected candidate CNV detection application. 42.根据权利要求41所述的试剂盒，其中所述控制电路系统被进一步配置成通过鉴定以下各项来确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述召回程度：42. The kit of claim 41, wherein the control circuitry is further configured to be associated with each candidate CNV detection application in the plurality of candidate CNV detection applications by identifying the following The recall degree of: -真阳性，在所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置相匹配的情况下；- true positives, where the positions of the new CNVs in the set of new CNVs match the corresponding positions of the artificial CNVs in the set of artificial CNVs; -假阳性，在与所述人工CNV集中的人工CNV的位置不同的位置处检测到所述新CNV集中的新CNV的位置的情况下；以及- false positives, where the position of a new CNV in the new set of CNVs is detected at a different position than the position of the artificial CNVs in the set of artificial CNVs; and -假阴性，在所述人工CNV集中的人工CNV的位置处没有检测到所述新CNV集中的新CNV的情况下。- False negatives, where no new CNVs in the new set of CNVs are detected at the positions of the artificial CNVs in the set of artificial CNVs. 43.根据权利要求41所述的试剂盒，其中所述控制电路系统被进一步配置成测量所述新CNV集中的新CNV的位置与所述人工CNV集中的人工CNV的对应位置的重叠程度，以确定与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的所述精确程度。43. The kit of claim 41, wherein the control circuitry is further configured to measure the degree of overlap between the positions of the new CNVs in the new CNV set and the corresponding positions of the artificial CNVs in the artificial CNV set, to The degree of accuracy associated with each candidate CNV detection application of the plurality of candidate CNV detection applications is determined. 44.根据权利要求43所述的试剂盒，其中所述控制电路系统被进一步配置成基于测得的所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的重叠程度，通过使用所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序将最高精确程度分配给所述多个候选CNV检测应用程序中的第一候选CNV检测应用程序。44. The kit of claim 43, wherein the control circuitry is further configured to be based on the measured location of the new CNV in the new CNV set and the artificial CNV in the artificial CNV set The degree of overlap of the corresponding positions of the CNVs by using each candidate CNV detection application of the plurality of candidate CNV detection applications to assign the highest degree of accuracy to the first candidate of the plurality of candidate CNV detection applications CNV detection application. 45.根据权利要求43所述的试剂盒，其中所述控制电路系统被进一步配置成设置指定阈值以确定所述新CNV集中的所述新CNV的所述位置与所述人工CNV集中的所述人工CNV的所述对应位置的所述重叠程度。45. The kit of claim 43, wherein the control circuitry is further configured to set specified thresholds to determine the location of the new CNVs in the new CNV set and the artificial CNV set the degree of overlap of the corresponding positions of the artificial CNVs. 46.根据权利要求41所述的试剂盒，其中所述遗传DNA读数通过全基因组测序、外显子组测序或两者生成。46. The kit of claim 41, wherein the genetic DNA reads are generated by whole genome sequencing, exome sequencing, or both. 47.根据权利要求41所述的试剂盒，其中所述控制电路系统被进一步配置成生成与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关联的精确-召回曲线关系，并且其中所述选择所述多个候选CNV检测应用程序之一为最优取决于所述召回程度与所述精确程度之间的平衡，其中与所述多个候选CNV检测应用程序中的每个候选CNV检测应用程序相关的所述召回程度与所述精确程度之间的所述平衡由所生成的精确-召回曲线关系中对应的精确-召回曲线下面积指示。47. The kit of claim 41, wherein the control circuitry is further configured to generate a precision-recall curve relationship associated with each candidate CNV detection application in the plurality of candidate CNV detection applications , and wherein said selecting one of said plurality of candidate CNV detection applications to be optimal depends on the balance between said degree of recall and said degree of precision, wherein with each of said plurality of candidate CNV detection applications The balance between the degree of recall and the degree of precision associated with each candidate CNV detection application is indicated by the corresponding area under the precision-recall curve in the generated precision-recall curve relationship. 48.根据权利要求41所述的试剂盒，其进一步包括湿实验室，所述湿实验室被配置成在所述湿实验室布置中处理所述受试者的生物样品以至少得到所述受试者的所述基因组的所述部分，以便生成所述遗传DNA读数。48. The kit of claim 41, further comprising a wet lab configured to process a biological sample of the subject in the wet lab arrangement to obtain at least the subject. the portion of the genome of the subject in order to generate the genetic DNA read.
